Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
]	O

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

See	O
(	O
,	O
)	O
for	O
additional	O
Blood	B-D001794
Pressure	I-D001794

See	O
Clinical	O
Studies	O
(	O
14.6,	O
14.7)	O
for	O
additional	O
Blood	B-D001794
Pressure	I-D001794

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(	O
14.7)]	O
,	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
%	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-	O
controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

This	O
Risk	B-D012306

Diclofenac	B-D004008
Potassium	B-D011188

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
718	O
Patients	B-D010361

In	O
a	O
6	O
month,	O
double-blind	O
trial	O
comparing	O
Diclofenac	B-D004008

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

This	O
Risk	B-D012306

[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
WARNING:	O
Risk	B-D012306

•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4,	O
5.1)	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O
	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

•Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

•Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

•Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

•If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

•In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

The	O
rates	O
of	O
Hypertension	B-D006973

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O
,	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
Sulfonamides	B-D013449

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
•Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
•Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
•Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
•Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
•Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
Greater	O
Than	O
or	O
Equal	O
to	O
2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
Placebo	O
NAP	O
DCF	O
IBU	O
N=4146	O
N=1864	O
N=1366	O
N=387	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(greater	O
than	O
or	O
equal	O
to	O
5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(greater	O
than	O
or	O
equal	O
to	O
5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
Greater	O
Than	O
or	O
Equal	O
to	O
5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies	O
:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Associated	O
with	O
Treatment	O
Discontinuation	O
Of	O
the	O
382	O
Patients	B-D010361

One	O
patient	O
each	O
discontinued	O
treatment	O
for	O
the	O
following	O
reasons:	O
gastrointestinal	O
upset;	O
Light	B-D008027

Incidence	B-D015994
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
s	O
The	O
following	O
table	O
summarizes	O
the	O
Incidence	B-D015994

The	O
prescriber	O
should	O
be	O
aware	O
that	O
these	O
figures	O
cannot	O
be	O
used	O
to	O
predict	O
the	O
Incidence	B-D015994

Similarly,	O
the	O
cited	O
frequencies	O
cannot	O
be	O
compared	O
with	O
figures	O
obtained	O
from	O
other	O
clinical	O
investigations	O
involving	O
different	O
treatments,	O
uses,	O
and	O
investigators	O

Adverse	O
Events	O
Reported	O
by	O
at	O
Least	O
1%	O
of	O
butalbital	B-C004470
,	O
Aspirin	B-D001241

All	O
reported	O
adverse	O
events,	O
except	O
those	O
already	O
presented	O
in	O
the	O
previous	O
table,	O
are	O
included	O

It	O
is	O
important	O
to	O
emphasize	O
that,	O
although	O
the	O
adverse	O
events	O
reported	O
did	O
occur	O
while	O
the	O
patient	O
was	O
receiving	O
the	O
combination	O
product,	O
the	O
adverse	O
events	O
were	O
not	O
necessarily	O
caused	O
by	O
butalbital	B-C004470
,	O
Aspirin	B-D001241

Adverse	O
events	O
are	O
classified	O
by	O
body	O
system	O
and	O
frequency	O

“Frequent”	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
which	O
occurred	O
in	O
at	O
least	O
1/100	O
(1%)	O
of	O
the	O
Patients	B-D010361

“Infrequent”	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
that	O
occurred	O
in	O
less	O
than	O
1/100	O
Patients	B-D010361

All	O
adverse	O
events	O
tabulated	O
below	O
are	O
classified	O
as	O
infrequent	O

Central	O
Nervous:	O
Headache	B-D006261

Autonomic	O
Nervous:	O
dry	O
Mouth	B-D009055

Gastrointestinal:	O
Vomiting	B-D014839

Cardiovascular:	O
Tachycardia	B-D013610

Musculoskeletal:	O
Leg	B-D007866

Genitourinary:	O
Diuresis	B-D004231

Miscellaneous:	O
Pruritus	B-D011537

Voluntary	O
reports	O
of	O
adverse	O
drug	O
events,	O
TEMPO	B-C003959

Many	O
or	O
most	O
of	O
these	O
events	O
may	O
have	O
no	O
causal	O
relationship	O
with	O
the	O
drug	O
and	O
are	O
listed	O
according	O
to	O
body	O
system	O

Central	O
Nervous:	O
Abuse,	O
addiction,	O
Anxiety	B-D001007

Autonomic	O
Nervous:	O
epitaxis,	O
Flushing	B-D005483

Gastrointestinal:	O
Anorexia	B-D000855

Cardiovascular:	O
Chest	B-D002637
Pain	I-D002637

Skin	B-D012867
:	O
Erythema	B-D004890

Urinary:	O
Kidney	B-D007668

Miscellaneous:	O
allergic	O
reaction,	O
anaphylactic	O
Shock	B-D012769

The	O
following	O
adverse	O
drug	O
events	O
may	O
be	O
borne	O
in	O
mind	O
as	O
potential	O
effects	O
of	O
the	O
components	O
of	O
this	O
product	O

Potential	O
effects	O
of	O
high	O
dosage	O
are	O
listed	O
in	O
the	O
OVERDOSAGE	O
section	O
of	O
this	O
insert	O

Aspirin	B-D001241
:	O
Occult	B-D009780
Blood	I-D009780

Caffeine	B-D002110
:	O
Cardia	B-D002299

Codeine	B-D003061
:	O
Nausea	B-D009325

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
AGGRENOX	O
increases	O
the	O
Risk	B-D012306
of	O
Bleeding	O
AGGRENOX	O
increases	O
the	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307

Intracranial	O
Hemorrhage	B-D006470
In	O
Europe	B-D005060
an	O
Stroke	B-D020521
Prevention	O
Study-2	O
(ESPS2),	O
the	O
Incidence	B-D015994

Gastrointestinal	O
(GI)	O
Side	O
Effects	O
GI	O
side	O
effects	O
include	O
Stomach	B-D013270

Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
Dyspepsia	B-D004415

Inform	O
Patients	B-D010361

In	O
ESPS2,	O
the	O
Incidence	B-D015994

Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
Avoid	O
using	O
Aspirin	B-D001241

Alcohol	O
Warning	O
Because	O
AGGRENOX	O
contains	O
Aspirin	B-D001241

5.2	O
Renal	O
Failure	O
Avoid	O
Aspirin	B-D001241

5.3	O
Hepatic	B-D048550
Insufficiency	I-D048550
Elevations	O
of	O
hepatic	O
Enzymes	B-D004798

5.4	O
Pregnancy	B-D011247
Because	O
AGGRENOX	O
contains	O
Aspirin	B-D001241

Maternal	O
Aspirin	B-D001241

Because	O
of	O
the	O
above	O
and	O
because	O
of	O
the	O
known	O
effects	O
of	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
on	O
the	O
fetal	O
Cardiovascular	B-D002319
System	I-D002319

Aspirin	B-D001241
has	O
been	O
shown	O
to	O
be	O
teratogenic	O
in	O
Rats	B-D051381

These	O
doses,	O
which	O
also	O
resulted	O
in	O
a	O
high	O
resorption	O
rate	O
in	O
Rats	B-D051381

Reproduction	B-D012098
studies	O
with	O
Dipyridamole	B-D004176

When	O
330	O
mg	O
Aspirin	B-D001241

There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
of	O
the	O
use	O
of	O
AGGRENOX	O
in	O
Pregnant	B-D037841
Women	I-D037841

If	O
AGGRENOX	O
is	O
used	O
during	O
Pregnancy	B-D011247

5.5	O
Coronary	B-D003324
Artery	I-D003324
Disease	I-D003324
Dipyridamole	B-D004176
has	O
a	O
vasodilatory	O
effect	O

Chest	B-D002637
Pain	I-D002637

For	O
Stroke	B-D020521

5.6	O
Hypotension	B-D007022
Dipyridamole	B-D004176
produces	O
peripheral	O
Vasodilation	B-D014664

5.7	O
General	O
AGGRENOX	O
Capsules	B-D002214

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Hypersensitivity	B-D006967
[	O
see	O
Contraindications	B-D000075202
(4.1)	O
]	O
Allergy	O
[	O
see	O
Contraindications	B-D000075202
(4.2)	O
]	O
Risk	B-D012306
of	O
Bleeding	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(>10%	O
and	O
greater	O
than	O
placebo)	O
were	O
Headache	B-D006261

at	O
(800)	O
542-6257	O
or	O
(800)	O
459-9906	O
TTY	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
efficacy	O
and	O
Safety	B-D012449

ESPS2	O
was	O
a	O
double-blind,	O
placebo-controlled	O
study	O
that	O
evaluated	O
6602	O
Patients	B-D010361

Patients	B-D010361
were	O
randomized	O
to	O
either	O
AGGRENOX,	O
Aspirin	B-D001241

This	O
24-month,	O
multicenter,	O
double-blind,	O
randomized	O
study	O
(ESPS2)	O
was	O
conducted	O
to	O
compare	O
the	O
efficacy	O
and	O
Safety	B-D012449

The	O
study	O
was	O
conducted	O
in	O
a	O
total	O
of	O
6602	O
Male	B-D008297

Table	O
1	O
presents	O
the	O
Incidence	B-D015994

There	O
is	O
no	O
clear	O
benefit	O
of	O
the	O
Dipyridamole	B-D004176

Table	O
1	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
in	O
ESPS2a	O
Individual	O
Treatment	O
Group	O
AGGRENOX	O
ER-DP	O
Alone	O
ASA	O
Alone	O
Placebo	O
Body	O
System/Preferred	O
Term	O
aReported	O
by	O
≥1%	O
of	O
Patients	B-D010361

Note:	O
ER-DP	O
=	O
extended-release	O
Dipyridamole	B-D004176

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O

NOS	O
=	O
not	O
otherwise	O
specified	O

1650	O
1654	O
1649	O
1649	O
Total	O
Number	O
of	O
Patients	B-D010361
Total	O
Number	O
(%)	O
of	O
Patients	B-D010361
With	O
atLeast	O
One	O
On-Treatment	O
AdverseEvent	O
1319	O
(80%)	O
1305	O
(79%)	O
1323	O
(80%)	O
1304	O
(79%)	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Disorders	O
Headache	B-D006261
647	O
(39%)	O
634	O
(38%)	O
558	O
(34%)	O
543	O
(33%)	O
Convulsions	O
28	O
(2%)	O
15	O
(1%)	O
28	O
(2%)	O
26	O
(2%)	O
Gastrointestinal	O
System	O
Disorders	O
Dyspepsia	B-D004415
303	O
(18%)	O
288	O
(17%)	O
299	O
(18%)	O
275	O
(17%)	O
Abdominal	B-D015746
Pain	I-D015746
289	O
(18%)	O
255	O
(15%)	O
262	O
(16%)	O
239	O
(14%)	O
Nausea	B-D009325
264	O
(16%)	O
254	O
(15%)	O
210	O
(13%)	O
232	O
(14%)	O
Diarrhea	B-D003967
210	O
(13%)	O
257	O
(16%)	O
112	O
(7%)	O
161	O
(10%)	O
Vomiting	B-D014839
138	O
(8%)	O
129	O
(8%)	O
101	O
(6%)	O
118	O
(7%)	O
Hemorrhage	B-D006470
Rectum	B-D012007
26	O
(2%)	O
22	O
(1%)	O
16	O
(1%)	O
13	O
(1%)	O
Melena	B-D008551
31	O
(2%)	O
10	O
(1%)	O
20	O
(1%)	O
13	O
(1%)	O
Hemorrhoids	B-D006484
16	O
(1%)	O
13	O
(1%)	O
10	O
(1%)	O
10	O
(1%)	O
GI	O
Hemorrhage	B-D006470
20	O
(1%)	O
5	O
(0%)	O
15	O
(1%)	O
7	O
(0%)	O
Body	O
as	O
a	O
Whole	O
-	O
General	O
Disorders	O
Pain	B-D010146
105	O
(6%)	O
88	O
(5%)	O
103	O
(6%)	O
99	O
(6%)	O
Fatigue	B-D005221
95	O
(6%)	O
93	O
(6%)	O
97	O
(6%)	O
90	O
(5%)	O
Back	B-D001416
Pain	I-D001416
76	O
(5%)	O
77	O
(5%)	O
74	O
(4%)	O
65	O
(4%)	O
Accidental	O
Injury	O
42	O
(3%)	O
24	O
(1%)	O
51	O
(3%)	O
37	O
(2%)	O
Malaise	O
27	O
(2%)	O
23	O
(1%)	O
26	O
(2%)	O
22	O
(1%)	O
Asthenia	B-D001247
29	O
(2%)	O
19	O
(1%)	O
17	O
(1%)	O
18	O
(1%)	O
Syncope	B-D013575
17	O
(1%)	O
13	O
(1%)	O
16	O
(1%)	O
8	O
(0%)	O
Psychiatric	O
Disorders	O
Amnesia	B-D000647
39	O
(2%)	O
40	O
(2%)	O
57	O
(3%)	O
34	O
(2%)	O
Confusion	B-D003221
18	O
(1%)	O
9	O
(1%)	O
22	O
(1%)	O
15	O
(1%)	O
Anorexia	B-D000855
19	O
(1%)	O
17	O
(1%)	O
10	O
(1%)	O
15	O
(1%)	O
Somnolence	O
20	O
(1%)	O
13	O
(1%)	O
18	O
(1%)	O
9	O
(1%)	O
Musculoskeletal	B-D009141
System	I-D009141
Disorders	O
Arthralgia	B-D018771
91	O
(6%)	O
75	O
(5%)	O
91	O
(6%)	O
76	O
(5%)	O
Arthritis	B-D001168
34	O
(2%)	O
25	O
(2%)	O
17	O
(1%)	O
19	O
(1%)	O
Art	B-D001154
hrosis	O
18	O
(1%)	O
22	O
(1%)	O
13	O
(1%)	O
14	O
(1%)	O
Myalgia	B-D063806
20	O
(1%)	O
16	O
(1%)	O
11	O
(1%)	O
11	O
(1%)	O
Respiratory	B-D012137
System	I-D012137
Disorders	O
Cough	B-D003371
ing	O
25	O
(2%)	O
18	O
(1%)	O
32	O
(2%)	O
21	O
(1%)	O
Upper	O
Respiratory	O
Tract	O
Infection	O
16	O
(1%)	O
9	O
(1%)	O
16	O
(1%)	O
14	O
(1%)	O
Cardiovascular	O
Disorders,	O
General	O
Cardia	B-D002299
c	O
Failure	O
26	O
(2%)	O
17	O
(1%)	O
30	O
(2%)	O
25	O
(2%)	O
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders	O
Hemorrhage	B-D006470
NOS	O
52	O
(3%)	O
24	O
(1%)	O
46	O
(3%)	O
24	O
(1%)	O
Epistaxis	B-D004844
39	O
(2%)	O
16	O
(1%)	O
45	O
(3%)	O
25	O
(2%)	O
Purpura	B-D011693
23	O
(1%)	O
8	O
(0%)	O
9	O
(1%)	O
7	O
(0%)	O
Neoplasm	O
Neoplasm	O
NOS	O
28	O
(2%)	O
16	O
(1%)	O
23	O
(1%)	O
20	O
(1%)	O
Red	O
Blood	B-D001769
Cell	O
Disorders	O
Anemia	B-D000740
27	O
(2%)	O
16	O
(1%)	O
19	O
(1%)	O
9	O
(1%)	O
Discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
ESPS2	O
was	O
25%	O
for	O
AGGRENOX,	O
25%	O
for	O
extended-release	O
Dipyridamole	B-D004176

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O

Total	O
Number	O
of	O
Patients	B-D010361
1650	O
1654	O
1649	O
1649	O
Patients	B-D010361
with	O
at	O
least	O
one	O
Adverse	O
Eventthat	O
led	O
to	O
treatment	O
discontinuation	O
417	O
(25%)	O
419	O
(25%)	O
318	O
(19%)	O
352	O
(21%)	O
Headache	B-D006261
165	O
(10%)	O
166	O
(10%)	O
57	O
(3%)	O
69	O
(4%)	O
Dizziness	B-D004244
85	O
(5%)	O
97	O
(6%)	O
69	O
(4%)	O
68	O
(4%)	O
Nausea	B-D009325
91	O
(6%)	O
95	O
(6%)	O
51	O
(3%)	O
53	O
(3%)	O
Abdominal	B-D015746
Pain	I-D015746
74	O
(4%)	O
64	O
(4%)	O
56	O
(3%)	O
52	O
(3%)	O
Dyspepsia	B-D004415
59	O
(4%)	O
61	O
(4%)	O
49	O
(3%)	O
46	O
(3%)	O
Vomiting	B-D014839
53	O
(3%)	O
52	O
(3%)	O
28	O
(2%)	O
24	O
(1%)	O
Diarrhea	B-D003967
35	O
(2%)	O
41	O
(2%)	O
9	O
(<1%)	O
16	O
(<1%)	O
Stroke	B-D020521
39	O
(2%)	O
48	O
(3%)	O
57	O
(3%)	O
73	O
(4%)	O
Transient	O
Ischemic	O
Attack	O
35	O
(2%)	O
40	O
(2%)	O
26	O
(2%)	O
48	O
(3%)	O
Angina	B-D000787
Pectoris	I-D000787
23	O
(1%)	O
20	O
(1%)	O
16	O
(<1%)	O
26	O
(2%)	O
Headache	B-D006261
was	O
most	O
notable	O
in	O
the	O
first	O
month	O
of	O
treatment	O

Other	O
Adverse	O
Events	O
Adverse	O
reactions	O
that	O
occurred	O
in	O
less	O
than	O
1%	O
of	O
Patients	B-D010361

Body	O
as	O
a	O
Whole:	O
Allergic	O
reaction,	O
Fever	B-D005334

Patients	B-D010361
with	O
high	O
frequency	O
Hearing	B-D034381
Loss	I-D034381

In	O
these	O
Patients	B-D010361

6.2	O
Post-Marketing	O
Experience	O
The	O
following	O
is	O
a	O
list	O
of	O
additional	O
adverse	O
reactions	O
that	O
have	O
been	O
reported	O
either	O
in	O
the	O
Literature	B-D008091

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Decisions	O
to	O
include	O
these	O
reactions	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
reaction,	O
(2)	O
frequency	O
of	O
reporting,	O
or	O
(3)	O
strength	O
of	O
causal	O
connection	O
to	O
AGGRENOX	O

Body	O
as	O
a	O
Whole:	O
Hypothermia	B-D007035
,	O
Chest	B-D002637
Pain	I-D002637

PrevidolRx	O
Plus	O
Analgesic	O
PakGenPak	O
Solutions	B-D012996
LLCPrevidolRx	O
Plus	O
Analgesic	O
Pak	O
(Part	O
1	O
of	O
2)	O
DESCRIPTION:	O
Diclofenac	B-D004008

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(see	O
WARNINGS)	O
Diclofenac	B-D004008
Sodium	B-D012964

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(see	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
Cardiovascular	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
Celecoxib	B-D000068579

New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

Fluid	O
retention	O
and	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Renal	O
papillary	O
Necrosis	B-D009336

Use	O
Celecoxib	B-D000068579

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
Celecoxib	B-D000068579

Serious	O
Skin	B-D012867

Discontinue	O
Celecoxib	B-D000068579

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

Therefore,	O
treatment	O
with	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

Celecoxib	B-D000068579
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
Celecoxib	B-D000068579

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

ZIPSOR	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
ZIPSOR	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
ZIPSOR	O
in	O
Patients	B-D010361

If	O
ZIPSOR	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
ZIPSOR	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy	O

but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
Patients	B-D010361

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
ZIPSOR	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
Acetaminophen	B-D000082

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
ZIPSOR,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
ZIPSOR	O
in	O
Patients	B-D010361

If	O
ZIPSOR	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
ZIPSOR	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
ZIPSOR	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
ZIPSOR	O
in	O
Patients	B-D010361

If	O
ZIPSOR	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
ZIPSOR	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

ZIPSOR	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
ZIPSOR,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
ZIPSOR	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
ZIPSOR,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
ZIPSOR	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
1%)	O
are	O
gastrointestinal	O
experiences	O
including	O
Abdominal	B-D015746
Pain	I-D015746

at	O
1-866-458-6389	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
Safety	B-D012449

In	O
Patients	B-D010361

(see	O
Table	O
1)	O
Table	O
1	O
Incidence	B-D015994
of	O
Treatment	O
Emergent	O
Adverse	O
Reactions	O
with	O
Incidence	B-D015994
≥	O
1%	O
of	O
ZIPSOR	O
Treated	O
Patients	B-D010361
in	O
Multiple-Dose	O
Studies	O
*There	O
was	O
greater	O
use	O
of	O
concomitant	O
opioid	O
rescue	O
medication	O
in	O
placebo	O
treated	O
Patients	B-D010361

MedDRA	O
System	O
Organ	O
Class	O
and	O
Preferred	O
Term	O
ZIPSOR*	O
25	O
mg	O
n=345	O
n	O
(%)	O
Placebo*	O
n=327	O
n	O
(%)	O
Any	O
Adverse	O
Events	O
144	O
(41.7)	O
181	O
(55.4)	O
Abdominal	B-D015746
Pain	I-D015746
24	O
(7.0)	O
11	O
(3.4)	O
Constipation	B-D003248
11	O
(3.2)	O
9	O
(2.8)	O
Diarrhea	B-D003967
8	O
(2.3)	O
9	O
(2.8)	O
Dyspepsia	B-D004415
4	O
(1.2)	O
8	O
(2.4)	O
Nausea	B-D009325
57	O
(16.5)	O
66	O
(20.2)	O
Vomiting	B-D014839
20	O
(5.8)	O
26	O
(8.0)	O
Dizziness	B-D004244
12	O
(3.5)	O
17	O
(5.2)	O
Headache	B-D006261
43	O
(12.5)	O
56	O
(17.1)	O
Somnolence	O
9	O
(2.6)	O
6	O
(1.8)	O
Pruritus	B-D011537
5	O
(1.4)	O
6	O
(1.8)	O
Sweating	B-D013546
Increase	O
4	O
(1.2)	O
2	O
(0.6)	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
in	O
Patients	B-D010361

Do	O
not	O
exceed	O
a	O
total	O
combined	O
duration	O
of	O
use	O
of	O
SPRIX	O
and	O
other	O
Ketorolac	B-D020910

SPRIX	O
is	O
not	O
indicated	O
for	O
use	O
in	O
pediatric	O
Patients	B-D010361

Gastrointestinal	O
Risk	B-D012306
Ketorolac	B-D020911
Tromethamine	I-D020911

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Therefore,	O
SPRIX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

Elderly	O
Patients	B-D010361

Bleeding	O
Risk	B-D012306
Ketorolac	B-D020911
Tromethamine	I-D020911

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

SPRIX	O
nas	B-C015378

Renal	O
Risk	B-D012306
SPRIX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

WARNING:	O
LIMITATIONS	O
OF	O
USE,	O
GASTROINTESTINAL,	O
BLEEDING,	O
CARDIOVASCULAR,	O
and	O
RENAL	O
Risk	B-D012306

Limitations	O
of	O
Use	O
–	O
The	O
total	O
duration	O
of	O
use	O
of	O
SPRIX	O
and	O
other	O
Ketorolac	B-D020910

(2.1)	O
Gastrointestinal	O
(GI)	O
Risk	B-D012306
–	O
Ketorolac	B-D020910
can	O
cause	O
Peptic	B-D010437
Ulcer	I-D010437

SPRIX	O
is	O
CONTRAINDICATED	O
in	O
Patients	B-D010361

(4)	O
Bleeding	O
Risk	B-D012306
–	O
SPRIX	O
inhibits	O
platelet	O
function	O
and	O
is	O
CONTRAINDICATED	O
in	O
Patients	B-D010361

(4)	O
Cardiovascular	O
(CV)	O
Risk	B-D012306
–	O
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
CV	O
Disease	B-D004194

(5.6)	O
SPRIX	O
is	O
CONTRAINDICATED	O
for	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4)	O
Renal	O
Risk	B-D012306

(4)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
SPRIX	O
should	O
not	O
be	O
used	O
concomitantly	O
with	O
IM/IV	O
or	O
oral	O
Ketorolac	B-D020910

(5.1)	O
Ketorolac	B-D020910
can	O
cause	O
serious	O
GI	O
adverse	O
events	O
including	O
bleeding,	O
Ulcer	B-D014456

SPRIX	O
should	O
be	O
prescribed	O
with	O
caution	O
in	O
Patients	B-D010361

Elderly	O
Patients	B-D010361

(4,	O
5.2)	O
NSAIDs	O
Affect	B-D000339

SPRIX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Do	O
not	O
use	O
SPRIX	O
in	O
Patients	B-D010361

(4,	O
5.3)	O
Ketorolac	B-D020910
can	O
cause	O
renal	O
injury	O

SPRIX	O
should	O
not	O
be	O
used	O
in	O
Patients	B-D010361

(4,	O
5.4,	O
12.4)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

SPRIX	O
should	O
be	O
discontinued	O
immediately	O
in	O
Patients	B-D010361

(4,	O
5.5,	O
5.7,	O
5.11)	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

(5.6)	O
Fluid	O
retention	O
and	O
Edema	B-D004487

SPRIX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

(5.4,	O
5.6)	O
NSAIDs	O
can	O
cause	O
serious	O
dermatologic	O
adverse	O
reactions	O
such	O
as	O
exfoliative	O
Dermatitis	B-D003872

SPRIX	O
should	O
be	O
discontinued	O
immediately	O
in	O
Patients	B-D010361

(4,	O
5.7)	O
During	O
Pregnancy	B-D011247

(5.8)	O
5.1	O
Limitations	O
of	O
Use	O
The	O
total	O
duration	O
of	O
use	O
of	O
SPRIX	O
alone	O
or	O
sequentially	O
with	O
other	O
Form	B-D020478

SPRIX	O
must	O
not	O
be	O
used	O
concomitantly	O
with	O
other	O
Form	B-D020478

5.2	O
Gastrointestinal	O
(GI)	O
Effects	O
-	O
Risk	B-D012306
of	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
SPRIX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

Ketorolac	B-D020911
Tromethamine	I-D020911

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Minor	O
upper	O
GI	O
problems,	O
such	O
as	O
Dyspepsia	B-D004415

The	O
Incidence	B-D015994

Even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

In	O
addition	O
to	O
past	O
History	B-D006664

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

This	O
should	O
include	O
discontinuation	O
of	O
SPRIX	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

For	O
high	O
Risk	B-D012306

Use	O
great	O
care	O
when	O
giving	O
SPRIX	O
to	O
Patients	B-D010361

5.3	O
Hematological	O
Effects	O
Because	O
Prostaglandins	B-D011453

The	O
effects	O
of	O
NSAIDs	O
other	O
than	O
Aspirin	B-D001241

Patients	B-D010361
on	O
therapeutic	O
doses	O
of	O
Anticoagulants	B-D000925

The	O
concurrent	O
use	O
of	O
Ketorolac	B-D020911
Tromethamine	I-D020911

Until	O
data	O
from	O
such	O
studies	O
are	O
available,	O
carefully	O
weigh	O
the	O
benefits	O
against	O
the	O
Risk	B-D012306

Monitor	O
Patients	B-D010361

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
Clinical	B-D016430
Trial	I-D016430

Therefore,	O
use	O
SPRIX	O
with	O
caution	O
in	O
the	O
postoperative	O
setting	O
when	O
Hemostasis	B-D006487

Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
Blood	B-D001769

Do	O
not	O
use	O
SPRIX	O
in	O
Patients	B-D010361

5.4	O
Renal	O
Effects	O
Ketorolac	B-D020910
and	O
its	O
metabolites	O
are	O
eliminated	O
primarily	O
by	O
the	O
Kidney	B-D007668

Patients	B-D010361
with	O
reduced	O
Creatinine	B-D003404

SPRIX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

In	O
Patients	B-D010361

Decreased	O
intravascular	O
volume	O
such	O
as	O
when	O
oral	O
intake	O
is	O
poor	O
increases	O
the	O
Risk	B-D012306

Therefore,	O
Patients	B-D010361

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Use	O
SPRIX	O
with	O
caution	O
in	O
Patients	B-D010361

Assess	O
the	O
Risk	B-D012306

Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

5.5	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

SPRIX	O
should	O
be	O
discontinued	O
immediately	O
in	O
Patients	B-D010361

SPRIX	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.6	O
Cardiovascular	O
Effects	O
Cardiovascular	O
(CV)	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Hypertension	B-D006973
NSAIDs	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
Thiazides	B-D049971

Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention,	O
Edema	B-D004487

Therefore,	O
only	O
use	O
SPRIX	O
very	O
cautiously	O
in	O
Patients	B-D010361

5.7	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Ketorolac	B-D020910

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

5.8	O
Pregnancy	B-D011247
Starting	O
at	O
30	O
weeks	O
gestation,	O
SPRIX	O
can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
due	O
to	O
an	O
increased	O
Risk	B-D012306

If	O
SPRIX	O
is	O
used	O
at	O
or	O
after	O
30	O
weeks	O
gestation,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
a	O
Fetus	B-D005333

5.9	O
Hepatic	O
Effects	O
Use	O
SPRIX	O
with	O
caution	O
in	O
Patients	B-D010361

Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

Evaluate	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.10	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
SPRIX	O
in	O
reducing	O
Inflammation	B-D007249

5.11	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
SPRIX	O
with	O
the	O
Eye	B-D005123

If	O
Eye	B-D005123

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Gastrointestinal	O
effects	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hemorrhage	B-D006470
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Renal	O
effects	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Anaphylactoid	O
reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Cardiovascular	O
thrombotic	O
events	O
[see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Congestive	O
Heart	B-D006333
Failure	I-D006333

These	O
reactions	O
were	O
generally	O
mild	O
and	O
transient	O
in	O
Nature	B-D019368

The	O
most	O
common	O
drug-related	O
adverse	O
events	O
Lead	B-D007854

The	O
most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
2%)	O
in	O
Patients	B-D010361

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
American	O
Regent,	O
Inc	O

at	O
1-800-734-9236	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Experience	O
from	O
SPRIX	O
Clinical	O
Studies	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
SPRIX	O
in	O
Patients	B-D010361

The	O
studies	O
enrolled	O
828	O
Patients	B-D010361

The	O
Patients	B-D010361

Most	O
Patients	B-D010361

Table	O
1	O

Post-operative	O
Patients	B-D010361
with	O
Adverse	O
Reactions	O
Observed	O
at	O
a	O
rate	O
of	O
2%	O
or	O
more	O
and	O
at	O
least	O
twice	O
the	O
Incidence	B-D015994

SPRIX	O
(N=455)	O
Placebo	O
(N=	O
245)	O
nas	B-C015378

Six	O
of	O
the	O
seven	O
Patients	B-D010361

6.2	O
Adverse	O
Reactions	O
Reported	O
in	O
Clinical	B-D016430
Trial	I-D016430
s	O
with	O
Other	O
Dosage	B-D004304
Forms	I-D004304
of	O
Ketorolac	B-D020910
or	O
Other	O
NSAIDs	O
Adverse	O
reaction	O
rates	O
increase	O
with	O
higher	O
doses	O
of	O
Ketorolac	B-D020910

It	O
is	O
necessary	O
to	O
remain	O
alert	O
for	O
the	O
severe	O
complications	O
of	O
treatment	O
with	O
Ketorolac	B-D020910

These	O
complications	O
can	O
be	O
serious	O
in	O
certain	O
Patients	B-D010361

In	O
Patients	B-D010361

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

GASTROINTESTINAL	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[see	O
Warnings	O
]	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
Fever	B-D005334

This	O
Risk	B-D012306

Etodolac	B-D017308
extended-release	O
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
A	O
total	O
of	O
1552	O
Patients	B-D010361

In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
Incidence	B-D015994

As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
Time	B-D013995

In	O
Patients	B-D010361

Additional	O
NSAID	O
Adverse	O
Experiences	O
Reported	O
Occasionally	O
with	O
NSAIDs	O
or	O
Etodolac	B-D017308
Extended-Release	O
Tablets	B-D013607
Include	O
Body	O
as	O
a	O
whole	O
-	O
allergic	O
reaction,	O
anaphylactic/anaphylactoid	O
reactions	O
(including	O
Shock	B-D012769

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS)	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

at	O
1-866-562-4597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

WARNING:	O
Risk	B-D012306

ADMINISTRATION	O
OF	O
Misoprostol	B-D016595

Uterine	B-D014597
Rupture	I-D014597

THE	O
Risk	B-D012306

Arthrotec	B-C078133

Patients	B-D010361

Arthrotec	B-C078133

In	O
such	O
Patients	B-D010361

is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
Misoprostol	B-D016595

will	O
begin	O
Arthrotec	B-C078133

WARNING:	O
Risk	B-D012306

Arthrotec	B-C078133

ADMINISTRATION	O
OF	O
Misoprostol	B-D016595

Uterine	B-D014597
Rupture	I-D014597

THE	O
Risk	B-D012306

Arthrotec	B-C078133

Patients	B-D010361

Arthrotec	B-C078133

In	O
such	O
Patients	B-D010361

is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
Misoprostol	B-D016595

will	O
begin	O
Arthrotec	B-C078133

Cardiovascular	O
Thrombotic	O
Events	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Arthrotec	B-C078133

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Arthrotec	B-C078133

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Arthrotec	B-C078133

Monitor	O
Patients	B-D010361

Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Arthrotec	B-C078133

If	O
Arthrotec	B-C078133

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Arthrotec	B-C078133

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

These	O
increases	O
were	O
generally	O
transient,	O
and	O
enzyme	O
levels	O
returned	O
to	O
within	O
the	O
normal	O
range	O
upon	O
discontinuation	O
of	O
therapy	O
with	O
Arthrotec	B-C078133

The	O
Misoprostol	B-D016595

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Arthrotec	B-C078133

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Arthrotec	B-C078133

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Arthrotec	B-C078133

If	O
Arthrotec	B-C078133

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Arthrotec	B-C078133

The	O
renal	O
effects	O
of	O
Arthrotec	B-C078133

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Arthrotec	B-C078133

If	O
Arthrotec	B-C078133

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
/misoprostol	O
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Arthrotec	B-C078133

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Arthrotec	B-C078133

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Arthrotec	B-C078133

Advise	O
Pregnant	B-D037841
Women	I-D037841

Verify	O
the	O
Pregnancy	B-D011247

Advise	O
Female	B-D005260

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Arthrotec	B-C078133

NSAIDs,	O
including	O
Arthrotec	B-C078133

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Arthrotec	B-C078133

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
2%	O
from	O
Clinical	B-D016430
Trial	I-D016430

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Adverse	O
reaction	O
information	O
for	O
Arthrotec	B-C078133

Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
Incidence	B-D015994

These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
Patients	B-D010361

For	O
GI	O
Ulcer	B-D014456

GI	O
disorder	O
Arthrotec	B-C078133

Diarrhea	B-D003967
and	O
Abdominal	B-D015746
Pain	I-D015746

Rare	O
instances	O
of	O
profound	O
Diarrhea	B-D003967

Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
Disease	B-D004194

The	O
Incidence	B-D015994

Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
Misoprostol	B-D016595

Postmenopausal	O
Vagina	B-D014621

If	O
it	O
occurs,	O
diagnostic	O
Work	B-D014937

Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
Safety	B-D012449

Other	O
adverse	O
experiences	O
reported	O
occasionally	O
with	O
Arthrotec	B-C078133

Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Digestive:	O
Anorexia	B-D000855

Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional:	O
Alanine	B-D000409

Musculoskeletal	B-D009141
System	I-D009141

Psychiatric:	O
Anxiety	B-D001007

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505

Special	O
senses:	O
Taste	B-D013649

Renal	O
and	O
urinary	O
disorders:	O
Dysuria	B-D053159

Vision:	O
Diplopia	B-D004172

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
whole:	O
Death	B-D003643

Cardiovascular	B-D002319
System	I-D002319

Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Congenital,	O
familial	O
and	O
genetic	O
disorders:	O
birth	O
defects	O

Digestive:	O
Enteritis	B-D004751

Female	B-D005260
reproductive	O
disorders:	O
intermenstrual	O
bleeding,	O
Leukorrhea	B-D007973

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Hypersensitivity	B-D006967
:	O
Angioedema	B-D000799

Liver	B-D008099
and	O
biliary	O
system:	O
abnormal	O
hepatic	O
function,	O
Bilirubin	B-D001663

Male	B-D008297
reproductive	O
disorders:	O
impotence,	O
perineal	O
Pain	B-D010146

Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
Glycosuria	B-D006029

Pregnancy	B-D011247
,	O
puerperium	O
and	O
perinatal	O
conditions:	O
abnormal	O
Uterine	B-D014590
Contraction	I-D014590

Psychiatric:	O
Confusion	B-D003221

Reproductive	O
system	O
and	O
Breast	B-D001940

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages:	O
acne,	O
bruising,	O
Erythema	B-D004892
Multiforme	I-D004892

Special	O
senses:	O
Hearing	B-D006309

Renal	O
and	O
urinary	O
disorders:	O
Cystitis	B-D003556

Vision:	O
Amblyopia	B-D000550

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

•	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306

Cardiovascular	O
Risk	B-D012306
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

(5.1)	O
•	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
(4,	O
5.1)	O
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs),	O
including	O
Diclofenac	B-D004008

Elderly	O
Patients	B-D010361

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

The	O
lowest	O
possible	O
dose	O
of	O
Diclofenac	B-D004008

(5.1)	O
•NSAIDs,	O
including	O
Diclofenac	B-D004008

Diclofenac	B-D004008
Sodium	B-D012964

(5.2)	O
•Elevation	O
of	O
one	O
or	O
more	O
Liver	B-D008099

Diclofenac	B-D004008
Sodium	B-D012964

(5.3)	O
•Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Diclofenac	B-D004008
Sodium	B-D012964

(5.6)	O
•Hypertension	O
can	O
occur	O
with	O
NSAID	O
treatment	O

Blood	B-D001794
Pressure	I-D001794

(5.4)	O
•Fluid	O
retention	O
and	O
Edema	B-D004487

Diclofenac	B-D004008
Sodium	B-D012964

(5.5)	O
•Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

(5.7)	O
•NSAIDs	O
can	O
cause	O
serious	O
Skin	B-D012867

Diclofenac	B-D004008
Sodium	B-D012964

(5.8)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.3	O
Hepatic	O
Effects	O
Elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy	O

Borderline	O
elevations	O
(i.e	O

less	O
than	O
3	O
Time	B-D013995

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
Liver	B-D008099

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
Physicians	B-D010820

Caution	O
should	O
be	O
Exercise	B-D015444

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Diclofenac	B-D004008

Blood	B-D001794
Pressure	I-D001794

5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

Diclofenac	B-D004008
Sodium	B-D012964

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

Therefore,	O
treatment	O
with	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

Diclofenac	B-D004008
Sodium	B-D012964

Diclofenac	B-D004008
Sodium	B-D012964

5.9	O
Pregnancy	B-D011247
As	O
with	O
other	O
NSAIDs,	O
Diclofenac	B-D004008

5.10	O
Corticosteroid	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.12	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
Blood	B-D001769

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Unlike	O
Aspirin	B-D001241

Patients	B-D010361
treated	O
with	O
Diclofenac	B-D004008

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
Art	B-D001154

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008

5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
Diclofenac	B-D004008

Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
Eye	B-D005123

5.16	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
Patients	B-D010361

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sand	B-D000080463
oz	O
Inc	O

at	O
1-800-398-5876	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Of	O
these,	O
513	O
Patients	B-D010361

Additionally,	O
583	O
Patients	B-D010361

Of	O
these,	O
355	O
Patients	B-D010361

Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
Safety	B-D012449

Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
Patients	B-D010361

These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>1%	O
of	O
treated	O
Patients	B-D010361

Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported	O

Application	O
site	O
Dermatitis	B-D003872

Table	O
1:	O
Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
Patients	B-D010361
)	O
–	O
Short-term	O
Controlled	O
Trials	O
Adverse	O
Reaction†	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
N=913	O
Placebo	O
(vehicle)	O
N=876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
Dermatitis	B-D003872

In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
Patients	B-D010361

Application	O
site	O
reactions,	O
including	O
application	O
site	O
Dermatitis	B-D003872

Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
Safety	B-D012449

In	O
this	O
study,	O
where	O
Patients	B-D010361

Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
Patients	B-D010361

The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
Dermatitis	B-D003872

TAMPER-EVIDENT	O
BOTTLE	O
DO	O
NOT	O
USE	O
IF	O
INNER	O
FOIL	O
SEAL	O
IMPRINTED	O
WITH	O
“SEALED	O
for	O
YOUR	O
PROTECTION”IS	O
BROKEN	O
OR	O
MISSING	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
•	O
Celecoxib	B-D000068579
Capsules	B-D002214

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
•	O
Celecoxib	B-D000068579
Capsules	B-D002214

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

•	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

Celecoxib	B-D000068579
Capsules	B-D002214

•	O
Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
Celecoxib	B-D000068579

•	O
New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

•	O
Fluid	O
retention	O
and	O
Edema	B-D004487

Celecoxib	B-D000068579
Capsules	B-D002214

•	O
Renal	O
papillary	O
Necrosis	B-D009336

Use	O
Celecoxib	B-D000068579

•	O
Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
Celecoxib	B-D000068579

•	O
Serious	O
Skin	B-D012867

Discontinue	O
Celecoxib	B-D000068579

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Celecoxib	B-D000068579
Capsules	B-D002214

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

Therefore,	O
treatment	O
with	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

Celecoxib	B-D000068579
Capsules	B-D002214

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

Celecoxib	B-D000068579
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
Capsules	B-D002214

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
Celecoxib	B-D000068579

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Watson	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
Placebo	O
NAP	O
DCF	O
IBU	O
N=4146	O
N=1864	O
N=1366	O
N=387	O
N=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
-	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
>5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
Cardiovascular	O
Risk	B-D012306
•	O
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
•	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5.WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

•Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

•Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
Celecoxib	B-D000068579

•New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

•Fluid	O
retention	O
and	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

•Renal	O
papillary	O
Necrosis	B-D009336

Use	O
Celecoxib	B-D000068579

•Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
Celecoxib	B-D000068579

•Serious	O
Skin	B-D012867

Discontinue	O
Celecoxib	B-D000068579

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

Therefore,	O
treatment	O
with	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9Pregnancy	O
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

Celecoxib	B-D000068579
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
Celecoxib	B-D000068579

6.ADVERSE	O
REACTIONS	O
Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Actavis	O
at	O
1-800-272-5525	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
Cardiovascular	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
CELEBREX	O
immediately	O
if	O
abnormal	O
Liver	B-D008099

New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

Fluid	O
retention	O
and	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Renal	O
papillary	O
Necrosis	B-D009336

Use	O
CELEBREX	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
Heart	B-D006333
Failure	I-D006333

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
CELEBREX	O
in	O
Patients	B-D010361

Serious	O
Skin	B-D012867

Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
Skin	B-D012867

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
CELEBREX	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
CELEBREX,	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
CELEBREX,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
Ulcer	B-D014456

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
CELEBREX	O
is	O
not	O
recommended	O
in	O
these	O
Patients	B-D010361

If	O
CELEBREX	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

CELEBREX	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
CELEBREX	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

CELEBREX	O
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
CELEBREX	O
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
Inflammation	B-D007249

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
CELEBREX	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
Risk	B-D012306

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
CELEBREX-treated	O
Patients	B-D010361

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
CELEBREX	O
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
Dyspepsia	B-D004415

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
Diclofenac	B-D004008

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
Dysmenorrhea	B-D004412

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

2.Etodolac	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
1.NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1,000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Voltaren®	O
Gel	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy	O

Borderline	O
elevations	O
(i.e	O

less	O
than	O
3	O
Time	B-D013995

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
Liver	B-D008099

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/orAST	O
occurred	O
in	O
about	O
4%	O
of	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
Physicians	B-D010820

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Caution	O
should	O
be	O
Exercise	B-D015444

(5.3)	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

(5.6)	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

Voltaren®	O
Gel	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

(5.7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.3	O
Hepatic	O
Effects	O
Elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy	O

Borderline	O
elevations	O
(i.e	O

less	O
than	O
3	O
Time	B-D013995

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
Liver	B-D008099

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/orAST	O
occurred	O
in	O
about	O
4%	O
of	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
Physicians	B-D010820

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Caution	O
should	O
be	O
Exercise	B-D015444

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Voltaren®	O
Gel,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Voltaren®	O
Gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Blood	B-D001794
Pressure	I-D001794

5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

Voltaren®	O
Gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Voltaren®	O
Gel	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
Voltaren®	O
Gel	O
is	O
not	O
recommended	O
in	O
Patients	B-D010361

If	O
Voltaren®	O
Gel	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

Voltaren®	O
Gel	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Voltaren®	O
Gel,	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

Voltaren®	O
Gel	O
should	O
not	O
be	O
applied	O
to	O
open	O
Skin	B-D012867

Voltaren®	O
Gel	O
should	O
not	O
be	O
allowed	O
to	O
come	O
into	O
contact	O
with	O
the	O
Eye	B-D005123

The	O
effect	O
of	O
Voltaren®	O
Gel	O
under	O
Occlusive	B-D009779
Dressings	I-D009779

5.9	O
Pregnancy	B-D011247
As	O
with	O
other	O
NSAIDs,	O
Voltaren®	O
Gel	O
should	O
be	O
avoided	O
in	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
treatment	O
Voltaren®	O
Gel	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.12	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
Blood	B-D001769

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
including	O
Voltaren®	O
Gel,	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

NSAIDs	O
inhibit	O
Platelet	B-D010974
Aggregation	I-D010974

Unlike	O
Aspirin	B-D001241

Patients	B-D010361
treated	O
with	O
Voltaren®	O
Gel	O
who	O
may	O
be	O
adversely	O
Affect	B-D000339

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
Art	B-D001154

The	O
potential	O
effects	O
of	O
Voltaren®	O
Gel	O
on	O
Skin	B-D012867

5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
Voltaren®	O
Gel	O
with	O
Eye	B-D005123

Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
Eye	B-D005123

5.16	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

6	O
ADVERSE	O
REACTIONS	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
development,	O
913	O
Patients	B-D010361

Of	O
these,	O
513	O
Patients	B-D010361

Additionally,	O
583	O
Patients	B-D010361

Of	O
these,	O
355	O
Patients	B-D010361

Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
Safety	B-D012449

Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
Patients	B-D010361

These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
1%	O
of	O
treated	O
Patients	B-D010361

Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported	O

Application	O
site	O
Dermatitis	B-D003872

Table	O
1:	O
Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥	O
1%	O
Voltaren®	O
Gel	O
Patients	B-D010361
)	O
–	O
Short-term	O
Controlled	O
Trials	O
Adverse	O
Reaction	O
†	O
Voltaren	O
®	O
Gel	O
N	O
=	O
913	O
Placebo	O
(vehicle)	O
N	O
=	O
876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
Dermatitis	B-D003872

In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
Patients	B-D010361

Application	O
site	O
reactions,	O
including	O
application	O
site	O
Dermatitis	B-D003872

Long-term	O
Open-label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
Safety	B-D012449

In	O
this	O
study,	O
where	O
Patients	B-D010361

Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
Patients	B-D010361

The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
Dermatitis	B-D003872

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

(	O
5.1)	O
NALFON	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O

NALFON	O
®	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

If	O
NALFON	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
NALFON,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
Inflammation	B-D007249

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
NALFON	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
NALFON,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Fenoprofen	B-D005279

Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

If	O
NALFON	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
NALFON	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
NALFON	O
in	O
Patients	B-D010361

If	O
NALFON	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Fenoprofen	B-D005279
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
NALFON	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
fenoprop	B-C009264
fen,	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

NALFON	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Fenoprofen	B-D005279
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
NALFON,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
NALFON	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
NALFON,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
NALFON	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Ocular	O
Effects	O
Studies	O
to	O
date	O
have	O
not	O
shown	O
changes	O
in	O
the	O
Eye	B-D005123

However,	O
adverse	O
ocular	O
effects	O
have	O
been	O
observed	O
with	O
other	O
anti-inflammatory	O
drugs	O

Eye	B-D005123
examinations,	O
therefore,	O
should	O
be	O
performed	O
if	O
visual	O
disturbances	O
occur	O
in	O
Patients	B-D010361

5.15	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Caution	O
should	O
be	O
Exercise	B-D015444

5.16	O
Impact	O
on	O
Hearing	B-D006309
Since	O
the	O
Safety	B-D012449

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
5%)	O
are	O
Dyspepsia	B-D004415
,	O
Headache	B-D006261

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Xspire	O
Pharma	O
at	O
1-601-990-9497	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
studies	O
for	O
Rheum	B-D012250

These	O
encompass	O
Observation	B-D019370

For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
Patients	B-D010361

During	O
short-term	O
studies	O
for	O
Analgesia	B-D000698

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
>1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—	O
During	O
Clinical	B-D016430
Trial	I-D016430

In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
Dyspepsia	B-D004415

2.3%	O
placebo),	O
Nausea	B-D009325

7.1%),	O
Constipation	B-D003248

1.5%),	O
Vomiting	B-D014839

1.9%),	O
Abdominal	B-D015746
Pain	I-D015746

1.1%),	O
and	O
Diarrhea	B-D003967

4.1%)	O

The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
Patients	B-D010361

Nervous	B-D009420
System	I-D009420
—	O
The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
Headache	B-D006261

7.5%)	O
and	O
somnolence	O
(8.5%	O
vs	O

6.4%)	O

Dizziness	B-D004244
(6.5%	O
vs	O

5.6%),	O
Tremor	B-D014202

0.4%),	O
and	O
Confusion	B-D003221

none)	O
were	O
noted	O
less	O
frequently	O

Nalfon	O
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Skin	B-D012867
and	O
Appendages—	O
Increased	O
Sweating	B-D013546

0.4%),	O
Pruritus	B-D011537

0.8%),	O
and	O
rash	O
(3.7%	O
vs	O

0.4%)	O
were	O
reported	O

Nalfon	O
was	O
discontinued	O
in	O
about	O
1%	O
of	O
Patients	B-D010361

Special	O
Senses	O
—	O
Tinnitus	B-D014012
(4.5%	O
vs	O

0.4%),	O
blurred	O
vision	O
(2.2%	O
vs	O

none),	O
and	O
decreased	O
Hearing	B-D006309

none)	O
were	O
reported	O

Nalfon	O
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Cardiovascular	O
—	O
Palpitations	O
(2.5%	O
vs	O

0.4%)	O

Nalfon	O
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
Patients	B-D010361

Miscellaneous	O
—	O
Nervousness	O
(5.7%	O
vs	O

1.5%),	O
Asthenia	B-D001247

0.4%),	O
peripheral	O
Edema	B-D004487

0.4%),	O
Dyspnea	B-D004417

none),	O
Fatigue	B-D005221

1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs	O

5.6%),	O
and	O
nas	B-C015378
opharyngitis	O
(1.2%	O
vs	O

none)	O

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—Gastritis,	O
Peptic	B-D010437
Ulcer	I-D010437

Increases	O
in	O
Alkaline	B-D000469
Phosphatase	I-D000469

Cardiovascular—Atrial	O
fibrillation,	O
Pulmonary	B-D011654
Edema	I-D011654

Genitourinary	O
Tract—Renal	O
failure,	O
Dysuria	B-D053159

Hypersensitivity	B-D006967
—Angioedema	O
(angioneurotic	O
Edema	B-D004487

Hematologic—Purpura,	O
bruising,	O
Hemorrhage	B-D006470

Nervous	B-D009420
System	I-D009420
—Depression,	O
disorientation,	O
Seizures	B-D012640

Special	O
Senses—Burning	O
Tongue	B-D014059

Skin	B-D012867
and	O
Appendages—Exfoliative	O
Dermatitis	B-D003872

Miscellaneous—Anaphylaxis,	O
Urticaria	B-D014581

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

WARNING	O
CARDIOVASCULAR	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

•Diclofenac	O
Potassium	B-D011188

GASTROINTESTINAL	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug	O

ADVERSE	O
REACTIONS	O
In	O
718	O
Patients	B-D010361

In	O
a	O
6	O
month,	O
double-blind	O
trial	O
comparing	O
Diclofenac	B-D004008

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

(5.1)	O
Avoid	O
use	O
in	O
Patients	B-D010361

(5.2,	O
5.3)	O
Interrupt	O
Aspirin	B-D001241

(5.6,	O
7.1)	O
5.1	O
Risk	B-D012306
of	O
Bleeding	O
Aspirin	B-D001241
and	O
extended-release	O
Dipyridamole	B-D004176

Risk	B-D012307
Factors	I-D012307

Intracranial	O
Hemorrhage	B-D006470
In	O
Europe	B-D005060
an	O
Stroke	B-D020521
Prevention	O
Study-2	O
(ESPS2),	O
the	O
annualized	O
event	O
rate	O
for	O
intracranial	O
Hemorrhage	B-D006470

Gastrointestinal	O
(GI)	O
Side	O
Effects	O
GI	O
side	O
effects	O
include	O
Stomach	B-D013270

Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
Dyspepsia	B-D004415

Inform	O
Patients	B-D010361

In	O
ESPS2,	O
the	O
annualized	O
event	O
rate	O
for	O
gastrointestinal	O
bleeding	O
was	O
2.97%/year	O
in	O
the	O
Aspirin	B-D001241

Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
Avoid	O
using	O
Aspirin	B-D001241

Alcohol	O
Warning	O
Because	O
Aspirin	B-D001241

5.2	O
Renal	O
Failure	O
Avoid	O
Aspirin	B-D001241

5.3	O
Hepatic	B-D048550
Insufficiency	I-D048550
Elevations	O
of	O
hepatic	O
Enzymes	B-D004798

5.4	O
Coronary	B-D003324
Artery	I-D003324
Disease	I-D003324
Dipyridamole	B-D004176
has	O
a	O
vasodilatory	O
effect	O

Chest	B-D002637
Pain	I-D002637

For	O
Stroke	B-D020521

5.5	O
Hypotension	B-D007022
Dipyridamole	B-D004176
produces	O
peripheral	O
Vasodilation	B-D014664

5.6	O
Stress	O
TES	B-C004551

Intake	O
of	O
Aspirin	B-D001241

5.7	O
General	O
Aspirin	B-D001241
and	O
extended-release	O
Dipyridamole	B-D004176

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Hypersensitivity	B-D006967
[see	O
Contraindications	B-D000075202
(4.1)]	O
Allergy	O
[see	O
Contraindications	B-D000075202
(4.2)]	O
Risk	B-D012306
of	O
Bleeding	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(>10%	O
and	O
greater	O
than	O
placebo)	O
were	O
Headache	B-D006261

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Amneal	O
Pharmaceuticals	O
at	O
1-877-835-5472	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
efficacy	O
and	O
Safety	B-D012449

ESPS2	O
was	O
a	O
double-blind,	O
placebo-controlled	O
study	O
that	O
evaluated	O
6,602	O
Patients	B-D010361

Patients	B-D010361
were	O
randomized	O
to	O
either	O
Aspirin	B-D001241

This	O
24-month,	O
multicenter,	O
double-blind,	O
randomized	O
study	O
(ESPS2)	O
was	O
conducted	O
to	O
compare	O
the	O
efficacy	O
and	O
Safety	B-D012449

The	O
study	O
was	O
conducted	O
in	O
a	O
total	O
of	O
6,602	O
Male	B-D008297

Table	O
1	O
presents	O
the	O
annualized	O
event	O
rate	O
for	O
adverse	O
events	O
that	O
occurred	O
in	O
1%/year	O
or	O
more	O
of	O
Patients	B-D010361

There	O
is	O
no	O
clear	O
benefit	O
of	O
the	O
Dipyridamole	B-D004176

Table	O
1:	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
in	O
ESPS2	O
a	O
Individual	O
Treatment	O
Group	O
Body	O
System/Preferred	O
Term	O
Aspirin	B-D001241
and	O
Extended-release	O
Dipyridamole	B-D004176
ER-DP	O
Alone	O
ASA	O
Alone	O
Placebo	O
n	O
(%/year)b	O
n	O
(%/year)b	O
n	O
(%/year)b	O
n	O
(%/year)b	O
1,650	O
1,654	O
1,649	O
1,649	O
Total	O
Number	O
of	O
Patients	B-D010361
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Disorders	O
Headache	B-D006261
647	O
(28.25)	O
634	O
(27.91)	O
558	O
(22.10)	O
543	O
(22.29)	O
Gastrointestinal	O
System	O
Disorders	O
Dyspepsia	B-D004415
303	O
(13.23)	O
288	O
(12.68)	O
299	O
(11.84)	O
275	O
(11.29)	O
Abdominal	B-D015746
Pain	I-D015746
289	O
(12.62)	O
255	O
(11.22)	O
262	O
(10.38)	O
239	O
(9.81)	O
Nausea	B-D009325
264	O
(11.53)	O
254	O
(11.18)	O
210	O
(8.32)	O
232	O
(9.53)	O
Diarrhea	B-D003967
210	O
(9.17)	O
257	O
(11.31)	O
112	O
(4.44)	O
161	O
(6.61)	O
Vomiting	B-D014839
138	O
(6.03)	O
129	O
(5.68)	O
101	O
(4.00)	O
118	O
(4.84)	O
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders	O
Hemorrhage	B-D006470
NOS	O
52	O
(2.27)	O
24	O
(1.06)	O
46	O
(1.82)	O
24	O
(0.99)	O
aReported	O
by	O
≥1%/year	O
of	O
Patients	B-D010361

bAnnual	O
event	O
rate	O
per	O
100	O
pt-years	O
=	O
100*	O
number	O
of	O
subjects	O
with	O
event/subject-years	O

Subject-years	O
is	O
defined	O
as	O
cumulative	O
number	O
of	O
days	O
on	O
treatment	O
divided	O
by	O
365.25	O

Note:	O
ER-DP	O
=	O
extended-release	O
Dipyridamole	B-D004176

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O

NOS	O
=	O
not	O
otherwise	O
specified	O

Discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
ESPS2	O
was	O
25%	O
for	O
Aspirin	B-D001241

Table	O
2:	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
that	O
Led	O
to	O
the	O
Discontinuation	O
of	O
Treatmenta	O
Treatment	O
Groups	O
Aspirin	B-D001241
and	O
Extended-release	O
Dipyridamole	B-D004176
ER-DP	O
ASA	O
Placebo	O
n	O
(%/year)b	O
n	O
(%/year)b	O
n	O
(%/year)b	O
n	O
(%/year)b	O
Total	O
Number	O
of	O
Patients	B-D010361
1,650	O
1,654	O
1,649	O
1,649	O
Patients	B-D010361
with	O
at	O
least	O
one	O
Adverse	O
Event	O
that	O
led	O
to	O
treatment	O
discontinuation	O
417	O
(18.21)	O
419	O
(18.44)	O
318	O
(12.59)	O
352	O
(14.45)	O
Headache	B-D006261
165	O
(7.20)	O
166	O
(7.31)	O
57	O
(2.26)	O
69	O
(2.83)	O
Nausea	B-D009325
91	O
(3.97)	O
95	O
(4.18)	O
51	O
(2.02)	O
53	O
(2.18)	O
Abdominal	B-D015746
Pain	I-D015746
74	O
(3.23)	O
64	O
(2.82)	O
56	O
(2.22)	O
52	O
(2.13)	O
Vomiting	B-D014839
53	O
(2.31)	O
52	O
(2.29)	O
28	O
(1.11)	O
24	O
(0.99)	O
aReported	O
by	O
≥1%/year	O
of	O
Patients	B-D010361

bAnnual	O
event	O
rate	O
per	O
100	O
pt-years	O
=	O
100*	O
number	O
of	O
subjects	O
with	O
event/subject-years	O

Subject-years	O
is	O
defined	O
as	O
cumulative	O
number	O
of	O
days	O
on	O
treatment	O
divided	O
by	O
365.25	O

Note:	O
ER-DP	O
=	O
extended-release	O
Dipyridamole	B-D004176

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O

Headache	B-D006261
was	O
most	O
notable	O
in	O
the	O
first	O
month	O
of	O
treatment	O

6.2	O
Post-Marketing	O
Experience	O
The	O
following	O
is	O
a	O
list	O
of	O
additional	O
adverse	O
reactions	O
that	O
have	O
been	O
reported	O
either	O
in	O
the	O
Literature	B-D008091

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Decisions	O
to	O
include	O
these	O
reactions	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
reaction,	O
(2)	O
frequency	O
of	O
reporting,	O
or	O
(3)	O
strength	O
of	O
causal	O
connection	O
to	O
Aspirin	B-D001241

Body	O
as	O
a	O
Whole:	O
Hypothermia	B-D007035
,	O
Chest	B-D002637
Pain	I-D002637

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
Diclofenac	B-D004008
Sodium	B-D012964

(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
Blood	B-D001794
Pressure	I-D001794

(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
Diclofenac	B-D004008

(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
use	O
of	O
Diclofenac	B-D004008

(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Diclofenac	B-D004008
Sodium	B-D012964

Monitor	O
Patients	B-D010361

(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
Diclofenac	B-D004008

(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
Pregnant	B-D037841
Women	I-D037841

(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

(5.11,	O
7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

more	O
than	O
3	O
Time	B-D013995

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactoid	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Diclofenac	B-D004008

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Diclofenac	B-D004008

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
Art	B-D001154

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008

5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
Diclofenac	B-D004008

Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
Eye	B-D005123

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
Hemorrhage	B-D006470

Do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
2%	O
of	O
Patients	B-D010361

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Amneal	O
Pharmaceuticals	O
at	O
1-877-835-5472	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
development,	O
913	O
Patients	B-D010361

Of	O
these,	O
513	O
Patients	B-D010361

Additionally,	O
583	O
Patients	B-D010361

Of	O
these,	O
355	O
Patients	B-D010361

Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
Safety	B-D012449

Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
Patients	B-D010361

These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
1%	O
of	O
treated	O
Patients	B-D010361

Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported	O

Application	O
site	O
Dermatitis	B-D003872

Table	O
1	O

Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
Gel	O
Patients	B-D010361
)-Short-term	O
Controlled	O
Trials	O
Adverse	O
Reaction	O
†	O
Diclofenac	B-D004008
Sodium	B-D012964

In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
Patients	B-D010361

Application	O
site	O
reactions,	O
including	O
application	O
site	O
Dermatitis	B-D003872

Long-Term	O
Open-Label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
Safety	B-D012449

In	O
this	O
study,	O
where	O
Patients	B-D010361

Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
Patients	B-D010361

The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
Dermatitis	B-D003872

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

(	O
5.1)	O
Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O

Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279

If	O
Fenoprofen	B-D005279

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Fenoprofen	B-D005279

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Fenoprofen	B-D005279

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Fenoprofen	B-D005279

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Fenoprofen	B-D005279

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279

If	O
Fenoprofen	B-D005279

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Fenoprofen	B-D005279

The	O
renal	O
effects	O
of	O
Fenoprofen	B-D005279

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279

If	O
Fenoprofen	B-D005279

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Fenoprofen	B-D005279
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Fenoprofen	B-D005279

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
fenoprop	B-C009264
fen,	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Fenoprofen	B-D005279
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Fenoprofen	B-D005279

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Fenoprofen	B-D005279

NSAIDs,	O
including	O
Fenoprofen	B-D005279

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Fenoprofen	B-D005279

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Ocular	O
Effects	O
Studies	O
to	O
date	O
have	O
not	O
shown	O
changes	O
in	O
the	O
Eye	B-D005123

However,	O
adverse	O
ocular	O
effects	O
have	O
been	O
observed	O
with	O
other	O
anti-inflammatory	O
drugs	O

Eye	B-D005123
examinations,	O
therefore,	O
should	O
be	O
performed	O
if	O
visual	O
disturbances	O
occur	O
in	O
Patients	B-D010361

5.15	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Caution	O
should	O
be	O
Exercise	B-D015444

5.16	O
Impact	O
on	O
Hearing	B-D006309
Since	O
the	O
Safety	B-D012449

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
5%)	O
are	O
Dyspepsia	B-D004415
,	O
Headache	B-D006261

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Xspire	O
Pharma	O
at	O
1-601-990-9497	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
studies	O
for	O
Rheum	B-D012250

These	O
encompass	O
Observation	B-D019370

For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
Patients	B-D010361

During	O
short-term	O
studies	O
for	O
Analgesia	B-D000698

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
>1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—	O
During	O
Clinical	B-D016430
Trial	I-D016430

In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
Dyspepsia	B-D004415

2.3%	O
placebo),	O
Nausea	B-D009325

7.1%),	O
Constipation	B-D003248

1.5%),	O
Vomiting	B-D014839

1.9%),	O
Abdominal	B-D015746
Pain	I-D015746

1.1%),	O
and	O
Diarrhea	B-D003967

4.1%)	O

The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
Patients	B-D010361

Nervous	B-D009420
System	I-D009420
—	O
The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
Headache	B-D006261

7.5%)	O
and	O
somnolence	O
(8.5%	O
vs	O

6.4%)	O

Dizziness	B-D004244
(6.5%	O
vs	O

5.6%),	O
Tremor	B-D014202

0.4%),	O
and	O
Confusion	B-D003221

none)	O
were	O
noted	O
less	O
frequently	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Skin	B-D012867
and	O
Appendages—	O
Increased	O
Sweating	B-D013546

0.4%),	O
Pruritus	B-D011537

0.8%),	O
and	O
rash	O
(3.7%	O
vs	O

0.4%)	O
were	O
reported	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
about	O
1%	O
of	O
Patients	B-D010361

Special	O
Senses	O
—	O
Tinnitus	B-D014012
(4.5%	O
vs	O

0.4%),	O
blurred	O
vision	O
(2.2%	O
vs	O

none),	O
and	O
decreased	O
Hearing	B-D006309

none)	O
were	O
reported	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Cardiovascular	O
—	O
Palpitations	O
(2.5%	O
vs	O

0.4%)	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
Patients	B-D010361

Miscellaneous	O
—	O
Nervousness	O
(5.7%	O
vs	O

1.5%),	O
Asthenia	B-D001247

0.4%),	O
peripheral	O
Edema	B-D004487

0.4%),	O
Dyspnea	B-D004417

none),	O
Fatigue	B-D005221

1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs	O

5.6%),	O
and	O
nas	B-C015378
opharyngitis	O
(1.2%	O
vs	O

none)	O

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—Gastritis,	O
Peptic	B-D010437
Ulcer	I-D010437

Increases	O
in	O
Alkaline	B-D000469
Phosphatase	I-D000469

Cardiovascular—Atrial	O
fibrillation,	O
Pulmonary	B-D011654
Edema	I-D011654

Genitourinary	O
Tract—Renal	O
failure,	O
Dysuria	B-D053159

Hypersensitivity	B-D006967
—Angioedema	O
(angioneurotic	O
Edema	B-D004487

Hematologic—Purpura,	O
bruising,	O
Hemorrhage	B-D006470

Nervous	B-D009420
System	I-D009420
—Depression,	O
disorientation,	O
Seizures	B-D012640

Special	O
Senses—Burning	O
Tongue	B-D014059

Skin	B-D012867
and	O
Appendages—Exfoliative	O
Dermatitis	B-D003872

Miscellaneous—Anaphylaxis,	O
Urticaria	B-D014581

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
Diclofenac	B-D004008
Sodium	B-D012964

(4	O
,	O
5.1)	O
NSAIDs,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964

Monitor	O
Patients	B-D010361

(5.14)	O
Eye	B-D005123
Contact:	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008

(5.15)	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs:	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDS	O

(5.16)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
was	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Diclofenac	B-D004008

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

Do	O
not	O
apply	O
Diclofenac	B-D004008

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

The	O
effects	O
of	O
Diclofenac	B-D004008

There	O
was	O
no	O
significant	O
change	O
in	O
Platelet	B-D010974
Aggregation	I-D010974

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Sun	O
Exposure	O
Instruct	O
Patients	B-D010361

The	O
potential	O
effects	O
of	O
Diclofenac	B-D004008

5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
Diclofenac	B-D004008

Advise	O
Patients	B-D010361

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
Diclofenac	B-D004008

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
Diclofenac	B-D004008

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
with	O
Diclofenac	B-D004008

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
Diclofenac	B-D004008

The	O
Population	B-D011153

The	O
most	O
common	O
adverse	O
events	O
with	O
Diclofenac	B-D004008

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
Site	O
Reactions	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
Patients	B-D010361

Application	O
site	O
reactions	O
were	O
Character	B-D002605

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
Skin	B-D012867

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
Dermatitis	B-D003872

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
Safety	B-D012449

Adverse	O
Events	O
Common	O
to	O
the	O
NSAID	O
Class	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
Diclofenac	B-D004008

The	O
combination	O
of	O
Diclofenac	B-D004008

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
Creatinine	B-D003404

7%),	O
Urea	B-D014508

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
Liver	B-D008099

Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥	O
1%	O
of	O
Patients	B-D010361

Treatment	O
Group:	O
Diclofenac	B-D004008
Sodium	B-D012964
Topical	O
SolutionN=911	O
Topical	O
PlaceboN=332	O
Adverse	O
Reaction	O
†	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
†Preferred	O
Term	O
according	O
to	O
COSTART	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-U.S	O

postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
Diclofenac	B-D004008

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.7)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
Cardiovascular	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.7)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
CELEBREX	O
immediately	O
if	O
abnormal	O
Liver	B-D008099

New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

Fluid	O
retention	O
and	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Renal	O
papillary	O
Necrosis	B-D009336

Use	O
CELEBREX	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
Heart	B-D006333
Failure	I-D006333

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
CELEBREX	O
in	O
Patients	B-D010361

Serious	O
Skin	B-D012867

Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
Skin	B-D012867

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
CELEBREX	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
CELEBREX,	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
CELEBREX,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
Ulcer	B-D014456

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
CELEBREX	O
is	O
not	O
recommended	O
in	O
these	O
Patients	B-D010361

If	O
CELEBREX	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

CELEBREX	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
CELEBREX	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

CELEBREX	O
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
CELEBREX	O
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
GI	O
Cancer	O
in	O
Familial	O
Adenoma	B-D000236
tous	O
Polyposis	O
Treatment	O
with	O
CELEBREX	O
in	O
FAP	O
has	O
not	O
been	O
shown	O
to	O
reduce	O
the	O
Risk	B-D012306

Therefore,	O
the	O
usual	O
care	O
of	O
FAP	O
Patients	B-D010361

In	O
particular,	O
the	O
frequency	O
of	O
routine	O
endoscopic	O
surveillance	O
should	O
not	O
be	O
decreased	O
and	O
prophylactic	O
Colectomy	B-D003082

5.16	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
Inflammation	B-D007249

5.17	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
CELEBREX	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
Risk	B-D012306

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
CELEBREX-treated	O
Patients	B-D010361

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
CELEBREX	O
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
Dyspepsia	B-D004415

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
Diclofenac	B-D004008

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
Dysmenorrhea	B-D004412

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

Adverse	O
Events	O
from	O
the	O
Familial	O
Adenoma	B-D000236
tous	O
Polyposis	O
Study:	O
The	O
adverse	O
event	O
Profil	B-C546490

Intestinal	O
anastomotic	O
Ulcer	B-D014456

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.7)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

ADVERSE	O
REACTIONS	O
Of	O
the	O
423	O
Patients	B-D010361

Eighty-seven	O
percent	O
(87%)	O
of	O
the	O
Diclofenac	B-D004008

The	O
majority	O
of	O
these	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
upon	O
discontinuation	O
of	O
therapy	O

Of	O
the	O
211	O
Patients	B-D010361

Application	O
site	O
reactions	O
(ASRs)	O
were	O
the	O
most	O
frequent	O
AEs	O
in	O
both	O
Diclofenac	B-D004008

Of	O
note,	O
four	O
reactions,	O
contact	O
Dermatitis	B-D003872

Eighteen	O
percent	O
of	O
Diclofenac	B-D004008

These	O
discontinuations	O
were	O
mainly	O
due	O
to	O
Skin	B-D012867

Table	O
1	O
below	O
presents	O
the	O
AEs	O
reported	O
at	O
an	O
Incidence	B-D015994

Table	O
1	O

Adverse	O
Events	O
Reported	O
(>1%	O
in	O
Any	O
Treatment	O
Group)	O
During	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
Phase	O
3	O
Clinical	B-D016430
Trial	I-D016430
s	O
Incidence	B-D015994
s	O
for	O
60-Day	O
and	O
90-Day	O
Treatments	O
60-day	O
Treatment	O
90-day	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
(%)	O
Vehicle	O
(%)	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
(%)	O
Vehicle	O
(%)	O
N=48	O
N=49	O
N=114	O
N=114	O
BODY	O
AS	O
A	O
WHOLE	O
21	O
20	O
20	O
18	O
Abdominal	B-D015746
Pain	I-D015746
2	O
0	O
1	O
0	O
Accidental	O
Injury	O
0	O
0	O
4	O
2	O
Allergic	O
Reaction	O
0	O
0	O
1	O
3	O
Asthenia	B-D001247
0	O
0	O
2	O
0	O
Back	B-D001416
Pain	I-D001416
4	O
0	O
2	O
2	O
Chest	B-D002637
Pain	I-D002637
2	O
0	O
1	O
0	O
Chills	B-D023341
0	O
2	O
0	O
0	O
Flu	O
Syndrome	B-D013577
10	O
6	O
1	O
4	O
Headache	B-D006261
0	O
6	O
7	O
6	O
Infection	O
4	O
6	O
4	O
5	O
Neck	B-D019547
Pain	I-D019547
0	O
0	O
2	O
0	O
Pain	B-D010146
2	O
0	O
2	O
2	O
Cardiovascular	B-D002319
System	I-D002319

Adverse	O
Reactions	O
Reported	O
for	O
Oral	O
Diclofenac	B-D004008
Dosage	O
Form	B-D020478
(not	O
topical	O
Diclofenac	B-D004008

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

Cardiovascular:	O
Hypertension	B-D006973

Digestive:	O
Diarrhea	B-D003967

Hemic	O
and	O
Lymph	B-D008196
atic:	O
hemoglobin	B-C032001
D	I-C032001

Metabolic	O
and	O
Nutritional	O
Disorders:	O
Azotemia	B-D053099

Nervous	B-D009420
System	I-D009420
:	O
Dizziness	B-D004244

Respiratory:	O
Epistaxis	B-D004844

Skin	B-D012867
and	O
Appendages:	O
rash*,	O
Pruritus	B-D011537

Special	O
Senses:	O
Tinnitus	B-D014012

Urogenital:	O
Nephrotic	B-D009404
Syndrome	I-D009404

Cardiovascular	O
Risk	B-D012306
•NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS.)	O
•Diclofenac	O
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
Appetite	B-D001066

BOXED	O
WARNING	O
SECTION	O
WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

ADVERSE	O
REACTIONS	O
Of	O
the	O
423	O
Patients	B-D010361

Eighty-seven	O
percent	O
(87%)	O
of	O
the	O
Diclofenac	B-D004008

The	O
majority	O
of	O
these	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
upon	O
discontinuation	O
of	O
therapy	O

Of	O
the	O
211	O
Patients	B-D010361

Application	O
site	O
reactions	O
(ASRs)	O
were	O
the	O
most	O
frequent	O
AEs	O
in	O
both	O
Diclofenac	B-D004008

Of	O
note,	O
four	O
reactions,	O
contact	O
Dermatitis	B-D003872

Eighteen	O
percent	O
of	O
Diclofenac	B-D004008

These	O
discontinuations	O
were	O
mainly	O
due	O
to	O
Skin	B-D012867

Table	O
1	O
below	O
presents	O
the	O
AEs	O
reported	O
at	O
an	O
Incidence	B-D015994

Table	O
1	O

Adverse	O
Events	O
Reported	O
(>1%	O
in	O
Any	O
Treatment	O
Group)	O
During	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
Phase	O
3	O
Clinical	B-D016430
Trial	I-D016430
s	O
Incidence	B-D015994
s	O
for	O
60-Day	O
and	O
90-Day	O
Treatments	O
60-day	O
Treatment	O
90-day	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
(%)N=48	O
Gel	O
Vehicle	O
(%)N=49	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
(%)N=114	O
Gel	O
Vehicle	O
(%)N=114	O
BODY	O
AS	O
A	O
WHOLE	O
21	O
20	O
20	O
18	O
Abdominal	B-D015746
Pain	I-D015746
2	O
0	O
1	O
0	O
Accidental	O
Injury	O
0	O
0	O
4	O
2	O
Allergic	O
Reaction	O
0	O
0	O
1	O
3	O
Asthenia	B-D001247
0	O
0	O
2	O
0	O
Back	B-D001416
Pain	I-D001416
4	O
0	O
2	O
2	O
Chest	B-D002637
Pain	I-D002637
2	O
0	O
1	O
0	O
Chills	B-D023341
0	O
2	O
0	O
0	O
Flu	O
Syndrome	B-D013577
10	O
6	O
1	O
4	O
Headache	B-D006261
0	O
6	O
7	O
6	O
Infection	O
4	O
6	O
4	O
5	O
Neck	B-D019547
Pain	I-D019547
0	O
0	O
2	O
0	O
Pain	B-D010146
2	O
0	O
2	O
2	O
Cardiovascular	B-D002319
System	I-D002319

Adverse	O
Reactions	O
Reported	O
for	O
Oral	O
Diclofenac	B-D004008
Dosage	O
Form	B-D020478
(not	O
topical	O
Diclofenac	B-D004008

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

Cardiovascular:	O
Hypertension	B-D006973

Digestive:	O
Diarrhea	B-D003967

Hemic	O
and	O
Lymph	B-D008196
atic:	O
hemoglobin	B-C032001
D	I-C032001

Metabolic	O
and	O
Nutritional	O
Disorders:	O
Azotemia	B-D053099

Nervous	B-D009420
System	I-D009420
:	O
Dizziness	B-D004244

Respiratory:	O
Epistaxis	B-D004844

Skin	B-D012867
and	O
Appendages:	O
rash*,	O
Pruritus	B-D011537

Special	O
Senses:	O
Tinnitus	B-D014012

Urogenital:	O
Nephrotic	B-D009404
Syndrome	I-D009404

Cardiovascular	O
Thrombotic	O
Events	O
•Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs1)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

•Etodolac	O
Capsules	B-D002214

Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS	O
)	O

1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
nonsteroidal	O
anti-inflammatory	O
drug	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
or	O
Equal	O
to	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

Musculoskeletal	O
-	O
Arthralgia	B-D018771
	O

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Musculoskeletal	O
-	O
Muscle	O
Pain	B-D010146

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Urogenital	B-D014566
System	I-D014566

Cardiovascular	O
Risk	B-D012306
•NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

•Diclofenac	O
Sodium	B-D012964
Extended-release	O
Tablets	B-D013607
are	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
Pain	B-D010146

Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

(	O
5.1)	O
Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O

Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(	O
4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279

If	O
Fenoprofen	B-D005279

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Fenoprofen	B-D005279

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Fenoprofen	B-D005279

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Fenoprofen	B-D005279

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Fenoprofen	B-D005279

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279

If	O
Fenoprofen	B-D005279

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Fenoprofen	B-D005279

The	O
renal	O
effects	O
of	O
Fenoprofen	B-D005279

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279

If	O
Fenoprofen	B-D005279

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Fenoprofen	B-D005279
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Fenoprofen	B-D005279

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
fenoprop	B-C009264
fen,	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Fenoprofen	B-D005279
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Fenoprofen	B-D005279

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Fenoprofen	B-D005279

NSAIDs,	O
including	O
Fenoprofen	B-D005279

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Fenoprofen	B-D005279

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Ocular	O
Effects	O
Studies	O
to	O
date	O
have	O
not	O
shown	O
changes	O
in	O
the	O
Eye	B-D005123

However,	O
adverse	O
ocular	O
effects	O
have	O
been	O
observed	O
with	O
other	O
anti-inflammatory	O
drugs	O

Eye	B-D005123
examinations,	O
therefore,	O
should	O
be	O
performed	O
if	O
visual	O
disturbances	O
occur	O
in	O
Patients	B-D010361

5.15	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Caution	O
should	O
be	O
Exercise	B-D015444

5.16	O
Impact	O
on	O
Hearing	B-D006309
Since	O
the	O
Safety	B-D012449

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
5%)	O
are	O
Dyspepsia	B-D004415
,	O
Headache	B-D006261

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Xspire	O
Pharma	O
at	O
1-601-990-9497	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
studies	O
for	O
Rheum	B-D012250

These	O
encompass	O
Observation	B-D019370

For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
Patients	B-D010361

During	O
short-term	O
studies	O
for	O
Analgesia	B-D000698

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
>1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—	O
During	O
Clinical	B-D016430
Trial	I-D016430

In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
Dyspepsia	B-D004415

2.3%	O
placebo),	O
Nausea	B-D009325

7.1%),	O
Constipation	B-D003248

1.5%),	O
Vomiting	B-D014839

1.9%),	O
Abdominal	B-D015746
Pain	I-D015746

1.1%),	O
and	O
Diarrhea	B-D003967

4.1%)	O

The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
Patients	B-D010361

Nervous	B-D009420
System	I-D009420
—	O
The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
Headache	B-D006261

7.5%)	O
and	O
somnolence	O
(8.5%	O
vs	O

6.4%)	O

Dizziness	B-D004244
(6.5%	O
vs	O

5.6%),	O
Tremor	B-D014202

0.4%),	O
and	O
Confusion	B-D003221

none)	O
were	O
noted	O
less	O
frequently	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Skin	B-D012867
and	O
Appendages—	O
Increased	O
Sweating	B-D013546

0.4%),	O
Pruritus	B-D011537

0.8%),	O
and	O
rash	O
(3.7%	O
vs	O

0.4%)	O
were	O
reported	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
about	O
1%	O
of	O
Patients	B-D010361

Special	O
Senses	O
—	O
Tinnitus	B-D014012
(4.5%	O
vs	O

0.4%),	O
blurred	O
vision	O
(2.2%	O
vs	O

none),	O
and	O
decreased	O
Hearing	B-D006309

none)	O
were	O
reported	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Cardiovascular	O
—	O
Palpitations	O
(2.5%	O
vs	O

0.4%)	O

Fenoprofen	B-D005279
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
Patients	B-D010361

Miscellaneous	O
—	O
Nervousness	O
(5.7%	O
vs	O

1.5%),	O
Asthenia	B-D001247

0.4%),	O
peripheral	O
Edema	B-D004487

0.4%),	O
Dyspnea	B-D004417

none),	O
Fatigue	B-D005221

1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs	O

5.6%),	O
and	O
nas	B-C015378
opharyngitis	O
(1.2%	O
vs	O

none)	O

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—Gastritis,	O
Peptic	B-D010437
Ulcer	I-D010437

Increases	O
in	O
Alkaline	B-D000469
Phosphatase	I-D000469

Cardiovascular—Atrial	O
fibrillation,	O
Pulmonary	B-D011654
Edema	I-D011654

Genitourinary	O
Tract—Renal	O
failure,	O
Dysuria	B-D053159

Hypersensitivity	B-D006967
—Angioedema	O
(angioneurotic	O
Edema	B-D004487

Hematologic—Purpura,	O
bruising,	O
Hemorrhage	B-D006470

Nervous	B-D009420
System	I-D009420
—Depression,	O
disorientation,	O
Seizures	B-D012640

Special	O
Senses—Burning	O
Tongue	B-D014059

Skin	B-D012867
and	O
Appendages—Exfoliative	O
Dermatitis	B-D003872

Miscellaneous—Anaphylaxis,	O
Urticaria	B-D014581

WARNING:	O
Risk	B-D012306

ADMINISTRATION	O
OF	O
Misoprostol	B-D016595

Uterine	B-D014597
Rupture	I-D014597

THE	O
Risk	B-D012306

Diclofenac	B-D004008

Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

In	O
such	O
Patients	B-D010361

is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
Misoprostol	B-D016595

will	O
begin	O
Diclofenac	B-D004008

WARNING:	O
Risk	B-D012306

Diclofenac	B-D004008

ADMINISTRATION	O
OF	O
Misoprostol	B-D016595

Uterine	B-D014597
Rupture	I-D014597

THE	O
Risk	B-D012306

Diclofenac	B-D004008

Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

In	O
such	O
Patients	B-D010361

is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
Misoprostol	B-D016595

will	O
begin	O
Diclofenac	B-D004008

Cardiovascular	O
Thrombotic	O
Events	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964

Monitor	O
Patients	B-D010361

Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

These	O
increases	O
were	O
generally	O
transient,	O
and	O
enzyme	O
levels	O
returned	O
to	O
within	O
the	O
normal	O
range	O
upon	O
discontinuation	O
of	O
therapy	O
with	O
Diclofenac	B-D004008

The	O
Misoprostol	B-D016595

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
/misoprostol	O
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Diclofenac	B-D004008

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Diclofenac	B-D004008
Sodium	B-D012964

Advise	O
Pregnant	B-D037841
Women	I-D037841

Verify	O
the	O
Pregnancy	B-D011247

Advise	O
Female	B-D005260

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>	O
2%	O
from	O
Clinical	B-D016430
Trial	I-D016430

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Adverse	O
reaction	O
information	O
for	O
Diclofenac	B-D004008

These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
Patients	B-D010361

For	O
GI	O
Ulcer	B-D014456

GI	O
disorder	O
Diclofenac	B-D004008
Sodium	B-D012964

Diarrhea	B-D003967
and	O
Abdominal	B-D015746
Pain	I-D015746

Rare	O
instances	O
of	O
profound	O
Diarrhea	B-D003967

Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
Disease	B-D004194

The	O
Incidence	B-D015994

Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
Misoprostol	B-D016595

Postmenopausal	O
Vagina	B-D014621

If	O
it	O
occurs,	O
diagnostic	O
Work	B-D014937

Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
Safety	B-D012449

Other	O
adverse	O
experiences	O
reported	O
occasionally	O
with	O
Diclofenac	B-D004008

Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Digestive:	O
Anorexia	B-D000855

Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional:	O
Alanine	B-D000409

Musculoskeletal	B-D009141
System	I-D009141

Psychiatric:	O
Anxiety	B-D001007

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505

Special	O
senses:	O
Taste	B-D013649

Renal	O
and	O
urinary	O
disorders:	O
Dysuria	B-D053159

Vision:	O
Diplopia	B-D004172

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
whole:	O
Death	B-D003643

Cardiovascular	B-D002319
System	I-D002319

Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Congenital,	O
familial	O
and	O
genetic	O
disorders:	O
birth	O
defects	O

Digestive:	O
Enteritis	B-D004751

Female	B-D005260
reproductive	O
disorders:	O
intermenstrual	O
bleeding,	O
Leukorrhea	B-D007973

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Hypersensitivity	B-D006967
:	O
Angioedema	B-D000799

Liver	B-D008099
and	O
biliary	O
system:	O
abnormal	O
hepatic	O
function,	O
Bilirubin	B-D001663

Male	B-D008297
reproductive	O
disorders:	O
impotence,	O
perineal	O
Pain	B-D010146

Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
Glycosuria	B-D006029

Pregnancy	B-D011247
,	O
puerperium	O
and	O
perinatal	O
conditions:	O
abnormal	O
Uterine	B-D014590
Contraction	I-D014590

Psychiatric:	O
Confusion	B-D003221

Reproductive	O
system	O
and	O
Breast	B-D001940

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages:	O
acne,	O
bruising,	O
Erythema	B-D004892
Multiforme	I-D004892

Special	O
senses:	O
Hearing	B-D006309

Renal	O
and	O
urinary	O
disorders:	O
Cystitis	B-D003556

Vision:	O
Amblyopia	B-D000550

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
adverse	O
reactions	O
are	O
drowsiness	O
and	O
Dizziness	B-D004244

Less	O
frequent	O
adverse	O
reactions	O
are	O
Light	B-D008027

A	O
single	O
Incidence	B-D015994

Several	O
cases	O
of	O
dermatological	O
reactions	O
including	O
toxic	O
epidermal	O
necrolysis	O
and	O
Erythema	B-D004892
Multiforme	I-D004892

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Etodolac	B-D017308
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1,000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O

PENNSAID	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
PENNSAID	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

(5.9,	O
5.14)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
Pregnant	B-D037841
Women	I-D037841

Exposure	O
to	O
Light	B-D008027

(5.11)	O
Eye	B-D005123
Contact:	O
Avoid	O
contact	O
of	O
PENNSAID	O
with	O
Eye	B-D005123

(5.15)	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs:	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs	O

(5.16)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
PENNSAID	O
in	O
Patients	B-D010361

If	O
PENNSAID	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
PENNSAID	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
3,700	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
PENNSAID	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
Acetaminophen	B-D000082

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
PENNSAID,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
PENNSAID	O
in	O
Patients	B-D010361

If	O
PENNSAID	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
PENNSAID	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
PENNSAID	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
PENNSAID	O
in	O
Patients	B-D010361

If	O
PENNSAID	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
PENNSAID	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

PENNSAID	O
is	O
contraindicated	O
in	O
Patients	B-D010361

Do	O
not	O
apply	O
PENNSAID	O
to	O
open	O
Skin	B-D012867

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
PENNSAID,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
PENNSAID	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
PENNSAID,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
PENNSAID	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Sun	O
Exposure	O
Instruct	O
Patients	B-D010361

The	O
potential	O
effects	O
of	O
PENNSAID	O
on	O
Skin	B-D012867

5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
PENNSAID	O
with	O
Eye	B-D005123

Advise	O
Patients	B-D010361

5.16	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
PENNSAID	O
1.5%	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
Hemorrhage	B-D006470

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
PENNSAID	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
The	O
most	O
common	O
adverse	O
reactions	O
with	O
PENNSAID	O
are	O
application	O
site	O
reactions	O

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Horizon	O
at	O
1-866-479-6742	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
PENNSAID	O
of	O
130	O
Patients	B-D010361

This	O
Population	B-D011153

The	O
most	O
common	O
adverse	O
events	O
with	O
PENNSAID	O
were	O
application	O
site	O
Skin	B-D012867

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
study	O

Application	O
Site	O
Reactions:	O
In	O
this	O
controlled	O
trial,	O
application	O
site	O
reactions	O
were	O
Character	B-D002605

Other	O
Common	O
Adverse	O
Reactions:	O
Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
>1%	O
of	O
Patients	B-D010361

Table	O
1:	O
Incidence	B-D015994
of	O
Adverse	O
Reactions	O
Occurring	O
in	O
>1%	O
of	O
Subjects	O
with	O
Osteoarthritis	B-D010003
Using	O
PENNSAID	O
and	O
More	O
Often	O
than	O
in	O
Subjects	O
with	O
OA	O
Using	O
Vehicle	O
Control	O
(Pooled)	O
Adverse	O
Reaction	O
PENNSAIDN=130n	O
(%)	O
Vehicle	O
ControlN=129n	O
(%)	O
Urinary	B-D014551
Tract	I-D014551

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
PENNSAID	O
1.5%	O
of	O
911	O
Patients	B-D010361

The	O
Population	B-D011153

The	O
most	O
common	O
adverse	O
events	O
with	O
PENNSAID	O
1.5%	O
were	O
application	O
site	O
Skin	B-D012867

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
Site	O
Reactions:	O
In	O
controlled	O
trials,	O
application	O
site	O
reactions	O
were	O
Character	B-D002605

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
Skin	B-D012867

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
Dermatitis	B-D003872

In	O
the	O
open-label	O
uncontrolled	O
long-term	O
Safety	B-D012449

Other	O
Common	O
Adverse	O
Reactions:	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
PENNSAID	O
1.5%	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
Diarrhea	B-D003967

The	O
combination	O
of	O
PENNSAID	O
1.5%	O
and	O
oral	O
Diclofenac	B-D004008

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
Creatinine	B-D003404

7%),	O
Urea	B-D014508

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
Liver	B-D008099

Table	O
2	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
2:	O
Adverse	O
Reactions	O
Occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361
Treated	O
with	O
PENNSAID	O
1.5%	O
Topical	O
Solution	O
in	O
Placebo	O
and	O
Oral	O
Diclofenac	B-D004008
-Controlled	O
Trials	O
Treatment	O
Group:	O
PENNSAID	O
1.5%N=911	O
Topical	O
PlaceboN=332	O
Adverse	O
Reaction	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-	O
approval	O
use	O
of	O
PENNSAID	O
1.5%	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

Associated	O
with	O
Treatment	O
DiscontinuationOf	O
the	O
382	O
Patients	B-D010361

One	O
patient	O
each	O
discontinued	O
treatment	O
for	O
the	O
following	O
reasons:	O
gastrointestinal	O
upset;	O
Light	B-D008027

Incidence	B-D015994
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
sThe	O
following	O
table	O
summarizes	O
the	O
Incidence	B-D015994

The	O
prescriber	O
should	O
be	O
aware	O
that	O
these	O
figures	O
cannot	O
be	O
used	O
to	O
predict	O
the	O
Incidence	B-D015994

Similarly,	O
the	O
cited	O
frequencies	O
cannot	O
be	O
compared	O
with	O
figures	O
obtained	O
from	O
other	O
clinical	O
investigations	O
involving	O
different	O
treatments,	O
uses,	O
and	O
investigators	O

Adverse	O
Events	O
Reported	O
by	O
at	O
Least	O
1%	O
of	O
butalbital	B-C004470
,	O
Aspirin	B-D001241

All	O
reported	O
adverse	O
events,	O
except	O
those	O
already	O
presented	O
in	O
the	O
previous	O
table,	O
are	O
included	O

It	O
is	O
important	O
to	O
emphasize	O
that,	O
although	O
the	O
adverse	O
events	O
reported	O
did	O
occur	O
while	O
the	O
patient	O
was	O
receiving	O
butalbital	B-C004470
,	O
Aspirin	B-D001241

Adverse	O
events	O
are	O
classified	O
by	O
body	O
system	O
and	O
frequency	O

“Frequent”	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
which	O
occurred	O
in	O
at	O
least	O
1/100	O
(1%)	O
of	O
the	O
Patients	B-D010361

“Infrequent”	O
is	O
defined	O
as	O
an	O
adverse	O
event	O
that	O
occurred	O
in	O
less	O
than	O
1/100	O
Patients	B-D010361

All	O
adverse	O
events	O
tabulated	O
below	O
are	O
classified	O
as	O
infrequent	O

Central	O
Nervous:	O
Headache	B-D006261

Autonomic	O
Nervous:	O
dry	O
Mouth	B-D009055

Gastrointestinal:	O
Vomiting	B-D014839

Cardiovascular:	O
Tachycardia	B-D013610

Musculoskeletal:	O
Leg	B-D007866

Genitourinary:	O
Diuresis	B-D004231

Miscellaneous:	O
Pruritus	B-D011537

Voluntary	O
reports	O
of	O
adverse	O
drug	O
events,	O
TEMPO	B-C003959

Many	O
or	O
most	O
of	O
these	O
events	O
may	O
have	O
no	O
causal	O
relationship	O
with	O
the	O
drug	O
and	O
are	O
listed	O
according	O
to	O
body	O
system	O

Central	O
Nervous:	O
Abuse,	O
addiction,	O
Anxiety	B-D001007

Autonomic	O
Nervous:	O
Epistaxis	B-D004844

Gastrointestinal:	O
Anorexia	B-D000855

Cardiovascular:	O
Chest	B-D002637
Pain	I-D002637

Skin	B-D012867
:	O
Erythema	B-D004890

Urinary:	O
Kidney	B-D007668

Miscellaneous:	O
allergic	O
reaction,	O
anaphylactic	O
Shock	B-D012769

The	O
following	O
adverse	O
drug	O
events	O
may	O
be	O
borne	O
in	O
mind	O
as	O
potential	O
effects	O
of	O
the	O
components	O
of	O
butalbital	B-C004470

Potential	O
effects	O
of	O
high	O
dosage	O
are	O
listed	O
in	O
the	O
OVERDOSAGE	O
section	O
of	O
this	O
insert	O

Aspirin	B-D001241
:	O
Occult	B-D009780
Blood	I-D009780

Caffeine	B-D002110
:	O
Cardia	B-D002299

Codeine	B-D003061
:	O
Nausea	B-D009325

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
Celecoxib	B-D000068579

New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

Fluid	O
retention	O
and	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Renal	O
papillary	O
Necrosis	B-D009336

Use	O
Celecoxib	B-D000068579

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
Celecoxib	B-D000068579

Serious	O
Skin	B-D012867

Discontinue	O
Celecoxib	B-D000068579

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Border	O
line	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

Therefore,	O
treatment	O
with	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

Celecoxib	B-D000068579
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
Celecoxib	B-D000068579

6	O
ADVERSE	O
REACTIONS	O
Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4,146	O
Placeb	O
o	O
N=1,864	O
NAP	O
N=1,366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
AbdominalPain	O
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%	O
5.6%	O
8.8%	O
2.2%	O
3.5%	O
2.8%	O
3.8%	O
6.2%	O
1%	O
4.2%	O
7.7%	O
5.3%	O
12.2%3.6%	O
6%	O
9%	O
9.3%	O
10.9%4.1%	O
3.4%	O
9%	O
5.8%	O
12.8%	O
3.5%	O
6.7%	O
Bodyasawhole	O
Back	B-D001415
Pain	B-D010146
PeripheralEdema	O
Injury-Accidental	O
2.8%	O
2.1%	O
2.9%	O
3.6%	O
1.1%	O
2.3%	O
2.2%	O
2.1%	O
3%	O
2.6%	O
1%	O
2.6%	O
0.9%	O
3.5%	O
3.2%	O
Central,	O
Peripheral	O
Nervoussystem	O
Dizziness	B-D004244
Headache	B-D006261
2%15.8%	O
1.7%	O
20.2%	O
2.6%	O
14.5%	O
1.3%	O
15.5%	O
2.3%	O
15.4%	O
PsychiatricInsomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
Rhinitis	B-D012220
Sinusitis	B-D012852
UpperRespiratory	O
Infection	O
2.3%	O
2%	O
5%	O
8.1%	O
1.1%	O
1.3%	O
4.3%	O
6.7%	O
1.7%	O
2.4%	O
4%	O
9.9%	O
1.6%	O
2.3%	O
5.4%	O
9.8%	O
2.6%	O
0.6%	O
5.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
CBX	O
=	O
Celecoxib	B-D000068579
100	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
Patients	B-D010361

Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

INDOCIN	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
INDOCIN	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
P	O
ost	O
C	O
oronary	O
A	O
rtery	O
B	O
ypass	O
G	O
raft	O
(CABG)	O
S	O
urgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(	O
4	O
)]	O

Post-MI	O
P	O
atients	O
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
INDOCIN	O
in	O
Patients	B-D010361

If	O
INDOCIN	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
G	O
astrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Indomethacin	B-D007213

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding	O
,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
INDOCIN	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
INDOCIN,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Indomethacin	B-D007213

Avoid	O
the	O
use	O
of	O
INDOCIN	O
in	O
Patients	B-D010361

If	O
INDOCIN	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
INDOCIN	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
INDOCIN	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
INDOCIN	O
in	O
Patients	B-D010361

If	O
INDOCIN	O
is	O
used	O
in	O
Patients	B-D010361

It	O
has	O
been	O
reported	O
that	O
the	O
addition	O
of	O
the	O
Potassium	B-D011188

Indomethacin	B-D007213
and	O
Triamterene	B-D014223

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

Both	O
Indomethacin	B-D007213
and	O
Potassium	B-D011188

The	O
potential	O
effects	O
of	O
Indomethacin	B-D007213

5.7	O
Anaphylact	O
ic	O
Reactions	O
Indomethacin	B-D007213
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
INDOCIN	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Indomethacin	B-D007213

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

INDOCIN	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Indomethacin	B-D007213
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
INDOCIN,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
INDOCIN	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
INDOCIN,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions,	O
such	O
as	O
coagulation	O
disorders,	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
INDOCIN	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
INDOCIN	O
may	O
aggravate	O
Depression	B-D003863

Discontinue	O
INDOCIN	O
if	O
severe	O
CNS	O
adverse	O
reactions	O
develop	O

INDOCIN	O
may	O
cause	O
drowsiness;	O
therefore,	O
caution	O
Patients	B-D010361

Indomethacin	B-D007213
may	O
also	O
cause	O
Headache	B-D006261

Headache	B-D006261
which	O
persists	O
despite	O
dosage	O
reduction	O
requires	O
cessation	O
of	O
therapy	O
with	O
INDOCIN	O

5.15	O
Ocular	O
Effects	O
Cornea	B-D003315
l	O
DEPO	B-C020884

Be	O
alert	O
to	O
the	O
possible	O
Association	B-D001244

It	O
is	O
advisable	O
to	O
discontinue	O
therapy	O
if	O
such	O
changes	O
are	O
observed	O

Blurred	O
vision	O
may	O
be	O
a	O
significant	O
symptom	O
and	O
warrants	O
a	O
thorough	O
ophthalmological	O
examination	O

Since	O
these	O
changes	O
may	O
be	O
asymptomatic,	O
ophthalmologic	O
examination	O
at	O
periodic	O
intervals	O
is	O
desirable	O
in	O
Patients	B-D010361

INDOCIN	O
is	O
not	O
indicated	O
for	O
long-term	O
treatment	O

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(	O
5.11	O
)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
3%)	O
are	O
Headache	B-D006261

(6)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Iroko	O
Pharmaceuticals,	O
LLC	O
at	O
1-877-757-0676	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
gastroscopic	O
study	O
in	O
45	O
Health	B-D006262

In	O
a	O
double-blind	O
comparative	O
Clinical	B-D000068397
Study	I-D000068397

The	O
Incidence	B-D015994

The	O
adverse	O
reactions	O
for	O
INDOCIN	O
Capsules	B-D002214
listed	O
in	O
the	O
following	O
table	O
have	O
been	O
arranged	O
into	O
two	O
groups:	O
(1)	O
Incidence	B-D015994

The	O
Incidence	B-D015994

The	O
Incidence	B-D015994

The	O
Probability	B-D011336

The	O
adverse	O
reactions	O
reported	O
with	O
INDOCIN	O
Capsules	B-D002214
may	O
also	O
occur	O
with	O
use	O
of	O
the	O
suspension	O

Table	O
1	O
Summary	O
of	O
Adverse	O
Reactions	O
for	O
INDOCIN	O
Capsules	B-D002214
Incidence	B-D015994
greater	O
than	O
1%	O
Incidence	B-D015994
less	O
than	O
1%	O
GASTROINTESTINAL	O
Nausea	B-D009325

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
Patients	B-D010361

However,	O
in	O
these	O
rarely	O
reported	O
events,	O
the	O
possibility	O
cannot	O
be	O
excluded	O

Therefore,	O
these	O
Observation	B-D019370

Eighty-seven	O
percent	O
(87%)	O
of	O
the	O
Diclofenac	B-D004008

The	O
majority	O
of	O
these	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
upon	O
discontinuation	O
of	O
therapy	O

Of	O
the	O
211	O
Patients	B-D010361

Application	O
site	O
reactions	O
(ASRs)	O
were	O
the	O
most	O
frequent	O
AEs	O
in	O
both	O
Diclofenac	B-D004008

Of	O
note,	O
four	O
reactions,	O
contact	O
Dermatitis	B-D003872

Eighteen	O
percent	O
of	O
Diclofenac	B-D004008

These	O
discontinuations	O
were	O
mainly	O
due	O
to	O
Skin	B-D012867

Table	O
1	O
below	O
presents	O
the	O
AEs	O
reported	O
at	O
an	O
Incidence	B-D015994

Table	O
1	O

Adverse	O
Events	O
Reported	O
(>1%	O
in	O
Any	O
Treatment	O
Group)	O
During	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
Phase	O
3	O
Clinical	B-D016430
Trial	I-D016430
s	O
Incidence	B-D015994
s	O
for	O
60-Day	O
and	O
90-Day	O
Treatments	O
60-day	O
Treatment	O
90-day	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964
(%)	O
Gel	O
Vehicle(%)	O
Diclofenac	B-D004008
Sodium	B-D012964
(%)	O
Gel	O
Vehicle(%)	O
N=48	O
N=49	O
N=114	O
N=114	O
BODY	O
AS	O
A	O
WHOLE	O
21	O
20	O
20	O
18	O
Abdominal	B-D015746
Pain	I-D015746
2	O
0	O
1	O
0	O
Accidental	O
Injury	O
0	O
0	O
4	O
2	O
Allergic	O
Reaction	O
0	O
0	O
1	O
3	O
Asthenia	B-D001247
0	O
0	O
2	O
0	O
Back	B-D001416
Pain	I-D001416
4	O
0	O
2	O
2	O
Chest	B-D002637
Pain	I-D002637
2	O
0	O
1	O
0	O
Chills	B-D023341
0	O
2	O
0	O
0	O
Flu	O
Syndrome	B-D013577
10	O
6	O
1	O
4	O
Headache	B-D006261
0	O
6	O
7	O
6	O
Infection	O
4	O
6	O
4	O
5	O
Neck	B-D019547
Pain	I-D019547
0	O
0	O
2	O
0	O
Pain	B-D010146
2	O
0	O
2	O
2	O
Cardiovascular	B-D002319
System	I-D002319

Adverse	O
Reactions	O
Reported	O
for	O
Oral	O
Diclofenac	B-D004008
Dosage	O
Form	B-D020478
(not	O
topical	O
Diclofenac	B-D004008

Cardiovascular:	O
Hypertension	B-D006973

Digestive:	O
Diarrhea	B-D003967

Hemic	O
and	O
Lymph	B-D008196
atic:	O
hemoglobin	B-C032001
D	I-C032001

Metabolic	O
and	O
Nutritional	O
Disorders:	O
Azotemia	B-D053099

Nervous	B-D009420
System	I-D009420
:	O
Dizziness	B-D004244

Respiratory:	O
Epistaxis	B-D004844

Skin	B-D012867
and	O
Appendages:	O
rash,	O
Pruritus	B-D011537

Special	O
Senses:	O
Tinnitus	B-D014012

Urogenital:	O
Nephrotic	B-D009404
Syndrome	I-D009404

Cardiovascular	O
Risk	B-D012306
•NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(see	O
WARNINGS.)	O
•Diclofenac	O
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(see	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

PENNSAID	O
is	O
contraindicated	O
in	O
the	O
perioperative	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306

Cardiovascular	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1)	O
PENNSAID	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
perioperative	O
Pain	B-D010146

(4)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
PENNSAID,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Use	O
the	O
lowest	O
effective	O
dose	O
of	O
PENNSAID	O
in	O
Patients	B-D010361

(5.1)	O
NSAIDs	O
can	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
Inflammation	B-D007249

Prescribe	O
PENNSAID	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
History	B-D006664

(5.2)	O
Elevation	O
of	O
one	O
or	O
more	O
Liver	B-D008099

Discontinue	O
PENNSAID	O
immediately	O
if	O
abnormal	O
Liver	B-D008099

(5.3)	O
Hypertension	B-D006973
can	O
occur	O
with	O
NSAID	O
treatment	O

Monitor	O
Blood	B-D001794
Pressure	I-D001794

(5.4)	O
Use	O
PENNSAID	O
with	O
caution	O
in	O
Patients	B-D010361

(5.5)	O
Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Use	O
PENNSAID	O
with	O
caution	O
in	O
Patients	B-D010361

(5.6)	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

(5.7)	O
NSAIDs	O
can	O
cause	O
serious	O
Skin	B-D012867

(5.8)	O
Not	O
for	O
use	O
during	O
Pregnancy	B-D011247

(5.9)	O
Do	O
not	O
administer	O
to	O
Patients	B-D010361

(5.10)	O
Avoid	O
exposure	O
of	O
treated	O
Knee	B-D007717

(5.11)	O
Avoid	O
contact	O
of	O
PENNSAID	O
with	O
Eye	B-D005123

(5.12)	O
Avoid	O
concurrent	O
use	O
with	O
oral	O
NSAIDs	O

(5.13)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

All	O
NSAIDs,	O
including	O
PENNSAID	O
and	O
COX-2	O
selective	O
and	O
nonselective	O
orally	O
administered	O
NSAIDs,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Inform	O
Patients	B-D010361

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Prescribe	O
NSAIDs,	O
including	O
PENNSAID,	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
History	B-D006664

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

For	O
high-risk	O
Patients	B-D010361

5.3	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
(less	O
than	O
3	O
Time	B-D013995

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
Liver	B-D008099

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
Patients	B-D010361

In	O
this	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy	O

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
inform	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
PENNSAID	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
Acetaminophen	B-D000082

Caution	O
Patients	B-D010361

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Use	O
NSAIDs,	O
including	O
PENNSAID,	O
with	O
caution	O
in	O
Patients	B-D010361

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Patients	B-D010361
taking	O
ACE-inhibitors,	O
Thiazides	B-D049971

5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
PENNSAID	O
with	O
caution	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Effects	O
Use	O
caution	O
when	O
initiating	O
treatment	O
with	O
PENNSAID	O
in	O
Patients	B-D010361

Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
PENNSAID	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
PENNSAID	O
is	O
not	O
recommended	O
in	O
Patients	B-D010361

If	O
PENNSAID	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

Do	O
not	O
prescribe	O
PENNSAID	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Seek	O
emergency	O
help	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Do	O
not	O
apply	O
PENNSAID	O
to	O
open	O
Skin	B-D012867

NSAIDs,	O
including	O
PENNSAID,	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

5.9	O
Pregnancy	B-D011247
PENNSAID	O
should	O
not	O
be	O
used	O
by	O
pregnant	O
or	O
Nursing	B-D009729

5.10	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross-reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.11	O
Sun	O
Exposure	O
Instruct	O
Patients	B-D010361

The	O
potential	O
effects	O
of	O
PENNSAID	O
on	O
Skin	B-D012867

5.12	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
PENNSAID	O
with	O
Eye	B-D005123

Advise	O
Patients	B-D010361

5.13	O
Oral	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
NSAIDs	O
with	O
PENNSAID	O
resulted	O
in	O
a	O
higher	O
rate	O
of	O
rectal	O
Hemorrhage	B-D006470

Therefore,	O
do	O
not	O
use	O
combination	O
therapy	O
with	O
PENNSAID	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
Risk	B-D012306

5.14	O
Corticosteroid	O
Treatment	O
PENNSAID	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

For	O
Patients	B-D010361

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
PENNSAID	O
in	O
reducing	O
Inflammation	B-D007249

5.16	O
Hematological	O
Effects	O
The	O
effects	O
of	O
PENNSAID	O
on	O
platelet	O
function	O
were	O
studied	O
in	O
10	O
Health	B-D006262

There	O
was	O
no	O
significant	O
change	O
in	O
Platelet	B-D010974
Aggregation	I-D010974

Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
Blood	B-D001769

Check	O
hemoglobin	O
or	O
Hematocrit	B-D006400

NSAIDs	O
inhibit	O
Platelet	B-D010974
Aggregation	I-D010974

Unlike	O
Aspirin	B-D001241

Carefully	O
monitor	O
Patients	B-D010361

5.17	O
Monitoring	O
Because	O
serious	O
GI	O
tract	O
Ulcer	B-D014456

Check	O
CBC	O
and	O
a	O
Chemistry	B-D002621

Discontinue	O
PENNSAID	O
if	O
abnormal	O
Liver	B-D008099

6	O

ADVERSE	O
REACTIONS	O
The	O
most	O
common	O
adverse	O
events	O
with	O
PENNSAID	O
are	O
application	O
site	O
reactions	O

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Mallinckrodt	O
Brand	O
Pharmaceuticals,	O
Inc	O

at	O
1-800-778-7898	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
PENNSAID	O
of	O
911	O
Patients	B-D010361

The	O
Population	B-D011153

The	O
most	O
common	O
adverse	O
events	O
with	O
PENNSAID	O
were	O
application	O
site	O
Skin	B-D012867

These	O
events	O
were	O
the	O
most	O
common	O
reason	O
for	O
withdrawing	O
from	O
the	O
studies	O

Application	O
site	O
reactions:	O
In	O
controlled	O
trials,	O
the	O
most	O
common	O
treatment-related	O
adverse	O
events	O
in	O
Patients	B-D010361

Application	O
site	O
reactions	O
were	O
Character	B-D002605

The	O
most	O
frequent	O
of	O
these	O
reactions	O
were	O
dry	O
Skin	B-D012867

In	O
one	O
controlled	O
trial,	O
a	O
higher	O
rate	O
of	O
contact	O
Dermatitis	B-D003872

In	O
the	O
open	O
label	O
uncontrolled	O
long-term	O
Safety	B-D012449

Adverse	O
events	O
common	O
to	O
the	O
NSAID	O
class:	O
In	O
controlled	O
trials,	O
subjects	O
treated	O
with	O
PENNSAID	O
experienced	O
some	O
adverse	O
events	O
associated	O
with	O
the	O
NSAID	O
class	O
more	O
frequently	O
than	O
subjects	O
using	O
placebo	O
(constipation,	O
Diarrhea	B-D003967

The	O
combination	O
of	O
PENNSAID	O
and	O
oral	O
Diclofenac	B-D004008

less	O
than	O
1%),	O
and	O
more	O
frequent	O
abnormal	O
Creatinine	B-D003404

7%),	O
Urea	B-D014508

12%),	O
and	O
hemoglobin	O
(13%	O
vs	O

9%),	O
but	O
no	O
difference	O
in	O
elevation	O
of	O
Liver	B-D008099

Table	O
1	O
lists	O
all	O
adverse	O
reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

Since	O
these	O
trials	O
were	O
of	O
different	O
durations,	O
these	O
percentages	O
do	O
not	O
capture	O
cumulative	O
rates	O
of	O
occurrence	O

Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
≥1%	O
of	O
Patients	B-D010361

†Preferred	O
Term	O
according	O
to	O
COSTART	O
Treatment	O
Group:	O
PENNSAID®	O
N=911	O
Topical	O
PlaceboN=332	O
Adverse	O
Reaction†	O
N	O
(%)	O
N	O
(%)	O
Dry	O
Skin	B-D012867
(Application	O
Site)	O
292	O
(32)	O
17	O
(5)	O
Contact	O
Dermatitis	B-D003872
(Application	O
Site)	O
83	O
(9)	O
6	O
(2)	O
Dyspepsia	B-D004415
72	O
(8)	O
13	O
(4)	O
Abdominal	B-D015746
Pain	I-D015746
54	O
(6)	O
10	O
(3)	O
Flatulence	B-D005414
35	O
(4)	O
1	O
(<1)	O
Pruritus	B-D011537
(Application	O
Site)	O
34	O
(4)	O
7	O
(2)	O
Diarrhea	B-D003967
33	O
(4)	O
7	O
(2)	O
Nausea	B-D009325
33	O
(4)	O
3	O
(1)	O
Pharyngitis	B-D010612
40	O
(4)	O
13	O
(4)	O
Constipation	B-D003248
29	O
(3)	O
1	O
(<1)	O
Edema	B-D004487
26	O
(3)	O
0	O
Rash	O
(Non-Application	O
Site)	O
25	O
(3)	O
5	O
(2)	O
Infection	O
25	O
(3)	O
8	O
(2)	O
Ecchymosis	B-D004438
19	O
(2)	O
1	O
(<1)	O
Dry	O
Skin	B-D012867
(Non-Application	O
Site)	O
19	O
(2)	O
1	O
(<1)	O
Contact	O
Dermatitis	B-D003872
,	O
vesicles	O
(Application	O
Site)	O
18	O
(2)	O
0	O
Paresthesia	B-D010292
(Non-Application	O
Site)	O
14	O
(2)	O
3	O
(<1)	O
Accidental	O
Injury	O
22	O
(2)	O
7	O
(2)	O
Pruritus	B-D011537
(Non-Application	O
Site)	O
15	O
(2)	O
2	O
(<1)	O
Sinusitis	B-D012852
10	O
(1)	O
2	O
(<1)	O
Halitosis	B-D006209
11	O
(1)	O
1	O
(<1)	O
Application	O
Site	O
Reaction	O
(not	O
otherwise	O
specified)	O
11	O
(1)	O
3	O
(<1)	O
6.2	O
Postmarketing	O
Experience	O
In	O
non-US	O
postmarketing	O
surveillance,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
post-approval	O
use	O
of	O
PENNSAID	O

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

This	O
Risk	B-D012306

Diclofenac	B-D004008
Potassium	B-D011188

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
718	O
Patients	B-D010361

In	O
a	O
6	O
month,	O
double-blind	O
trial	O
comparing	O
Diclofenac	B-D004008

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

•	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

•	O
Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
Celecoxib	B-D000068579

•	O
New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

•	O
Fluid	O
retention	O
and	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

•	O
Renal	O
papillary	O
Necrosis	B-D009336

Use	O
Celecoxib	B-D000068579

•	O
Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
Celecoxib	B-D000068579

•	O
Serious	O
Skin	B-D012867

Discontinue	O
Celecoxib	B-D000068579

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovasculardeath,	O
MI,	O
or	O
Stroke	B-D020521

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/orsymptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
PerforationNSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

Therefore,	O
treatment	O
with	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
postmarketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

Celecoxib	B-D000068579
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
Celecoxib	B-D000068579

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reactioninformation	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sydon	O
Labs,	O
LLC	O
at	O
1	O
866-487-4695	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4,	O
146	O
Placebo	O
N=1,	O
864	O
NAP	O
N=1,	O
366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%5.6%	O
8.8%	O
2.2%	O
3.5%	O
2.8%3.8%	O
6.2%	O
1%	O
4.2%	O
7.7%5.3%	O
12.2%	O
3.6%	O
6%	O
9%9.3%	O
10.9%	O
4.1%	O
3.4%	O
9%5.8%	O
12.8%	O
3.5%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%2.1%	O
2.9%	O
3.6%1.1%	O
2.3%	O
2.2%2.1%	O
3%	O
2.6%1%	O
2.6%	O
0.9%3.5%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
Patients	B-D010361

Thelower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
>5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
postdental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4	O
,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

The	O
rates	O
of	O
Hypertension	B-D006973

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>	O
2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CXB	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Vertigo	B-D014717

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-	O
controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

This	O
Risk	B-D012306

CAMBIA	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
CAMBIA	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

(5.10)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
CAMBIA	O
in	O
Patients	B-D010361

If	O
CAMBIA	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-	O
term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
high	O
Risk	B-D012306

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
CAMBIA	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
persist,	O
or	O
may	O
only	O
be	O
transient	O
with	O
continued	O
therapy	O

Borderline	O
elevations	O
(less	O
than	O
3	O
Time	B-D013995

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
Liver	B-D008099

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
Patients	B-D010361

In	O
this	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
CAMBIA	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
Acetaminophen	B-D000082

Caution	O
Patients	B-D010361

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
CAMBIA,	O
can	O
Lead	B-D007854

Use	O
NSAIDs,	O
including	O
CAMBIA,	O
with	O
caution	O
in	O
Patients	B-D010361

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
Thiazides	B-D049971

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
CAMBIA	O
in	O
Patients	B-D010361

If	O
CAMBIA	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CAMBIA	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
CAMBIA	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
CAMBIA	O
in	O
Patients	B-D010361

If	O
CAMBIA	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
CAMBIA	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

CAMBIA	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Medication	O
Overuse	O
Headache	B-D006261
Overuse	O
of	O
acute	O
migraine	O
drugs	O
(e.g.,	O
Ergotamine	B-D004878

Medication	O
overuse	O
Headache	B-D006261

Detoxification	O
of	O
Patients	B-D010361

5.11	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
CAMBIA	O
can	O
cause	O
fetal	O
harm	O
when	O
administered	O
to	O
a	O
pregnant	O
woman	O

Starting	O
at	O
30	O
weeks	O
gestation,	O
CAMBIA	O
and	O
other	O
NSAIDs	O
should	O
be	O
avoided	O
by	O
Pregnant	B-D037841
Women	I-D037841

If	O
this	O
drug	O
is	O
used	O
during	O
this	O
Time	B-D013995

5.12	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
CAMBIA	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
CAMBIA,	O
may	O
increase	O
the	O
Risk	B-D012306

Concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.13	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
CAMBIA	O
in	O
reducing	O
Inflammation	B-D007249

5.14	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

Discontinue	O
CAMBIA	O
if	O
abnormal	O
Liver	B-D008099

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.12)]	O
Most	O
common	O
adverse	O
reactions	O
(≥1%	O
and	O
>placebo)	O
were	O
Nausea	B-D009325

at	O
866-458-6389	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
Safety	B-D012449

Following	O
treatment	O
with	O
Diclofenac	B-D004008

The	O
most	O
common	O
adverse	O
reactions	O
(i.e.,	O
that	O
occurred	O
in	O
1%	O
or	O
more	O
of	O
CAMBIA-treated	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Reactions	O
With	O
Incidence	B-D015994
>1%	O
and	O
Greater	O
Than	O
Placebo	O
in	O
Studies	O
1	O
and	O
2	O
Combined	O
Adverse	O
Reactions	O
CAMBIA	O
N=634	O
Placebo	O
N=646	O
Gastrointestinal	O
Nausea	B-D009325
3%	O
2%	O
Nervous	B-D009420
System	I-D009420
Dizziness	B-D004244
1%	O
0.5%	O
The	O
most	O
common	O
adverse	O
events	O
resulting	O
in	O
discontinuation	O
of	O
Patients	B-D010361

No	O
withdrawals	O
were	O
due	O
to	O
a	O
serious	O
reaction	O

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Adverse	O
Reactions	O
Reported	O
With	O
Diclofenac	B-D004008
and	O
Other	O
NSAIDs	O
In	O
Patients	B-D010361

Additional	O
adverse	O
reactions	O
reported	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS	O
)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
Hypertension	B-D006973
(see	O
WARNINGS	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
Fever	B-D005334

at	O
1-844-874-7464	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
CELEBREX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
CELEBREX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
Risk	B-D012306

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

A	O
Randomized	B-D016449
Controlled	I-D016449
Trial	I-D016449

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
Risk	B-D012306

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
Naproxen	B-D009288

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

If	O
CELEBREX	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
CELEBREX	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
CELEBREX,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
Blood	B-D001794
Pressure	I-D001794

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

If	O
CELEBREX	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
CELEBREX	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

If	O
CELEBREX	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
Sulfonamides	B-D013449

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
CELEBREX	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

CELEBREX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
CELEBREX,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
CELEBREX	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

NSAIDs,	O
including	O
CELEBREX,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
CELEBREX-treated	O
Patients	B-D010361

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
CELEBREX	O
100	O
mg	O
to	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
Dyspepsia	B-D004415

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1%	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
Diclofenac	B-D004008

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
Dysmenorrhea	B-D004412

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
mg	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.7)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

•	O
VOLTAREN®	O
GEL	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

Elderly	O
Patients	B-D010361

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306

Cardiovascular	O
Risk	B-D012306
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

(5.1)	O

•	O
VOLTAREN®	O
GEL	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

Gastrointestinal	O
Risk	B-D012306
(4,	O
5.1)	O
•	O
Non-steroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs),	O
including	O
VOLTAREN®	O
GEL,	O
cause	O
an	O
increased	O
Risk	B-D012306

Elderly	O
Patients	B-D010361

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

The	O
lowest	O
possible	O
dose	O
of	O
VOLTAREN®	O
GEL	O
should	O
be	O
used	O
in	O
Patients	B-D010361

(5.1)	O
•NSAIDs,	O
including	O
Diclofenac	B-D004008

VOLTAREN®	O
GEL	O
should	O
be	O
prescribed	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
History	B-D006664

(5.2)	O
•Elevation	O
of	O
one	O
or	O
more	O
Liver	B-D008099

VOLTAREN®	O
GEL	O
should	O
be	O
discontinued	O
immediately	O
if	O
abnormal	O
Liver	B-D008099

(5.3)	O
•Long-term	O
administration	O
of	O
NSAIDs	O
can	O
result	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

VOLTAREN®	O
GEL	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

(5.6)	O
•Hypertension	O
can	O
occur	O
with	O
NSAID	O
treatment	O

Blood	B-D001794
Pressure	I-D001794

(5.4)	O
•Fluid	O
retention	O
and	O
Edema	B-D004487

VOLTAREN®	O
GEL	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

(5.5)	O
•Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

(5.7)	O
•NSAIDs	O
can	O
cause	O
serious	O
Skin	B-D012867

VOLTAREN®	O
GEL	O
should	O
be	O
discontinued	O
if	O
rash	O
or	O
other	O
signs	O
of	O
local	O
Skin	B-D012867

(5.8)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.3	O
Hepatic	O
Effects	O
Elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy	O

Borderline	O
elevations	O
(i.e	O

less	O
than	O
3	O
Time	B-D013995

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
Liver	B-D008099

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
Physicians	B-D010820

Caution	O
should	O
be	O
Exercise	B-D015444

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
VOLTAREN®	O
GEL,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
VOLTAREN®	O
GEL	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Blood	B-D001794
Pressure	I-D001794

5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

VOLTAREN®	O
GEL	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
VOLTAREN®	O
GEL	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
VOLTAREN®	O
GEL	O
is	O
not	O
recommended	O
in	O
Patients	B-D010361

If	O
VOLTAREN®	O
GEL	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

VOLTAREN®	O
GEL	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
VOLTAREN®	O
GEL,	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

VOLTAREN®	O
GEL	O
should	O
not	O
be	O
applied	O
to	O
open	O
Skin	B-D012867

VOLTAREN®	O
GEL	O
should	O
not	O
be	O
allowed	O
to	O
come	O
into	O
contact	O
with	O
the	O
Eye	B-D005123

5.9	O
Pregnancy	B-D011247
As	O
with	O
other	O
NSAIDs,	O
VOLTAREN®	O
GEL	O
should	O
be	O
avoided	O
in	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
treatment	O
VOLTAREN®	O
GEL	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.12	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
Blood	B-D001769

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
including	O
VOLTAREN®	O
GEL,	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Unlike	O
Aspirin	B-D001241

Patients	B-D010361
treated	O
with	O
VOLTAREN®	O
GEL	O
who	O
may	O
be	O
adversely	O
Affect	B-D000339

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
Art	B-D001154

The	O
potential	O
effects	O
of	O
VOLTAREN®	O
GEL	O
on	O
Skin	B-D012867

5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
VOLTAREN®	O
GEL	O
with	O
Eye	B-D005123

Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
Eye	B-D005123

5.16	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
>2%	O
of	O
Patients	B-D010361

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sand	B-D000080463
oz	O
Inc	O

at	O
1-800-398-5876	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Of	O
these,	O
513	O
Patients	B-D010361

Additionally,	O
583	O
Patients	B-D010361

Of	O
these,	O
355	O
Patients	B-D010361

Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
Safety	B-D012449

Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
Patients	B-D010361

These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
1%	O
of	O
treated	O
Patients	B-D010361

Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported	O

Application	O
site	O
Dermatitis	B-D003872

Table	O
1:	O
Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥1%	O
Voltaren®	O
Gel	O
Patients	B-D010361
)	O
–	O
Short-term	O
Controlled	O
Trials	O
Adverse	O
Reaction†	O
Voltaren®	O
Gel	O
N	O
=	O
913	O
Placebo	O
(vehicle)	O
N	O
=	O
876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
Dermatitis	B-D003872

In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
Patients	B-D010361

Application	O
site	O
reactions,	O
including	O
application	O
site	O
Dermatitis	B-D003872

Long-term	O
Open-label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
Safety	B-D012449

In	O
this	O
study,	O
where	O
Patients	B-D010361

Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
Patients	B-D010361

The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
Dermatitis	B-D003872

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
Cardiovascular	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
CELEBREX	O
immediately	O
if	O
abnormal	O
Liver	B-D008099

New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

Fluid	O
retention	O
and	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Renal	O
papillary	O
Necrosis	B-D009336

Use	O
CELEBREX	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
Heart	B-D006333
Failure	I-D006333

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
CELEBREX	O
in	O
Patients	B-D010361

Serious	O
Skin	B-D012867

Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
Skin	B-D012867

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
CELEBREX	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
CELEBREX,	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
CELEBREX,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
Ulcer	B-D014456

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

Celebrex	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
CELEBREX	O
is	O
not	O
recommended	O
in	O
these	O
Patients	B-D010361

If	O
CELEBREX	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

CELEBREX	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
CELEBREX	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

CELEBREX	O
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
CELEBREX	O
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
Inflammation	B-D007249

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
CELEBREX	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
Risk	B-D012306

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
CELEBREX-treated	O
Patients	B-D010361

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
CELEBREX	O
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
Dyspepsia	B-D004415

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
Diclofenac	B-D004008

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
Dysmenorrhea	B-D004412

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

·	O
Ibuprofen	B-D007052
Tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
Ibuprofen	B-D007052

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052

Adverse	O
reactions	O
observed	O
during	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
Observation	B-D019370

More	O
than	O
500	O
of	O
these	O
Patients	B-D010361

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
Clinical	B-D016430
Trial	I-D016430

The	O
increases	O
in	O
Incidence	B-D015994

Incidence	B-D015994
Greater	O
than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea	B-D009325
*,	O
epigastric	O
Pain	B-D010146

Henoch-Schonlein	O
Vasculitis	B-D014657

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
Patients	B-D010361

**Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O
Cardiovascular	O
Risk	B-D012306
NSAIDs1	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS	O
and	O
Clinical	B-D016430
Trial	I-D016430

Flector®	O
Patch	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS	O
)	O

1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug	O

ADVERSE	O
REACTIONS	O
In	O
controlled	O
trials	O
during	O
the	O
Prema	B-C070504

Adverse	O
Events	O
Lead	B-D007854
ing	O
to	O
Discontinuation	O
of	O
Treatment	O
In	O
the	O
controlled	O
trials,	O
3%	O
of	O
Patients	B-D010361

The	O
most	O
common	O
adverse	O
events	O
Lead	B-D007854

Application	O
site	O
reactions	O
Lead	B-D007854

Common	O
Adverse	O
Events	O
Localized	O
Reactions	O
Overall	B-D016424
,	O
the	O
most	O
common	O
adverse	O
events	O
associated	O
with	O
Flector®	O
Patch	O
treatment	O
were	O
Skin	B-D012867

Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

A	O
majority	O
of	O
Patients	B-D010361

Common	O
Adverse	O
Events	O
(by	O
body	O
system	O
and	O
preferred	O
term)	O
in	O
≥1%	O
of	O
Patients	B-D010361
treated	O
with	O
Flector®	O
Patch	O
or	O
Placebo	O
Patch1	O
Diclofenac	B-D004008
N=572	O
Placebo	O
N=564	O
N	O
Percent	O
N	O
Percent	O
1	O
The	O
table	O
lists	O
adverse	O
events	O
occurring	O
in	O
placebo-treated	O
Patients	B-D010361

Adverse	O
events	O
in	O
the	O
placebo	O
group	O
may	O
therefore	O
reflect	O
effects	O
of	O
the	O
non-active	O
ingredients	O

2	O
Includes:	O
application	O
site	O
dryness,	O
irritation,	O
Erythema	B-D004890

3	O
Includes:	O
Gastritis	B-D005756

4	O
Includes:	O
hypoaesthesia,	O
Dizziness	B-D004244

Application	O
Site	O
Conditions	O
64	O
11	O
70	O
12	O
Pruritus	B-D011537
31	O
5	O
44	O
8	O
Dermatitis	B-D003872
9	O
2	O
3	O
<	O
1	O
Burning	O
2	O
<1	O
8	O
1	O
Other2	O
22	O
4	O
15	O
3	O
Gastrointestinal	O
Disorders	O
49	O
9	O
33	O
6	O
Nausea	B-D009325
17	O
3	O
11	O
2	O
Dysgeusia	B-D004408
10	O
2	O
3	O
<	O
1	O
Dyspepsia	B-D004415
7	O
1	O
8	O
1	O
Other3	O
15	O
3	O
11	O
2	O
Nervous	B-D009420
System	I-D009420
Disorders	O
13	O
2	O
18	O
3	O
Headache	B-D006261
7	O
1	O
10	O
2	O
Paresthesia	B-D010292
6	O
1	O
8	O
1	O
Somnolence	O
4	O
1	O
6	O
1	O
Other4	O
4	O
1	O
3	O
<	O
1	O
Foreign	O
labeling	O
describes	O
that	O
dermal	O
allergic	O
reactions	O
may	O
occur	O
with	O
Flector®	O
Patch	O
treatment	O

Additionally,	O
the	O
treated	O
area	O
may	O
become	O
irritated	O
or	O
develop	O
itching,	O
Erythema	B-D004890

Cardiovascular	O
Risk	B-D012306
NSAIDs1	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Diclofenac	B-D004008
Potassium	B-D011188

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug	O

ADVERSE	O
REACTIONS	O
In	O
718	O
Patients	B-D010361

In	O
a	O
6	O
month,	O
double-blind	O
trial	O
comparing	O
Diclofenac	B-D004008

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
Fever	B-D005334

This	O
Risk	B-D012306

•	O
Celecoxib	B-D000068579
Capsules	B-D002214

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
•	O
Celecoxib	B-D000068579
Capsules	B-D002214

(4,	O
5.1)	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
Risk	B-D012306

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

A	O
Randomized	B-D016449
Controlled	I-D016449
Trial	I-D016449

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
Risk	B-D012306

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
Naproxen	B-D009288

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
•Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

•Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

•Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

•Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

•If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
anddiscontinue	O
Celecoxib	B-D000068579

•In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
Blood	B-D001794
Pressure	I-D001794

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
•Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
•Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
•Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
•Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
•Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Mylan	O
at	O
1-877-446-3679	O
(1-877-4-INFO-RX)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥	O
2%	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Celecoxib	B-D000068579
Capsules	B-D002214

Celecoxib	B-D000068579
Capsules	B-D002214
(N	O
=	O
4146)	O
Placebo	O
(N	O
=	O
1864)	O
NAP	O
(N	O
=	O
1366)	O
DCF	O
(N	O
=	O
387)	O
IBU	O
(N	O
=	O
345)	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%	O
5.6%	O
8.8%	O
2.2%	O
3.5%	O
2.8%	O
3.8%	O
6.2%	O
1.0%	O
4.2%	O
7.7%	O
5.3%	O
12.2%	O
3.6%	O
6.0%	O
9.0%	O
9.3%	O
10.9%	O
4.1%	O
3.4%	O
9.0%	O
5.8%	O
12.8%	O
3.5%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%	O
2.1%	O
2.9%	O
3.6%	O
1.1%	O
2.3%	O
2.2%	O
2.1%	O
3.0%	O
2.6%	O
1.0%	O
2.6%	O
0.9%	O
3.5%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
Headache	B-D006261
2.0%	O
15.8%	O
1.7%	O
20.2%	O
2.6%	O
14.5%	O
1.3%	O
15.5%	O
2.3%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
Rhinitis	B-D012220
Sinusitis	B-D012852
Upper	O
Respiratory	O
Infection	O
2.3%	O
2.0%	O
5.0%	O
8.1%	O
1.1%	O
1.3%	O
4.3%	O
6.7%	O
1.7%	O
2.4%	O
4.0%	O
9.9%	O
1.6%	O
2.3%	O
5.4%	O
9.8%	O
2.6%	O
0.6%	O
5.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
Following	O
Adverse	O
Reactions	O
Occurred	O
in	O
0.1%	O
to	O
1.9%	O
of	O
Patients	B-D010361
Treated	O
with	O
Celecoxib	B-D000068579
Capsules	B-D002214
(100	O
mg	O
to	O
200	O
mg	O
Twice	O
Daily	O
or	O
200	O
mg	O
Once	O
Daily)	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
Diverticulitis	B-D004238

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥	O
5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥	O
5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥	O
5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361
with	O
Events)	O
System	O
Organ	O
Class/	O
Preferred	O
Term	O
All	O
Doses	O
Twice	O
Daily	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N	O
=	O
77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N	O
=	O
82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N	O
=	O
83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
Pain	I-D015746

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
Reactions	O
from	O
Long-Term,	O
Placebo-Controlled	O
Polyp	O
Prevention	O
Studies	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Cardiovascular:	O
Vasculitis	B-D014657
,	O
deep	O
Venous	B-D020246
Thrombosis	I-D020246

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS	O
)	O

Etodolac	B-D017308
Capsules	B-D002214

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

,	O
Diarrhea	B-D003967

,	O
Flatulence	B-D005414

,	O
Nausea	B-D009325

,	O
abdominal	O
distension,	O
epigastric	O
Pain	B-D010146

,	O
Dizziness	B-D004244

,	O
Depression	B-D003863

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
Renal	B-D051437
Insufficiency	I-D051437

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
Hypertension	B-D006973
(see	O
WARNINGS	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
•	O
Celecoxib	B-D000068579
Capsules	B-D002214

[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
Gastrointe	O
stinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
WARNING:	O
Risk	B-D012306

•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
•	O
Celecoxib	B-D000068579
Capsules	B-D002214

(4,	O
5.1)	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Celecoxib	B-D000068579

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
Risk	B-D012306

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

A	O
Randomized	B-D016449
Controlled	I-D016449
Trial	I-D016449

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
Risk	B-D012306

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
Naproxen	B-D009288

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(	O
4	O
)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

•	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

•	O
Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

•	O
Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

•	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

•	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
Blood	B-D001794
Pressure	I-D001794

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

5.15	O
Risk	B-D012306
of	O
Allergic	O
Reactions	O
to	O
Tartrazine	B-D013645
This	O
product	O
contains	O
FD&C	O
Yellow	O
No	O

5	O
(tartrazine)	O
which	O
may	O
cause	O
allergic-type	O
reactions	O
(including	O
Bronchi	B-D001980

Although	O
the	O
Overall	B-D016424

5	O
(tartrazine)	O
sensitivity	O
in	O
the	O
general	O
Population	B-D011153

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
•	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
•	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
•	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
•	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
•	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
•	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
•	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
•	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Macleods	O
Pharma	O
USA,	O
Inc	O

at	O
1-888-943-3210	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%	O
5.6%	O
8.8%	O
2.2%	O
3.5%	O
2.8%	O
3.8%	O
6.2%	O
1.0%	O
4.2%	O
7.7%	O
5.3%	O
12.2%	O
3.6%	O
6.0%	O
9.0%	O
9.3%	O
10.9%	O
4.1%	O
3.4%	O
9.0%	O
5.8%	O
12.8%	O
3.5%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%	O
2.1%	O
2.9%	O
3.6%	O
1.1%	O
2.3%	O
2.2%	O
2.1%	O
3.0%	O
2.6%	O
1.0%	O
2.6%	O
0.9%	O
3.5%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1%	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS	O
.)	O
•	O
Indomethacin	B-D007213
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS	O
.)	O
ADVERSE	O
REACTIONS	O
The	O
adverse	O
reactions	O
for	O
Indomethacin	B-D007213

The	O
Incidence	B-D015994

The	O
Incidence	B-D015994

The	O
Probability	B-D011336

Incidence	B-D015994
greater	O
than	O
1%	O
Incidence	B-D015994
less	O
than	O
1%	O
*Reactions	O
occurring	O
in	O
3%	O
to	O
9%	O
of	O
Patients	B-D010361

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
Patients	B-D010361

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
Patients	B-D010361

However,	O
in	O
these	O
rarely	O
reported	O
events,	O
the	O
possibility	O
cannot	O
be	O
excluded	O

Therefore,	O
these	O
Observation	B-D019370

Genitourinary:	O
Urinary	O
frequency	O

A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
Fasciitis	B-D005208

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Aspirin	B-D001241
and	O
extended-release	O
Dipyridamole	B-D004176

Risk	B-D012307
Factors	I-D012307

Intracranial	O
Hemorrhage	B-D006470
In	O
Europe	B-D005060
an	O
Stroke	B-D020521
Prevention	O
Study-2	O
(ESPS2),	O
the	O
annualized	O
event	O
rate	O
for	O
intracranial	O
Hemorrhage	B-D006470

Gastrointestinal	O
(GI)	O
Side	O
Effects	O
GI	O
side	O
effects	O
include	O
Stomach	B-D013270

Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
Dyspepsia	B-D004415

Inform	O
Patients	B-D010361

In	O
ESPS2,	O
the	O
annualized	O
event	O
rate	O
for	O
gastrointestinal	O
bleeding	O
was	O
2.97%/year	O
in	O
the	O
Aspirin	B-D001241

Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
Avoid	O
using	O
Aspirin	B-D001241

Alcohol	O
Warning	O
Because	O
Aspirin	B-D001241

5.2	O
Renal	O
Failure	O
Avoid	O
Aspirin	B-D001241

5.3	O
Hepatic	B-D048550
Insufficiency	I-D048550
Elevations	O
of	O
hepatic	O
Enzymes	B-D004798

5.4	O
Coronary	B-D003324
Artery	I-D003324
Disease	I-D003324
Dipyridamole	B-D004176
has	O
a	O
vasodilatory	O
effect	O

Chest	B-D002637
Pain	I-D002637

For	O
Stroke	B-D020521

5.5	O
Hypotension	B-D007022
Dipyridamole	B-D004176
produces	O
peripheral	O
Vasodilation	B-D014664

5.6	O
General	O
Aspirin	B-D001241
and	O
extended-release	O
Dipyridamole	B-D004176

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Hypersensitivity	B-D006967
[see	O
Contraindications	B-D000075202
(4.1)	O
]	O

Allergy	O
[see	O
Contraindications	B-D000075202
(4.2)	O
]	O

Risk	B-D012306
of	O
Bleeding	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(>10%	O
and	O
greater	O
than	O
placebo)	O
were	O
Headache	B-D006261

6.1	O
Clinical	B-D016430
Trial	I-D016430

The	O
efficacy	O
and	O
Safety	B-D012449

ESPS2	O
was	O
a	O
double-blind,	O
placebo-controlled	O
study	O
that	O
evaluated	O
6602	O
Patients	B-D010361

Patients	B-D010361
were	O
randomized	O
to	O
either	O
Aspirin	B-D001241

This	O
24-month,	O
multicenter,	O
double-blind,	O
randomized	O
study	O
(ESPS2)	O
was	O
conducted	O
to	O
compare	O
the	O
efficacy	O
and	O
Safety	B-D012449

The	O
study	O
was	O
conducted	O
in	O
a	O
total	O
of	O
6602	O
Male	B-D008297

Table	O
1	O
presents	O
the	O
annualized	O
event	O
rate	O
for	O
adverse	O
events	O
that	O
occurred	O
in	O
1%/year	O
or	O
more	O
of	O
Patients	B-D010361

There	O
is	O
no	O
clear	O
benefit	O
of	O
the	O
Dipyridamole	B-D004176

Table	O
1	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
in	O
ESPS2	O
a	O
Individual	O
Treatment	O
Group	O
Body	O
System/Preferred	O
Term	O
Aspirin	B-D001241
and	O
Extended-Release	O
Dipyridamole	B-D004176
n	O
(%/year)b	O
ER-DP	O
Alone	O
n	O
(%/year)b	O
ASA	O
Alone	O
n	O
(%/year)b	O
Placebo	O
n	O
(%/year)b	O
Total	O
Number	O
of	O
Patients	B-D010361
1,650	O
1,654	O
1,649	O
1,649	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Disorders	O
Headache	B-D006261
647	O
(28.25)	O
634	O
(27.91)	O
558	O
(22.10)	O
543	O
(22.29)	O
Gastrointestinal	O
System	O
Disorders	O
Dyspepsia	B-D004415
303	O
(13.23)	O
288	O
(12.68)	O
299	O
(11.84)	O
275	O
(11.29)	O
Abdominal	B-D015746
Pain	I-D015746
289	O
(12.62)	O
255	O
(11.22)	O
262	O
(10.38)	O
239	O
(9.81)	O
Nausea	B-D009325
264	O
(11.53)	O
254	O
(11.18)	O
210	O
(8.32)	O
232	O
(9.53)	O
Diarrhea	B-D003967
210	O
(9.17)	O
257	O
(11.31)	O
112	O
(4.44)	O
161	O
(6.61)	O
Vomiting	B-D014839
138	O
(6.03)	O
129	O
(5.68)	O
101	O
(4.00)	O
118	O
(4.84)	O
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders	O
Hemorrhage	B-D006470
NOS	O
52	O
(2.27)	O
24	O
(1.06)	O
46	O
(1.82)	O
24	O
(0.99)	O
aReported	O
by	O
≥1%/year	O
of	O
Patients	B-D010361

bAnnual	O
event	O
rate	O
per	O
100	O
pt-years	O
=	O
100*	O
number	O
of	O
subjects	O
with	O
event/subject-years	O

Subject-years	O
is	O
defined	O
as	O
cumulative	O
number	O
of	O
days	O
on	O
treatment	O
divided	O
by	O
365.25	O

Note:	O
ER-DP	O
=	O
extended-release	O
Dipyridamole	B-D004176

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O

NOS	O
=	O
not	O
otherwise	O
specified	O

Discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
ESPS2	O
was	O
25%	O
for	O
Aspirin	B-D001241
and	O
Extended-Release	O
Dipyridamole	B-D004176
Group	O
Treatment	O
Groups	O
Aspirin	B-D001241
and	O
Extended-Release	O
Dipyridamole	B-D004176
n	O
(%/year)b	O
ER-DP	O
n	O
(%/year)b	O
ASA	O
n	O
(%/year)b	O
Placebo	O
n	O
(%/year)b	O
Total	O
Number	O
of	O
Patients	B-D010361
1,650	O
1,654	O
1,649	O
1,649	O
Patients	B-D010361
with	O
at	O
least	O
one	O
Adverse	O
Event	O
that	O
led	O
to	O
treatment	O
discontinuation	O
417	O
(18.21)	O
419	O
(18.44)	O
318	O
(12.59)	O
352	O
(14.45)	O
Headache	B-D006261
165	O
(7.20)	O
166	O
(7.31)	O
57	O
(2.26)	O
69	O
(2.83)	O
Nausea	B-D009325
91	O
(3.97)	O
95	O
(4.18)	O
51	O
(2.02)	O
53	O
(2.18)	O
Abdominal	B-D015746
Pain	I-D015746
74	O
(3.23)	O
64	O
(2.82)	O
56	O
(2.22)	O
52	O
(2.13)	O
Vomiting	B-D014839
53	O
(2.31)	O
52	O
(2.29)	O
28	O
(1.11)	O
24	O
(0.99)	O
aReported	O
by	O
≥1%/year	O
of	O
Patients	B-D010361

bAnnual	O
event	O
rate	O
per	O
100	O
pt-years	O
=	O
100*	O
number	O
of	O
subjects	O
with	O
event/subject-years	O

Subject-years	O
is	O
defined	O
as	O
cumulative	O
number	O
of	O
days	O
on	O
treatment	O
divided	O
by	O
365.25	O

Note:	O
ER-DP	O
=	O
extended-release	O
Dipyridamole	B-D004176

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O

Headache	B-D006261
was	O
most	O
notable	O
in	O
the	O
first	O
month	O
of	O
treatment	O

6.2	O
Post	O
Marketing	B-D040541
Experience	O
The	O
following	O
is	O
a	O
list	O
of	O
additional	O
adverse	O
reactions	O
that	O
have	O
been	O
reported	O
either	O
in	O
the	O
Literature	B-D008091

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Decisions	O
to	O
include	O
these	O
reactions	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
reaction,	O
(2)	O
frequency	O
of	O
reporting,	O
or	O
(3)	O
strength	O
of	O
causal	O
connection	O
to	O
Aspirin	B-D001241

Body	O
as	O
a	O
Whole:	O
Hypothermia	B-D007035
,	O
Chest	B-D002637
Pain	I-D002637

Allergy	O
alert:	O
Ibuprofen	B-D007052
may	O
cause	O
a	O
severe	O
allergic	O
reaction,	O
especially	O
in	O
people	O
allergic	O
to	O
Aspirin	B-D001241
	O

Symptoms	O
may	O
include	O
HIV	B-D006678

Stomach	B-D013270
bleeding	O
warning:	O
This	O
product	O
contains	O
an	O
NSAID,	O
which	O
may	O
cause	O
severe	O
Stomach	B-D013270

The	O
chance	O
is	O
higher	O
if	O
you	O
are	O
age	O
60	O
or	O
older	O
have	O
had	O
Stomach	B-D013276
Ulcer	I-D013276

This	O
Risk	B-D012306

—	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Eighty-seven	O
percent	O
(87%)	O
of	O
the	O
Diclofenac	B-D004008

The	O
majority	O
of	O
these	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
upon	O
discontinuation	O
of	O
therapy	O

Of	O
the	O
211	O
Patients	B-D010361

Application	O
site	O
reactions	O
(ASRs)	O
were	O
the	O
most	O
frequent	O
AEs	O
in	O
both	O
Diclofenac	B-D004008

Of	O
note,	O
four	O
reactions,	O
contact	O
Dermatitis	B-D003872

Eighteen	O
percent	O
of	O
Diclofenac	B-D004008

These	O
discontinuations	O
were	O
mainly	O
due	O
to	O
Skin	B-D012867

Table	O
1	O
below	O
presents	O
the	O
AEs	O
reported	O
at	O
an	O
Incidence	B-D015994

Table	O
1	O

Adverse	O
Events	O
Reported	O
(>1%	O
in	O
Any	O
Treatment	O
Group)	O
During	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
Phase	O
3	O
Clinical	B-D016430
Trial	I-D016430
s	O
Incidence	B-D015994
s	O
for	O
60-Day	O
and	O
90-Day	O
Treatments	O
60-day	O
Treatment	O
90-day	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
(%)	O
Gel	O
Vehicle	O
(%)	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
(%)	O
Gel	O
Vehicle	O
(%)	O
N=48	O
N=49	O
N=114	O
N=114	O
BODY	O
AS	O
A	O
WHOLE	O
21	O
20	O
20	O
18	O
Abdominal	B-D015746
Pain	I-D015746
2	O
0	O
1	O
0	O
Accidental	O
Injury	O
0	O
0	O
4	O
2	O
Allergic	O
Reaction	O
0	O
0	O
1	O
3	O
Asthenia	B-D001247
0	O
0	O
2	O
0	O
Back	B-D001416
Pain	I-D001416
4	O
0	O
2	O
2	O
Chest	B-D002637
Pain	I-D002637
2	O
0	O
1	O
0	O
Chills	B-D023341
0	O
2	O
0	O
0	O
Flu	O
Syndrome	B-D013577
10	O
6	O
1	O
4	O
Headache	B-D006261
0	O
6	O
7	O
6	O
Infection	O
4	O
6	O
4	O
5	O
Neck	B-D019547
Pain	I-D019547
0	O
0	O
2	O
0	O
Pain	B-D010146
2	O
0	O
2	O
2	O
Cardiovascular	B-D002319
System	I-D002319

Adverse	O
Reactions	O
Reported	O
for	O
Oral	O
Diclofenac	B-D004008
Dosage	O
Form	B-D020478
(not	O
topical	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%):	O
*Incidence	O
greater	O
than	O
1%	O
marked	O
with	O
asterisk	O

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

Cardiovascular:	O
Hypertension	B-D006973

Digestive:	O
Diarrhea	B-D003967

Hemic	O
and	O
Lymph	B-D008196
atic:	O
hemoglobin	B-C032001
D	I-C032001

Metabolic	O
and	O
Nutritional	O
Disorders:	O
Azotemia	B-D053099

Nervous	B-D009420
System	I-D009420
:	O
Dizziness	B-D004244

Respiratory:	O
Epistaxis	B-D004844

Skin	B-D012867
and	O
Appendages:	O
rash*,	O
Pruritus	B-D011537

Special	O
Senses:	O
Tinnitus	B-D014012

Urogenital:	O
Nephrotic	B-D009404
Syndrome	I-D009404

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
CELEBREX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
CELEBREX	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

[see	O
Contraindications	B-D000075202
(4)	O
and	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celebrex	O
in	O
Patients	B-D010361

If	O
Celebrex	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
CELEBREX	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
CELEBREX	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

The	O
rates	O
of	O
Hypertension	B-D006973

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

If	O
CELEBREX	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
CELEBREX	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

If	O
CELEBREX	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celebrex	O
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
Sulfonamides	B-D013449

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
CELEBREX	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

CELEBREX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
CELEBREX,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
CELEBREX	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

NSAIDs,	O
including	O
CELEBREX,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
CELEBREX-treated	O
Patients	B-D010361

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
CELEBREX	O
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;	O
NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;	O
DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;	O
IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
Dyspepsia	B-D004415

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
Diclofenac	B-D004008

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
Dysmenorrhea	B-D004412

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Etodolac	B-D017308
Capsules	B-D002214

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
That	O
or	O
Equal	O
to	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

,	O
Diarrhea	B-D003967

,	O
Flatulence	B-D005414

,	O
Nausea	B-D009325

,	O
Constipation	B-D003248

Nervous	B-D009420
System	I-D009420

,	O
Dizziness	B-D004244

,	O
Depression	B-D003863

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

*Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
–	O
Sepsis	B-D018805
,	O
Death	B-D003643

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Urogenital	B-D014566
System	I-D014566

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Voltaren®	O
Gel	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy	O

Borderline	O
elevations	O
(i.e	O

less	O
than	O
3	O
Time	B-D013995

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
Liver	B-D008099

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/orAST	O
occurred	O
in	O
about	O
4%	O
of	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
Physicians	B-D010820

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Caution	O
should	O
be	O
Exercise	B-D015444

(5.3)	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

(5.6)	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

Voltaren®	O
Gel	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

(5.7)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Gastrointestinal	O
Effects	O
–	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.3	O
Hepatic	O
Effects	O
Elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy	O

Borderline	O
elevations	O
(i.e	O

less	O
than	O
3	O
Time	B-D013995

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
Liver	B-D008099

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/orAST	O
occurred	O
in	O
about	O
4%	O
of	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

To	O
minimize	O
the	O
possibility	O
that	O
hepatic	O
injury	O
will	O
become	O
severe	O
between	O
transaminase	O
measurements,	O
Physicians	B-D010820

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Caution	O
should	O
be	O
Exercise	B-D015444

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Voltaren®	O
Gel,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Voltaren®	O
Gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Blood	B-D001794
Pressure	I-D001794

5.5	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

Voltaren®	O
Gel	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Voltaren®	O
Gel	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
Voltaren®	O
Gel	O
is	O
not	O
recommended	O
in	O
Patients	B-D010361

If	O
Voltaren®	O
Gel	O
therapy	O
is	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

Voltaren®	O
Gel	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Voltaren®	O
Gel,	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

Voltaren®	O
Gel	O
should	O
not	O
be	O
applied	O
to	O
open	O
Skin	B-D012867

Voltaren®	O
Gel	O
should	O
not	O
be	O
allowed	O
to	O
come	O
into	O
contact	O
with	O
the	O
Eye	B-D005123

The	O
effect	O
of	O
Voltaren®	O
Gel	O
under	O
Occlusive	B-D009779
Dressings	I-D009779

5.9	O
Pregnancy	B-D011247
As	O
with	O
other	O
NSAIDs,	O
Voltaren®	O
Gel	O
should	O
be	O
avoided	O
in	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
treatment	O
Voltaren®	O
Gel	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.12	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
Blood	B-D001769

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
including	O
Voltaren®	O
Gel,	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

NSAIDs	O
inhibit	O
Platelet	B-D010974
Aggregation	I-D010974

Unlike	O
Aspirin	B-D001241

Patients	B-D010361
treated	O
with	O
Voltaren®	O
Gel	O
who	O
may	O
be	O
adversely	O
Affect	B-D000339

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Sun	O
Exposure	O
Patients	B-D010361
should	O
minimize	O
or	O
avoid	O
exposure	O
to	O
natural	O
or	O
Art	B-D001154

The	O
potential	O
effects	O
of	O
Voltaren®	O
Gel	O
on	O
Skin	B-D012867

5.15	O
Eye	B-D005123
Exposure	O
Contact	O
of	O
Voltaren®	O
Gel	O
with	O
Eye	B-D005123

Patients	B-D010361
should	O
be	O
advised	O
that	O
if	O
Eye	B-D005123

5.16	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs,	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

6	O
ADVERSE	O
REACTIONS	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
development,	O
913	O
Patients	B-D010361

Of	O
these,	O
513	O
Patients	B-D010361

Additionally,	O
583	O
Patients	B-D010361

Of	O
these,	O
355	O
Patients	B-D010361

Duration	O
of	O
exposure	O
ranged	O
from	O
8	O
to	O
12	O
weeks	O
for	O
the	O
placebo-controlled	O
studies,	O
and	O
up	O
to	O
12	O
months	O
for	O
the	O
open-label	O
Safety	B-D012449

Short-Term	O
Placebo-Controlled	O
Trials:	O
Adverse	O
reactions	O
observed	O
in	O
at	O
least	O
1%	O
of	O
Patients	B-D010361

These	O
were	O
the	O
only	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
1%	O
of	O
treated	O
Patients	B-D010361

Table	O
1	O
lists	O
the	O
types	O
of	O
application	O
site	O
reactions	O
reported	O

Application	O
site	O
Dermatitis	B-D003872

Table	O
1:	O
Non-serious	O
Application	O
Site	O
Adverse	O
Reactions	O
(≥	O
1%	O
Voltaren®	O
Gel	O
Patients	B-D010361
)	O
–	O
Short-term	O
Controlled	O
Trials	O
Adverse	O
Reaction	O
†	O
Voltaren	O
®	O
Gel	O
N	O
=	O
913	O
Placebo	O
(vehicle)	O
N	O
=	O
876	O
N	O
(%)	O
N	O
(%)	O
Any	O
application	O
site	O
reaction	O
62	O
(7)	O
19	O
(2)	O
Application	O
site	O
Dermatitis	B-D003872

In	O
the	O
placebo-controlled	O
trials,	O
the	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
was	O
5%	O
for	O
Patients	B-D010361

Application	O
site	O
reactions,	O
including	O
application	O
site	O
Dermatitis	B-D003872

Long-term	O
Open-label	O
Safety	B-D012449
Trial:	O
In	O
the	O
open-label,	O
long-term	O
Safety	B-D012449

In	O
this	O
study,	O
where	O
Patients	B-D010361

Adverse	O
reactions	O
that	O
led	O
to	O
the	O
discontinuation	O
of	O
the	O
study	O
drug	O
were	O
experienced	O
in	O
12%	O
of	O
Patients	B-D010361

The	O
most	O
common	O
adverse	O
reaction	O
that	O
led	O
to	O
discontinuation	O
of	O
the	O
study	O
was	O
application	O
site	O
Dermatitis	B-D003872

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

SPRIX®	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDS	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDS)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

(5.3)	O
Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
Blood	B-D001794
Pressure	I-D001794

(5.4,	O
7)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
SPRIX	O
in	O
Patients	B-D010361

(5.5)	O
Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
use	O
of	O
SPRIX	O
in	O
Patients	B-D010361

(5.6)	O
Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

(5.7)	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
SPRIX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

(5.8)	O
Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
SPRIX	O
at	O
first	O
appearance	O
of	O
Skin	B-D012867

(5.9)	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
Pregnant	B-D037841
Women	I-D037841

(5.10,	O
8.1)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Do	O
not	O
use	O
SPRIX	O
in	O
Patients	B-D010361

(5.11,	O
7)	O
Limitations	O
of	O
Use:	O
SPRIX	O
should	O
not	O
be	O
used	O
concomitantly	O
with	O
IM/IV	O
or	O
oral	O
Ketorolac	B-D020910

(5.15)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
SPRIX	O
in	O
Patients	B-D010361

If	O
SPRIX	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
SPRIX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

NSAIDs,	O
including	O
Ketorolac	B-D020910

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Do	O
not	O
use	O
Sprix	O
in	O
those	O
with	O
active	O
GI	O
bleeding	O

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
SPRIX	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

Use	O
great	O
care	O
when	O
giving	O
SPRIX	O
to	O
Patients	B-D010361

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
SPRIX,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Ketorolac	B-D020910

Avoid	O
the	O
use	O
of	O
SPRIX	O
in	O
Patients	B-D010361

If	O
SPRIX	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Ketorolac	B-D020910
and	O
its	O
metabolites	O
are	O
eliminated	O
primarily	O
by	O
the	O
Kidney	B-D007668

Patients	B-D010361
with	O
reduced	O
Creatinine	B-D003404

SPRIX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
SPRIX	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
SPRIX	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
SPRIX	O
in	O
Patients	B-D010361

If	O
SPRIX	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Ketorolac	B-D020910
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
SPRIX	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Ketorolac	B-D020910

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

SPRIX	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Ketorolac	B-D020910
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
SPRIX,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
SPRIX	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

Do	O
not	O
use	O
SPRIX	O
in	O
Patients	B-D010361

NSAIDs,	O
including	O
SPRIX,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

The	O
concurrent	O
use	O
of	O
Ketorolac	B-D020910

Until	O
data	O
from	O
such	O
studies	O
are	O
available,	O
carefully	O
weigh	O
the	O
benefits	O
against	O
the	O
Risk	B-D012306

Monitor	O
Patients	B-D010361

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
Clinical	B-D016430
Trial	I-D016430

Therefore,	O
use	O
SPRIX	O
with	O
caution	O
in	O
the	O
postoperative	O
setting	O
when	O
Hemostasis	B-D006487

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
SPRIX	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
SPRIX	O
with	O
the	O
Eye	B-D005123

If	O
Eye	B-D005123

5.15	O
Limitations	O
of	O
Use	O
The	O
total	O
duration	O
of	O
use	O
of	O
SPRIX	O
alone	O
or	O
sequentially	O
with	O
other	O
Form	B-D020478

SPRIX	O
must	O
not	O
be	O
used	O
concomitantly	O
with	O
other	O
Form	B-D020478

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥2%)	O
in	O
Patients	B-D010361

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Zyla	O
Life	B-D019369
Science	B-D012586
s	O
US	O
Inc	O

at	O
1-800-518-1084	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
SPRIX	O
in	O
Patients	B-D010361

The	O
studies	O
enrolled	O
828	O
Patients	B-D010361

The	O
Patients	B-D010361

Most	O
Patients	B-D010361

The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
were	O
related	O
to	O
local	O
symptoms,	O
i.e.,	O
nas	B-C015378
al	O
discomfort	O
or	O
irritation	O

These	O
reactions	O
were	O
generally	O
mild	O
and	O
transient	O
in	O
Nature	B-D019368

The	O
most	O
common	O
drug-related	O
adverse	O
events	O
Lead	B-D007854

Table	O
1:	O
Post-Operative	O
Patients	B-D010361
with	O
Adverse	O
Reactions	O
Observed	O
at	O
a	O
Rate	O
of	O
2%	O
or	O
More	O
and	O
at	O
Least	O
Twice	O
the	O
Incidence	B-D015994
of	O
the	O
Placebo	O
Group	O

SPRIX	O
(N	O
=	O
455)	O
Placebo(N	O
=	O
245)	O
nas	B-C015378

Six	O
of	O
the	O
seven	O
Patients	B-D010361

Adverse	O
Reactions	O
Reported	O
in	O
Clinical	B-D016430
Trial	I-D016430
s	O
with	O
Other	O
Dosage	B-D004304
Forms	I-D004304
of	O
Ketorolac	B-D020910
or	O
Other	O
NSAIDs	O
Adverse	O
reaction	O
rates	O
increase	O
with	O
higher	O
doses	O
of	O
Ketorolac	B-D020910

It	O
is	O
necessary	O
to	O
remain	O
alert	O
for	O
the	O
severe	O
complications	O
of	O
treatment	O
with	O
Ketorolac	B-D020910

These	O
complications	O
can	O
be	O
serious	O
in	O
certain	O
Patients	B-D010361

In	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Other	O
observed	O
reactions	O
(reported	O
from	O
postmarketing	O
experience	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

Diclofenac	B-D004008
Potassium	B-D011188

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Diclofenac	B-D004008
Potassium	B-D011188

Monitor	O
Patients	B-D010361

(5.10)	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
high	O
Risk	B-D012306

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
persist,	O
or	O
may	O
only	O
be	O
transient	O
with	O
continued	O
therapy	O

Borderline	O
elevations	O
(less	O
than	O
3	O
Time	B-D013995

Of	O
the	O
markers	O
of	O
hepatic	O
function,	O
ALT	O
(SGPT)	O
is	O
recommended	O
for	O
the	O
monitoring	O
of	O
Liver	B-D008099

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
an	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
Patients	B-D010361

In	O
this	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
NSAID	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

Caution	O
Patients	B-D010361

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Use	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
Thiazides	B-D049971

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Diclofenac	B-D004008

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Diclofenac	B-D004008
Potassium	B-D011188

5.10	O
Medication	O
Overuse	O
Headache	B-D006261
Overuse	O
of	O
acute	O
migraine	O
drugs	O
(e.g.,	O
Ergotamine	B-D004878

Medication	O
overuse	O
Headache	B-D006261

Detoxification	O
of	O
Patients	B-D010361

5.11	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
Potassium	B-D011188

Starting	O
at	O
30	O
weeks	O
gestation,	O
Diclofenac	B-D004008

If	O
this	O
drug	O
is	O
used	O
during	O
this	O
Time	B-D013995

5.12	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

Concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.13	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.14	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

Discontinue	O
Diclofenac	B-D004008

5.15	O
Phenylketonurics	O
Diclofenac	B-D004008
Potassium	B-D011188

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.12)]	O
Most	O
common	O
adverse	O
reactions	O
(≥1%	O
and	O
>placebo)	O
were	O
Nausea	B-D009325

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
Safety	B-D012449

Following	O
treatment	O
with	O
Diclofenac	B-D004008

The	O
most	O
common	O
adverse	O
reactions	O
(i.e.,	O
that	O
occurred	O
in	O
1%	O
or	O
more	O
of	O
Diclofenac	B-D004008

Table	O
1:	O
Adverse	O
Reactions	O
With	O
Incidence	B-D015994
>1%	O
and	O
Greater	O
Than	O
Placebo	O
in	O
Studies	O
1	O
and	O
2	O
Combined	O
Adverse	O
Reactions	O
Diclofenac	B-D004008
Potassium	B-D011188
for	O
Oral	O
Solution	O
Placebo	O
N=634	O
N=646	O
Gastrointestinal	O
Nausea	B-D009325
3%	O
2%	O
Nervous	B-D009420
System	I-D009420
Dizziness	B-D004244
1%	O
0.5%	O
The	O
most	O
common	O
adverse	O
events	O
resulting	O
in	O
discontinuation	O
of	O
Patients	B-D010361

No	O
withdrawals	O
were	O
due	O
to	O
a	O
serious	O
reaction	O

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Adverse	O
Reactions	O
Reported	O
With	O
Diclofenac	B-D004008
and	O
Other	O
NSAIDs	O
In	O
Patients	B-D010361

Additional	O
adverse	O
reactions	O
reported	O
in	O
Patients	B-D010361

Risk	B-D012307
Factors	I-D012307

Intracranial	O
Hemorrhage	B-D006470
In	O
Europe	B-D005060
an	O
Stroke	B-D020521
Prevention	O
Study-2	O
(ESPS2),	O
the	O
annualized	O
event	O
rate	O
for	O
intracranial	O
Hemorrhage	B-D006470

Gastrointestinal	O
(GI)	O
Side	O
Effects	O
GI	O
side	O
effects	O
include	O
Stomach	B-D013270

Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
Dyspepsia	B-D004415

Inform	O
Patients	B-D010361

In	O
ESPS2,	O
the	O
annualized	O
event	O
rate	O
for	O
gastrointestinal	O
bleeding	O
was	O
2.97%/year	O
in	O
the	O
AGGRENOX	O
group,	O
1.58%/year	O
in	O
the	O
extended-release	O
Dipyridamole	B-D004176

Peptic	B-D010437
Ulcer	I-D010437
Disease	B-D004194
Avoid	O
using	O
Aspirin	B-D001241

Alcohol	O
Warning	O
Because	O
AGGRENOX	O
contains	O
Aspirin	B-D001241

5.2	O
Renal	O
Failure	O
Avoid	O
Aspirin	B-D001241

5.3	O
Hepatic	B-D048550
Insufficiency	I-D048550
Elevations	O
of	O
hepatic	O
Enzymes	B-D004798

5.4	O
Coronary	B-D003324
Artery	I-D003324
Disease	I-D003324
Dipyridamole	B-D004176
has	O
a	O
vasodilatory	O
effect	O

Chest	B-D002637
Pain	I-D002637

For	O
Stroke	B-D020521

5.5	O
Hypotension	B-D007022
Dipyridamole	B-D004176
produces	O
peripheral	O
Vasodilation	B-D014664

5.6	O
Stress	O
TES	B-C004551

Adenosine	B-D000241

Intake	O
of	O
AGGRENOX	O
Capsules	B-D002214

5.7	O
General	O
AGGRENOX	O
Capsules	B-D002214

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling:	O
Hypersensitivity	B-D006967
[see	O
Contraindications	B-D000075202
(4.1)]	O
Allergy	O
[see	O
Contraindications	B-D000075202
(4.2)]	O
Risk	B-D012306
of	O
Bleeding	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(>10%	O
and	O
greater	O
than	O
placebo)	O
were	O
Headache	B-D006261

at	O
(800)	O
542-6257	O
or	O
(800)	O
459-9906	O
TTY	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
efficacy	O
and	O
Safety	B-D012449

ESPS2	O
was	O
a	O
double-blind,	O
placebo-controlled	O
study	O
that	O
evaluated	O
6602	O
Patients	B-D010361

Patients	B-D010361
were	O
randomized	O
to	O
either	O
AGGRENOX,	O
Aspirin	B-D001241

This	O
24-month,	O
multicenter,	O
double-blind,	O
randomized	O
study	O
(ESPS2)	O
was	O
conducted	O
to	O
compare	O
the	O
efficacy	O
and	O
Safety	B-D012449

The	O
study	O
was	O
conducted	O
in	O
a	O
total	O
of	O
6602	O
Male	B-D008297

Table	O
1	O
presents	O
the	O
annualized	O
event	O
rate	O
for	O
adverse	O
events	O
that	O
occurred	O
in	O
1%/year	O
or	O
more	O
of	O
Patients	B-D010361

There	O
is	O
no	O
clear	O
benefit	O
of	O
the	O
Dipyridamole	B-D004176

Table	O
1	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
in	O
ESPS2a	O
Individual	O
Treatment	O
Group	O
Body	O
System/Preferred	O
Term	O
AGGRENOXn	O
(%/year)b	O
ER-DP	O
Alonen	O
(%/year)b	O
ASA	O
Alonen	O
(%/year)b	O
Placebon	O
(%/year)b	O
aReported	O
by	O
≥1%/year	O
of	O
Patients	B-D010361

bAnnual	O
event	O
rate	O
per	O
100	O
pt-years	O
=	O
100*	O
number	O
of	O
subjects	O
with	O
event/subject-years	O

Subject-years	O
is	O
defined	O
as	O
cumulative	O
number	O
of	O
days	O
on	O
treatment	O
divided	O
by	O
365.25	O

Note:	O
ER-DP	O
=	O
extended-release	O
Dipyridamole	B-D004176

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O

NOS	O
=	O
not	O
otherwise	O
specified	O

Total	O
Number	O
of	O
Patients	B-D010361
1650	O
1654	O
1649	O
1649	O
Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Disorders	O
Headache	B-D006261
647	O
(28.25)	O
634	O
(27.91)	O
558	O
(22.10)	O
543	O
(22.29)	O
Gastrointestinal	O
System	O
Disorders	O
Dyspepsia	B-D004415
303	O
(13.23)	O
288	O
(12.68)	O
299	O
(11.84)	O
275	O
(11.29)	O
Abdominal	B-D015746
Pain	I-D015746
289	O
(12.62)	O
255	O
(11.22)	O
262	O
(10.38)	O
239	O
(9.81)	O
Nausea	B-D009325
264	O
(11.53)	O
254	O
(11.18)	O
210	O
(8.32)	O
232	O
(9.53)	O
Diarrhea	B-D003967
210	O
(9.17)	O
257	O
(11.31)	O
112	O
(4.44)	O
161	O
(6.61)	O
Vomiting	B-D014839
138	O
(6.03)	O
129	O
(5.68)	O
101	O
(4.00)	O
118	O
(4.84)	O
Platelet,	O
Bleeding	O
and	O
Clotting	O
Disorders	O
Hemorrhage	B-D006470
NOS	O
52	O
(2.27)	O
24	O
(1.06)	O
46	O
(1.82)	O
24	O
(0.99)	O
Discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
ESPS2	O
was	O
25%	O
for	O
AGGRENOX,	O
25%	O
for	O
extended-release	O
Dipyridamole	B-D004176

Table	O
2	O
Incidence	B-D015994
of	O
Adverse	O
Events	O
that	O
Led	O
to	O
the	O
Discontinuation	O
of	O
Treatmenta	O
Treatment	O
Groups	O
AGGRENOXn	O
(%/year)b	O
ER-DPn	O
(%/year)b	O
ASAn	O
(%/year)b	O
Placebon	O
(%/year)b	O
aReported	O
by	O
≥1%/year	O
of	O
Patients	B-D010361

bAnnual	O
event	O
rate	O
per	O
100	O
pt-years	O
=	O
100*	O
number	O
of	O
subjects	O
with	O
event/subject-years	O

Subject-years	O
is	O
defined	O
as	O
cumulative	O
number	O
of	O
days	O
on	O
treatment	O
divided	O
by	O
365.25	O

Note:	O
ER-DP	O
=	O
extended-release	O
Dipyridamole	B-D004176

The	O
dosage	O
regimen	O
for	O
all	O
treatment	O
groups	O
is	O
BID	O

Total	O
Number	O
of	O
Patients	B-D010361
1650	O
1654	O
1649	O
1649	O
Patients	B-D010361
with	O
at	O
least	O
one	O
Adverse	O
Event	O
that	O
led	O
to	O
treatment	O
discontinuation	O
417	O
(18.21)	O
419	O
(18.44)	O
318	O
(12.59)	O
352	O
(14.45)	O
Headache	B-D006261
165	O
(7.20)	O
166	O
(7.31)	O
57	O
(2.26)	O
69	O
(2.83)	O
Nausea	B-D009325
91	O
(3.97)	O
95	O
(4.18)	O
51	O
(2.02)	O
53	O
(2.18)	O
Abdominal	B-D015746
Pain	I-D015746
74	O
(3.23)	O
64	O
(2.82)	O
56	O
(2.22)	O
52	O
(2.13)	O
Vomiting	B-D014839
53	O
(2.31)	O
52	O
(2.29)	O
28	O
(1.11)	O
24	O
(0.99)	O
Headache	B-D006261
was	O
most	O
notable	O
in	O
the	O
first	O
month	O
of	O
treatment	O

6.2	O
Post-Marketing	O
Experience	O
The	O
following	O
is	O
a	O
list	O
of	O
additional	O
adverse	O
reactions	O
that	O
have	O
been	O
reported	O
either	O
in	O
the	O
Literature	B-D008091

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Decisions	O
to	O
include	O
these	O
reactions	O
in	O
labeling	O
are	O
typically	O
based	O
on	O
one	O
or	O
more	O
of	O
the	O
following	O
factors:	O
(1)	O
seriousness	O
of	O
the	O
reaction,	O
(2)	O
frequency	O
of	O
reporting,	O
or	O
(3)	O
strength	O
of	O
causal	O
connection	O
to	O
AGGRENOX	O

Body	O
as	O
a	O
Whole:	O
Hypothermia	B-D007035
,	O
Chest	B-D002637
Pain	I-D002637

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Diclofenac	B-D004008
Potassium	B-D011188

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
•Hepatotoxicity	O
(see	O
WARNINGS)	O
•Hypertension	O
(see	O
WARNINGS)	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
•Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
•Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
•Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
718	O
Patients	B-D010361

In	O
a	O
6-month,	O
double-blind	O
trial	O
comparing	O
Diclofenac	B-D004008

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
Celecoxib	B-D000068579
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,	O
14.6)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

•	O
Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

•	O
Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
Celecoxib	B-D000068579

•	O
New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

•	O
Fluid	O
retention	O
and	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

•	O
Renal	O
papillary	O
Necrosis	B-D009336

Use	O
Celecoxib	B-D000068579

•	O
Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
Celecoxib	B-D000068579

•	O
Serious	O
Skin	B-D012867

Discontinue	O
Celecoxib	B-D000068579

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovasculardeath,	O
MI,	O
or	O
Stroke	B-D020521

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/orsymptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Celecoxib	B-D000068579
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
PerforationNSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

Therefore,	O
treatment	O
with	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
postmarketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

Celecoxib	B-D000068579
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
Celecoxib	B-D000068579
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

Celecoxib	B-D000068579
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Celecoxib	B-D000068579
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
Celecoxib	B-D000068579

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reactioninformation	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sydon	O
Labs,	O
LLC	O
at	O
1	O
866-487-4695	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
>2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4,	O
146	O
Placebo	O
N=1,	O
864	O
NAP	O
N=1,	O
366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
Diarrhea	B-D003967
Dyspepsia	B-D004415
Flatulence	B-D005414
Nausea	B-D009325
4.1%5.6%	O
8.8%	O
2.2%	O
3.5%	O
2.8%3.8%	O
6.2%	O
1%	O
4.2%	O
7.7%5.3%	O
12.2%	O
3.6%	O
6%	O
9%9.3%	O
10.9%	O
4.1%	O
3.4%	O
9%5.8%	O
12.8%	O
3.5%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
Peripheral	O
Edema	B-D004487
Injury-Accidental	O
2.8%2.1%	O
2.9%	O
3.6%1.1%	O
2.3%	O
2.2%2.1%	O
3%	O
2.6%1%	O
2.6%	O
0.9%3.5%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
Patients	B-D010361

Thelower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(>5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
>5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
postdental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

(5.1)	O
FENORTHO	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O

FENORTHO	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
FENORTHO	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
FENORTHO	O
in	O
Patients	B-D010361

If	O
FENORTHO	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
FENORTHO,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
Inflammation	B-D007249

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
FENORTHO	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
FENORTHO,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Fenoprofen	B-D005279

Avoid	O
the	O
use	O
of	O
FENORTHO	O
in	O
Patients	B-D010361

If	O
FENORTHO	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
FENORTHO	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
FENORTHO	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
FENORTHO	O
in	O
Patients	B-D010361

If	O
FENORTHO	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Fenoprofen	B-D005279
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
FENORTHO	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
fenoprop	B-C009264
fen,	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

FENORTHO	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Fenoprofen	B-D005279
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
FENORTHO,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
FENORTHO	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
FENORTHO,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
FENORTHO	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Ocular	O
Effects	O
Studies	O
to	O
date	O
have	O
not	O
shown	O
changes	O
in	O
the	O
Eye	B-D005123

However,	O
adverse	O
ocular	O
effects	O
have	O
been	O
observed	O
with	O
other	O
anti-inflammatory	O
drugs	O

Eye	B-D005123
examinations,	O
therefore,	O
should	O
be	O
performed	O
if	O
visual	O
disturbances	O
occur	O
in	O
Patients	B-D010361

5.15	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Caution	O
should	O
be	O
Exercise	B-D015444

5.16	O
Impact	O
on	O
Hearing	B-D006309
Since	O
the	O
Safety	B-D012449

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
5%)	O
are	O
Dyspepsia	B-D004415
,	O
Headache	B-D006261

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Sterling-Knight	O
Pharmaceuticals	O

LLC	O
at	O
1-888-460-1531	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
(6)	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
studies	O
for	O
Rheum	B-D012250

These	O
encompass	O
Observation	B-D019370

For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
Patients	B-D010361

During	O
short-term	O
studies	O
for	O
Analgesia	B-D000698

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
>1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—	O
During	O
Clinical	B-D016430
Trial	I-D016430

In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
Dyspepsia	B-D004415

2.3%	O
placebo),	O
Nausea	B-D009325

7.1%),	O
Constipation	B-D003248

1.5%),	O
Vomiting	B-D014839

1.9%),	O
Abdominal	B-D015746
Pain	I-D015746

1.1%),	O
and	O
Diarrhea	B-D003967

4.1%)	O

The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
Patients	B-D010361

Nervous	B-D009420
System	I-D009420
—	O
The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
Headache	B-D006261

7.5%)	O
and	O
somnolence	O
(8.5%	O
vs	O

6.4%)	O

Dizziness	B-D004244
(6.5%	O
vs	O

5.6%),	O
Tremor	B-D014202

0.4%),	O
and	O
Confusion	B-D003221

none)	O
were	O
noted	O
less	O
frequently	O

Fenortho	O
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Skin	B-D012867
and	O
Appendages—	O
Increased	O
Sweating	B-D013546

0.4%),	O
Pruritus	B-D011537

0.8%),	O
and	O
rash	O
(3.7%	O
vs	O

0.4%)	O
were	O
reported	O

Fenortho	O
was	O
discontinued	O
in	O
about	O
1%	O
of	O
Patients	B-D010361

Special	O
Senses	O
—	O
Tinnitus	B-D014012
(4.5%	O
vs	O

0.4%),	O
blurred	O
vision	O
(2.2%	O
vs	O

none),	O
and	O
decreased	O
Hearing	B-D006309

none)	O
were	O
reported	O

Fenortho	O
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Cardiovascular	O
—	O
Palpitations	O
(2.5%	O
vs	O

0.4%)	O

Fenortho	O
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
Patients	B-D010361

Miscellaneous	O
—	O
Nervousness	O
(5.7%	O
vs	O

1.5%),	O
Asthenia	B-D001247

0.4%),	O
peripheral	O
Edema	B-D004487

0.4%),	O
Dyspnea	B-D004417

none),	O
Fatigue	B-D005221

1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs	O

5.6%),	O
and	O
nas	B-C015378
opharyngitis	O
(1.2%	O
vs	O

none)	O

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—Gastritis,	O
Peptic	B-D010437
Ulcer	I-D010437

Increases	O
in	O
Alkaline	B-D000469
Phosphatase	I-D000469

Cardiovascular—Atrial	O
fibrillation,	O
Pulmonary	B-D011654
Edema	I-D011654

Genitourinary	O
Tract—Renal	O
failure,	O
Dysuria	B-D053159

Hypersensitivity	B-D006967
—Angioedema	O
(angioneurotic	O
Edema	B-D004487

Hematologic—Purpura,	O
bruising,	O
Hemorrhage	B-D006470

Nervous	B-D009420
System	I-D009420
—Depression,	O
disorientation,	O
Seizures	B-D012640

Special	O
Senses—Burning	O
Tongue	B-D014059

Skin	B-D012867
and	O
Appendages—Exfoliative	O
Dermatitis	B-D003872

Miscellaneous—Anaphylaxis,	O
Urticaria	B-D014581

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
)	O

WARNINGS	O
Diclofenac	B-D004008
Sodium	B-D012964

WARNINGS	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
)	O

WARNINGS	O
ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Gastrointestinal	O
experiences	O
including:	O
Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Fever	B-D005334

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(see	O
WARNINGS.)	O
•Diclofenac	O
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(see	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

This	O
Risk	B-D012306

•	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
3%	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

ADVERSE	O
REACTIONS	O
Of	O
the	O
423	O
Patients	B-D010361

Eighty-seven	O
percent	O
(87%)	O
of	O
the	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
treated	O
Patients	B-D010361

The	O
majority	O
of	O
these	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
upon	O
discontinuation	O
of	O
therapy	O

Of	O
the	O
211	O
Patients	B-D010361

Application	O
site	O
reactions	O
(ASRs)	O
were	O
the	O
most	O
frequent	O
AEs	O
in	O
both	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
and	O
vehicle-treated	O
groups	O

Of	O
note,	O
four	O
reactions,	O
contact	O
Dermatitis	B-D003872

Eighteen	O
percent	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
treated	O
Patients	B-D010361

These	O
discontinuations	O
were	O
mainly	O
due	O
to	O
Skin	B-D012867

Table	O
1	O
below	O
presents	O
the	O
AEs	O
reported	O
at	O
an	O
Incidence	B-D015994

Table	O
1	O

Adverse	O
Events	O
Reported	O
(>1%	O
in	O
Any	O
Treatment	O
Group)	O
During	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
Phase	O
3	O
Clinical	B-D016430
Trial	I-D016430
s	O
Incidence	B-D015994
s	O
for	O
60-Day	O
and	O
90-Day	O
Treatments	O
60-day	O
Treatment	O
90-day	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
(%)	O
Gel	O
Vehicle	O
(%)	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel	O
(%)	O
Gel	O
Vehicle	O
(%)	O
N=48	O
N=49	O
N=114	O
N=114	O
BODY	O
AS	O
A	O
WHOLE	O
21	O
20	O
20	O
18	O
Abdominal	B-D015746
Pain	I-D015746
2	O
0	O
1	O
0	O
Accidental	O
Injury	O
0	O
0	O
4	O
2	O
Allergic	O
Reaction	O
0	O
0	O
1	O
3	O
Asthenia	B-D001247
0	O
0	O
2	O
0	O
Back	B-D001416
Pain	I-D001416
4	O
0	O
2	O
2	O
Chest	B-D002637
Pain	I-D002637
2	O
0	O
1	O
0	O
Chills	B-D023341
0	O
2	O
0	O
0	O
Flu	O
Syndrome	B-D013577
10	O
6	O
1	O
4	O
Headache	B-D006261
0	O
6	O
7	O
6	O
Infection	O
4	O
6	O
4	O
5	O
Neck	B-D019547
Pain	I-D019547
0	O
0	O
2	O
0	O
Pain	B-D010146
2	O
0	O
2	O
2	O
Cardiovascular	B-D002319
System	I-D002319

Adverse	O
Reactions	O
Reported	O
for	O
Oral	O
Diclofenac	B-D004008
Dosage	O
Form	B-D020478
(not	O
topical	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel):	O
*Incidence	O
Greater	O
than	O
1%	O
marked	O
with	O
asterisk	O

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

Cardiovascular:	O
Hypertension	B-D006973

Digestive:	O
Diarrhea	B-D003967

Hemic	O
and	O
Lymph	B-D008196
atic:	O
hemoglobin	B-C032001
D	I-C032001

Metabolic	O
and	O
Nutritional	O
Disorders:	O
Azotemia	B-D053099

Nervous	B-D009420
System	I-D009420
:	O
Dizziness	B-D004244

Respiratory:	O
Epistaxis	B-D004844

Skin	B-D012867
and	O
Appendages:	O
rash*,	O
Pruritus	B-D011537

Special	O
Senses:	O
Tinnitus	B-D014012

Urogenital:	O
Nephrotic	B-D009404
Syndrome	I-D009404

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
•	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
•	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
Cardiovascular	O
Risk	B-D012306
•	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
•	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5.WARNINGS	O
AND	O
PRECAUTIONS	O
1.Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

2.Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

3.Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
CELEBREX	O
immediately	O
if	O
abnormal	O
Liver	B-D008099

4.New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

5.Fluid	O
retention	O
and	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

6.Renal	O
papillary	O
Necrosis	B-D009336

Use	O
CELEBREX	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
Heart	B-D006333
Failure	I-D006333

7.Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
CELEBREX	O
in	O
Patients	B-D010361

8.Serious	O
Skin	B-D012867

Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
Skin	B-D012867

5.1Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2Hypertension	O
As	O
with	O
all	O
NSAIDs,	O
CELEBREX	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
CELEBREX,	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
CELEBREX,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
Ulcer	B-D014456

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

Celebrex	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.5Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
CELEBREX	O
is	O
not	O
recommended	O
in	O
these	O
Patients	B-D010361

If	O
CELEBREX	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

CELEBREX	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8Skin	O
Reactions	O
CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9Pregnancy	O
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
CELEBREX	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

CELEBREX	O
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
CELEBREX	O
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
Inflammation	B-D007249

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
CELEBREX	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
Risk	B-D012306

6.ADVERSE	O
REACTIONS	O
Of	O
the	O
CELEBREX-treated	O
Patients	B-D010361

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
CBX	O
=	O
CELEBREX	O
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
Dyspepsia	B-D004415

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
Diclofenac	B-D004008

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
Dysmenorrhea	B-D004412

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies	O
:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Gastrointestinal	O
Risk	B-D012306
:	O
TREXIMET	O
contains	O
a	O
nonsteroidal	O
anti-inflammatory	O
drug	O
(NSAID)	O

NSAID-containing	O
products	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
adverse	O
reactions	O
reported	O
below	O
are	O
specific	O
to	O
the	O
Clinical	B-D016430
Trial	I-D016430

See	O
also	O
the	O
full	O
prescribing	O
information	O
for	O
Naproxen	B-D009288

Incidence	B-D015994
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848
s	O
Table	O
2	O
lists	O
adverse	O
events	O
that	O
occurred	O
in	O
2	O
placebo-controlled	O
Clinical	B-D016430
Trial	I-D016430

Only	O
events	O
that	O
occurred	O
at	O
a	O
frequency	O
of	O
2%	O
or	O
more	O
with	O
TREXIMET	O
and	O
were	O
more	O
frequent	O
than	O
in	O
the	O
placebo	O
group	O
are	O
included	O
in	O
Table	O
2	O

The	O
events	O
cited	O
reflect	O
experience	O
gained	O
under	O
closely	O
monitored	O
conditions	O
of	O
Clinical	B-D016430
Trial	I-D016430

In	O
actual	O
clinical	O
practice	O
or	O
in	O
other	O
Clinical	B-D016430
Trial	I-D016430

Table	O
2	O

Treatment-Emergent	O
Adverse	O
Events	O
Reported	O
by	O
at	O
Least	O
2%	O
of	O
Patients	B-D010361
in	O
2	O
Controlled	O
Migraine	O
Trialsa	O
aEvents	O
that	O
occurred	O
at	O
a	O
frequency	O
of	O
2%	O
or	O
more	O
in	O
the	O
group	O
treated	O
with	O
TREXIMET	O
and	O
that	O
occurred	O
more	O
frequently	O
in	O
the	O
group	O
treated	O
with	O
TREXIMET	O
than	O
in	O
the	O
placebo	O
group	O

Adverse	O
Event	O
Percent	O
of	O
Patients	B-D010361
Reporting	O
TREXIMET(n	O
=	O
737)	O
Placebo(n	O
=	O
752)	O
Sumatriptan	B-D018170
85	O
mg(n	O
=	O
735)	O
Naproxen	B-D009288
Sodium	B-D012964
500	O
mg(n	O
=	O
732)	O
Nervous	B-D009420
System	I-D009420

TREXIMET	O
was	O
generally	O
well	O
tolerated	O

Most	O
adverse	O
reactions	O
were	O
mild	O
and	O
transient	O

The	O
Incidence	B-D015994

There	O
were	O
insufficient	O
data	O
to	O
assess	O
the	O
impact	O
of	O
race	O
on	O
the	O
Incidence	B-D015994

Other	O
Events	O
Observed	O
in	O
Migraine	O
Clinical	B-D016430
Trial	I-D016430
s	O
Associated	O
With	O
the	O
Administration	O
of	O
TREXIMET	O
The	O
occurrence	O
of	O
less	O
commonly	O
reported	O
adverse	O
clinical	O
events	O
is	O
presented	O
in	O
this	O
section	O

Because	O
the	O
reports	O
include	O
events	O
observed	O
in	O
an	O
open-label,	O
long-term	O
Safety	B-D012449

Furthermore,	O
variability	O
associated	O
with	O
adverse	O
event	O
reporting,	O
the	O
Terminology	B-D020502

Event	O
frequencies	O
are	O
calculated	O
as	O
the	O
number	O
of	O
Patients	B-D010361

Events	O
listed	O
in	O
the	O
previous	O
table	O
and	O
text	O
are	O
not	O
included	O
below	O

Those	O
events	O
described	O
too	O
generally	O
to	O
be	O
informative	O
or	O
those	O
unlikely	O
to	O
be	O
associated	O
with	O
the	O
use	O
of	O
TREXIMET	O
are	O
excluded	O

Events	O
are	O
further	O
classified	O
within	O
body	O
system	O
categories	O
and	O
enumerated	O
in	O
order	O
of	O
decreasing	O
frequency	O
using	O
the	O
following	O
definitions:	O
frequent	O
adverse	O
events	O
are	O
those	O
occurring	O
in	O
at	O
least	O
1/100	O
Patients	B-D010361

Blood	B-D001769
and	O
Lymph	B-D008196
atic	O
Disorders:	O
Infrequent	O
was	O
Lymphadenopathy	B-D000072281

Rare	O
were	O
Anemia	B-D000740

Cardia	B-D002299
c	O
Disorders:	O
Infrequent	O
was	O
Tachycardia	B-D013610

Rare	O
were	O
Acute	B-D054058
Coronary	I-D054058
Syndrome	I-D054058

Ear	B-D004423
and	O
Labyrinth	O
Disorders:	O
Infrequent	O
were	O
Ear	B-D004423

Rare	O
were	O
Motion	B-D009041
Sickness	I-D009041

Endocrine,	O
Metabolic,	O
and	O
Nutrition	B-D009748
Disorders	I-D009748
:	O
Rare	O
were	O
Diabetes	B-D003920
Mellitus	I-D003920

Eye	B-D005123
Disorders:	O
Infrequent	O
was	O
Conjunctivitis	B-D003231

Rare	O
were	O
Cataract	B-D002386

Gastrointestinal	O
Disorders:	O
Frequent	O
was	O
Abdominal	B-D015746
Pain	I-D015746

Infrequent	O
were	O
abdominal	O
distention,	O
Constipation	B-D003248

Rare	O
were	O
Colitis	B-D003092

General	O
Disorders:	O
Frequent	O
was	O
Fatigue	B-D005221

Infrequent	O
were	O
feeling	O
jittery,	O
Lethargy	B-D053609

Rare	O
was	O
difficulty	O
in	O
Walking	B-D016138

Hepatobiliary	O
Disorders:	O
Rare	O
was	O
biliary	O
Colic	B-D003085

Infections	B-D007239
and	O
Infestations:	O
Rare	O
were	O
Kidney	B-D007668

Musculoskeletal	O
and	O
Connective	B-D003238
Tissue	I-D003238
:	O
Infrequent	O
were	O
Arthralgia	B-D018771

Nervous	B-D009420
System	I-D009420
Disorders:	O
Infrequent	O
were	O
burning	O
Sensation	B-D012677

Rare	O
were	O
Aphasia	B-D001037

Psychiatric	O
Disorders:	O
Infrequent	O
were	O
Anxiety	B-D001007

Rare	O
were	O
disorientation,	O
Panic	B-D010200

Renal	O
and	O
Urinary	O
Disorders:	O
Infrequent	O
was	O
Nephrolithiasis	B-D053040

Rare	O
was	O
Renal	B-D051437
Insufficiency	I-D051437

Respiratory,	O
Thoracic,	O
and	O
Mediastinal:	O
Infrequent	O
were	O
Asthma	B-D001249

Rare	O
was	O
Pleurisy	B-D010998

Skin	B-D012867
and	O
Subcutaneous	O
Disorders:	O
Infrequent	O
were	O
facial	O
swelling,	O
hyperhydrosis,	O
Pruritus	B-D011537

Rare	O
was	O
systemic	O
lupus	O
Erythema	B-D004890

Vascular	O
Disorders:	O
Infrequent	O
were	O
Flushing	B-D005483

Rare	O
were	O
Epistaxis	B-D004844

ADVERSE	O
REACTIONS	O
Hydrocodone	B-D006853
bitartrate	O
and	O
Ibuprofen	B-D007052

Adverse	O
event	O
rates	O
generally	O
increased	O
with	O
increasing	O
daily	O
dose	O

The	O
event	O
rates	O
reported	O
below	O
are	O
from	O
approximately	O
150	O
Patients	B-D010361

The	O
Overall	B-D016424

The	O
following	O
lists	O
adverse	O
events	O
that	O
occurred	O
with	O
an	O
Incidence	B-D015994

To	O
distinguish	O
different	O
rates	O
of	O
occurrence	O
in	O
clinical	O
studies,	O
the	O
adverse	O
events	O
are	O
listed	O
as	O
follows:	O
name	O
of	O
adverse	O
event	O
=	O
less	O
than	O
3%	O
adverse	O
events	O
marked	O
with	O
an	O
asterisk	O
*	O
=	O
3%	O
to	O
9%	O
adverse	O
event	O
rates	O
over	O
9%	O
are	O
in	O
parentheses	O

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

Cardiovascular:	O
Palpitations;	O
Vasodilation	B-D014664
	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Anxiety	B-D001007
*;	O
Confusion	B-D003221
;	O
Dizziness	B-D004244
(14%);	O
Hypertonia;	O
Insomnia*;	O
Nervousness*;	O
Paresthesia	B-D010292
;	O
Somnolence	O
(22%);	O
Thinking	B-D013850
abnormalities	O

Digestive:	O
Anorexia	B-D000855
;	O
Constipation	B-D003248
(22%);	O
Diarrhea	B-D003967
*;	O
Dry	O
Mouth	B-D009055
Ulcer	B-D014456

Metabolic	O
and	O
Nutritional	O
Disorders:	O
Edema	B-D004487
*	O

Respiratory:	O
Dyspnea	B-D004417
;	O
Hiccup	B-D006606
s;	O
Pharyngitis	B-D010612
;	O
Rhinitis	B-D012220
	O

Skin	B-D012867
and	O
Appendages:	O
Pruritus	B-D011537
*;	O
Sweating	B-D013546
*	O

Special	O
Senses:	O
Tinnitus	B-D014012
	O

Urogenital:	O
Urinary	O
frequency	O

Incidence	B-D015994
less	O
than	O
1%	O
Body	O
as	O
a	O
Whole:	O
Allergic	O
reaction	O

Cardiovascular:	O
Arrhythmia;	O
Hypotension	B-D007022
;	O
Tachycardia	B-D013610
	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Agitation;	O
Abnormal	O
Dreams	B-D004325

Digestive:	O
Chalky	O
stool;	O
"Clenching	O
teeth";	O
Dysphagia;	O
Esophageal	O
Spasm	B-D013035

Metabolic	O
and	O
Nutritional:	O
Weight	O
decrease	O

Musculoskeletal:	O
Arthralgia	B-D018771
;	O
Myalgia	B-D063806
	O

Respiratory:	O
Asthma	B-D001249
;	O
Bronchitis	B-D001991
;	O
Hoarseness	B-D006685
;	O
Increased	O
Cough	B-D003371

Skin	B-D012867
and	O
Appendages:	O
Rash;	O
Urticaria	B-D014581
	O

Special	O
Senses:	O
Altered	O
vision;	O
Bad	O
Taste	B-D013649

Urogenital:	O
Cystitis	B-D003556
;	O
Glycosuria	B-D006029
;	O
Impotence;	O
Urinary	B-D014549
Incontinence	I-D014549

Cardiovascular	O
Thrombotic	O
Events	O
•Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

•Etodolac	O
Extended-Release	O
Tablets	B-D013607
,	O
400	O
mg,	O
500	O
mg	O
and	O
600	O
mg	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
A	O
total	O
of	O
1552	O
Patients	B-D010361

In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
Incidence	B-D015994

As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
Time	B-D013995

In	O
Patients	B-D010361

gross	O
bleeding/perforation	O
Nausea	B-D009325

This	O
Risk	B-D012306

(5.1)	O
Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

[	O
see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O

Fenoprofen	B-D005279
®	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Fenoprofen	B-D005279
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[	O
see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279
in	O
Patients	B-D010361

If	O
Fenoprofen	B-D005279
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Fenoprofen	B-D005279
,	O
cause	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
events	O
including	O
Inflammation	B-D007249

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Fenoprofen	B-D005279
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Fenoprofen	B-D005279
,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Fenoprofen	B-D005279

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279
in	O
Patients	B-D010361

If	O
Fenoprofen	B-D005279
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Fenoprofen	B-D005279
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
Fenoprofen	B-D005279
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Fenoprofen	B-D005279
in	O
Patients	B-D010361

If	O
Fenoprofen	B-D005279
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Fenoprofen	B-D005279
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Fenoprofen	B-D005279
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
fenoprop	B-C009264
fen,	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Fenoprofen	B-D005279
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Fenoprofen	B-D005279
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Fenoprofen	B-D005279
,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Fenoprofen	B-D005279
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
Fenoprofen	B-D005279
,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Fenoprofen	B-D005279
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Ocular	O
Effects	O
Studies	O
to	O
date	O
have	O
not	O
shown	O
changes	O
in	O
the	O
Eye	B-D005123

However,	O
adverse	O
ocular	O
effects	O
have	O
been	O
observed	O
with	O
other	O
anti-inflammatory	O
drugs	O

Eye	B-D005123
examinations,	O
therefore,	O
should	O
be	O
performed	O
if	O
visual	O
disturbances	O
occur	O
in	O
Patients	B-D010361

5.15	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Caution	O
should	O
be	O
Exercise	B-D015444

5.16	O
Impact	O
on	O
Hearing	B-D006309
Since	O
the	O
Safety	B-D012449

6	O

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2)	O
]	O
Hepatotoxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3)	O
]	O
Hypertension	B-D006973
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6)	O
]	O
Anaphylactic	O
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9)	O
]	O
Hematologic	O
Toxicity	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
≥	O
5%)	O
are	O
Dyspepsia	B-D004415
,	O
Headache	B-D006261

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Belcher	O
Pharmaceuticals,	O
LLC	O
at	O
(727)	O
471-0850	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
(6)	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

During	O
clinical	O
studies	O
for	O
Rheum	B-D012250

These	O
encompass	O
Observation	B-D019370

For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
Patients	B-D010361

During	O
short-term	O
studies	O
for	O
Analgesia	B-D000698

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
>1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—	O
During	O
Clinical	B-D016430
Trial	I-D016430

In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
Dyspepsia	B-D004415

2.3%	O
placebo),	O
Nausea	B-D009325

7.1%),	O
Constipation	B-D003248

1.5%),	O
Vomiting	B-D014839

1.9%),	O
Abdominal	B-D015746
Pain	I-D015746

1.1%),	O
and	O
Diarrhea	B-D003967

4.1%)	O

The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
Patients	B-D010361

Nervous	B-D009420
System	I-D009420
—	O
The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
Headache	B-D006261

7.5%)	O
and	O
somnolence	O
(8.5%	O
vs	O

6.4%)	O

Dizziness	B-D004244
(6.5%	O
vs	O

5.6%),	O
Tremor	B-D014202

0.4%),	O
and	O
Confusion	B-D003221

none)	O
were	O
noted	O
less	O
frequently	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Skin	B-D012867
and	O
Appendages—	O
Increased	O
Sweating	B-D013546

0.4%),	O
Pruritus	B-D011537

0.8%),	O
and	O
rash	O
(3.7%	O
vs	O

0.4%)	O
were	O
reported	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
about	O
1%	O
of	O
Patients	B-D010361

Special	O
Senses	O
—	O
Tinnitus	B-D014012
(4.5%	O
vs	O

0.4%),	O
blurred	O
vision	O
(2.2%	O
vs	O

none),	O
and	O
decreased	O
Hearing	B-D006309

none)	O
were	O
reported	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Cardiovascular	O
—	O
Palpitations	O
(2.5%	O
vs	O

0.4%)	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
Patients	B-D010361

Miscellaneous	O
—	O
Nervousness	O
(5.7%	O
vs	O

1.5%),	O
Asthenia	B-D001247

0.4%),	O
peripheral	O
Edema	B-D004487

0.4%),	O
Dyspnea	B-D004417

none),	O
Fatigue	B-D005221

1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs	O

5.6%),	O
and	O
nas	B-C015378
opharyngitis	O
(1.2%	O
vs	O

none)	O

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—Gastritis,	O
Peptic	B-D010437
Ulcer	I-D010437

Increases	O
in	O
Alkaline	B-D000469
Phosphatase	I-D000469

Cardiovascular—Atrial	O
fibrillation,	O
Pulmonary	B-D011654
Edema	I-D011654

Genitourinary	O
Tract—Renal	O
failure,	O
Dysuria	B-D053159

Hypersensitivity	B-D006967
—Angioedema	O
(angioneurotic	O
Edema	B-D004487

Hematologic—Purpura,	O
bruising,	O
Hemorrhage	B-D006470

Nervous	B-D009420
System	I-D009420
—Depression,	O
disorientation,	O
Seizures	B-D012640

Special	O
Senses—Burning	O
Tongue	B-D014059

Skin	B-D012867
and	O
Appendages—Exfoliative	O
Dermatitis	B-D003872

Miscellaneous—Anaphylaxis,	O
Urticaria	B-D014581

ADVERSE	O
REACTIONS	O
Clinical	O
Practice:	O
The	O
following	O
events	O
have	O
been	O
Id	B-D007060

Because	O
they	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

The	O
events,	O
which	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness,	O
frequency	O
of	O
reporting,	O
possible	O
causal	O
connection	O
to	O
topical	O
Diclofenac	B-D004008
Sodium	B-D012964
Ophthalmic	O
Solution,	O
0.1%,	O
or	O
a	O
combination	O
of	O
these	O
factors,	O
include	O
Cornea	B-D003315

Ocular:	O
Transient	O
burning	O
and	O
stinging	O
were	O
reported	O
in	O
approximately	O
15%	O
of	O
Patients	B-D010361

In	O
Cataract	B-D002386

Elevated	O
Intraocular	B-D007429
Pressure	I-D007429

Lacrimation	O
complaints	O
were	O
reported	O
in	O
approximately	O
30%	O
of	O
case	O
studies	O
undergoing	O
incisional	O
refractive	O
surgery	O

The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
approximately	O
5%	O
or	O
less	O
of	O
the	O
Patients	B-D010361

Systemic:	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
3%	O
or	O
less	O
of	O
the	O
Patients	B-D010361

Cardiovascular	O
Risk	B-D012306
•	O
Non-Steroidal	O
Anti-inflammatory	O
Drugs	O
(NSAIDs),	O
a	O
component	O
of	O
VIMOVO,	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

•	O
VIMOVO	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
Naproxen	B-D009288

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
•	O
Naproxen	B-D009288
,	O
a	O
component	O
of	O
VIMOVO,	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1)	O
•	O
VIMOVO	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs,	O
including	O
Naproxen	B-D009288

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

The	O
Risk	B-D012306

VIMOVO	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Discontinue	O
use	O
immediately	O
if	O
abnormal	O
Liver	B-D008099

Blood	B-D001794
Pressure	I-D001794

VIMOVO	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Use	O
VIMOVO	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
Hypovolemia	B-D020896

Not	O
recommended	O
for	O
Patients	B-D010361

Do	O
not	O
use	O
VIMOVO	O
in	O
Patients	B-D010361

Discontinue	O
VIMOVO	O
at	O
first	O
appearance	O
of	O
Skin	B-D012867

(5.18)	O
•	O
Hypomagnesemia	O
has	O
been	O
reported	O
rarely	O
with	O
prolonged	O
treatment	O
with	O
PPIs	O
(5.19)	O
•	O
Avoid	O
concomitant	O
use	O
of	O
VIMOVO	O
with	O
St	O
John’s	O
Wort	O
or	O
Rifampin	B-D012293

(5.20,	O
7.16)	O
5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Clinical	B-D016430
Trial	I-D016430

All	O
NSAIDS,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Naproxen	B-D009288

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Blood	B-D001794
Pressure	I-D001794

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention,	O
Edema	B-D004487

5.4	O
Gastrointestinal	O
Effects	O
—	O
Risk	B-D012306
of	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Naproxen	B-D009288

While	O
VIMOVO	O
has	O
been	O
shown	O
to	O
significantly	O
decrease	O
the	O
occurrence	O
of	O
gastric	O
Ulcer	B-D014456

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

The	O
utility	O
of	O
periodic	O
laboratory	O
monitoring	O
has	O
not	O
been	O
demonstrated,	O
nor	O
has	O
it	O
been	O
adequately	O
assessed	O

VIMOVO	O
should	O
be	O
prescribed	O
with	O
caution	O
in	O
those	O
with	O
a	O
prior	O
History	B-D006664

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Patients	B-D010361
and	O
Physicians	B-D010820

This	O
should	O
include	O
discontinuation	O
of	O
the	O
NSAID	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

For	O
high	O
Risk	B-D012306

Epidemiological	O
studies	O
of	O
the	O
case-control	O
and	O
cohort	O
design	O
have	O
demonstrated	O
an	O
Association	B-D001244

In	O
two	O
studies,	O
concurrent	O
use	O
of	O
an	O
NSAID,	O
COX-2	O
inhibitor,	O
or	O
Aspirin	B-D001241

Although	O
these	O
studies	O
focused	O
on	O
upper	O
gastrointestinal	O
bleeding,	O
bleeding	O
at	O
other	O
sites	O
cannot	O
be	O
ruled	O
out	O

NSAIDs	O
should	O
be	O
given	O
with	O
care	O
to	O
Patients	B-D010361

Gastrointestinal	O
symptomatic	O
response	O
to	O
therapy	O
with	O
VIMOVO	O
does	O
not	O
preclude	O
the	O
presence	O
of	O
gastric	O
Mali	B-D008302

Atrophic	O
Gastritis	B-D005756

5.5	O
Active	O
Bleeding	O
When	O
active	O
and	O
clinically	O
significant	O
bleeding	O
from	O
any	O
source	O
occurs	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

5.7	O
Advanced	O
Renal	O
Disease	B-D004194
No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
VIMOVO	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
VIMOVO	O
is	O
not	O
recommended	O
in	O
these	O
Patients	B-D010361

If	O
VIMOVO	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient’s	O
renal	O
function	O
is	O
advisable	O
[see	O
Dosage	O
and	O
Administration	O
(2),	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.7)	O
and	O
Clinical	O
Pharmacology	B-D010600
(12.3)]	O

5.8	O
Anaphylactoid	O
Reactions	O
Anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

NSAIDs	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

Anaphylactoid	O
reactions,	O
like	O
Anaphylaxis	B-D000707

5.9	O
Skin	B-D012867
Reactions	O
NSAIDs	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.10	O
Pregnancy	B-D011247
Pregnancy	B-D011247
Category	O
C	O
In	O
late	O
Pregnancy	B-D011247

5.11	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

Hepatic	O
abnormalities	O
may	O
be	O
the	O
result	O
of	O
Hypersensitivity	B-D006967

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
essentially	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continued	O
therapy	O

The	O
SGPT	O
(ALT)	O
TES	B-C004551

Notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

Chronic	O
alcoholic	O
Liver	B-D008099

Caution	O
is	O
advised	O
when	O
high	O
doses	O
are	O
required	O
and	O
some	O
adjustment	O
of	O
dosage	O
may	O
be	O
required	O
in	O
these	O
Patients	B-D010361

It	O
is	O
prudent	O
to	O
use	O
the	O
lowest	O
effective	O
dose	O
for	O
the	O
shortest	O
possible	O
duration	O
of	O
adequate	O
treatment	O

VIMOVO	O
should	O
be	O
avoided	O
in	O
Patients	B-D010361

5.12	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
occult	O
or	O
gross	O
GI	O
Blood	B-D001769

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

NSAIDs	O
inhibit	O
Platelet	B-D010974
Aggregation	I-D010974

Unlike	O
Aspirin	B-D001241

Patients	B-D010361
receiving	O
VIMOVO	O
who	O
may	O
be	O
adversely	O
Affect	B-D000339

5.13	O
Pre-existing	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Concomitant	O
NSAID	O
Use	O
VIMOVO	O
contains	O
Naproxen	B-D009288

It	O
should	O
not	O
be	O
used	O
with	O
other	O
Naproxen	B-D009288

The	O
concomitant	O
use	O
of	O
VIMOVO	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
Risk	B-D012306

5.15	O
Corticosteroid	O
Treatment	O
VIMOVO	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O
and	O
the	O
patient	O
should	O
be	O
observed	O
closely	O
for	O
any	O
evidence	O
of	O
adverse	O
effects,	O
including	O
Adrenal	B-D000309
Insufficiency	I-D000309

5.16	O
Bone	O
Fracture	O
Several	O
studies	O
and	O
Literature	B-D008091

Those	O
Patients	B-D010361

Patients	B-D010361
should	O
use	O
the	O
lowest	O
effective	O
dose	O
and	O
shortest	O
duration	O
of	O
PPI	O
therapy	O
appropriate	O
to	O
the	O
condition	O
being	O
treated	O

Patients	B-D010361
at	O
Risk	B-D012306

Adequate	O
Vitamin	B-D014807
D	I-D014807

5.17	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
VIMOVO	O
in	O
reducing	O
Fever	B-D005334

5.18	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
their	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

Patients	B-D010361
with	O
initial	O
hemoglobin	O
values	O
of	O
10	O
g	O
or	O
less	O
who	O
are	O
to	O
receive	O
long-term	O
therapy	O
should	O
have	O
hemoglobin	O
values	O
determined	O
Periodical	B-D020492

Serum	B-D044967
Chromogranin	B-D053379
A	I-D053379

The	O
increased	O
CgA	O
level	O
may	O
cause	O
false	O
positive	O
results	O
in	O
diagnostic	O
investigations	O
for	O
Neuroendocrine	B-D018358
Tumors	I-D018358

Providers	O
should	O
TEMPO	B-C003959

If	O
serial	O
TES	B-C004551

for	O
monitoring),	O
the	O
same	O
commercial	O
laboratory	O
should	O
be	O
used	O
for	O
TES	B-C004551

5.19	O
Hypomagnesemia	O
Hypomagnesemia,	O
symptomatic	O
and	O
asymptomatic,	O
has	O
been	O
reported	O
rarely	O
in	O
Patients	B-D010361

Serious	O
adverse	O
events	O
include	O
Tetany	B-D013746

In	O
most	O
Patients	B-D010361

For	O
Patients	B-D010361

[see	O
Adverse	O
Reactions	O
(6.2)]	O
5.20	O
Concomitant	O
use	O
of	O
St	O
John's	O
Wort	O
or	O
Rifampin	B-D012293
with	O
VIMOVO	O
Drugs	O
that	O
induce	O
CYP2C19	O
or	O
CYP3A4	O
(such	O
as	O
St	O
John’s	O
Wort	O
or	O
Rifampin	B-D012293

Avoid	O
concomitant	O
use	O
of	O
VIMOVO	O
with	O
St	O
John’s	O
Wort	O
or	O
Rifampin	B-D012293

6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
in	O
Clinical	B-D016430
Trial	I-D016430

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reactions	O
reported	O
below	O
are	O
specific	O
to	O
the	O
Clinical	B-D016430
Trial	I-D016430

See	O
also	O
the	O
full	O
prescribing	O
information	O
for	O
Naproxen	B-D009288

The	O
Safety	B-D012449

Patients	B-D010361
received	O
either	O
500	O
mg/20	O
mg	O
of	O
VIMOVO	O
twice	O
daily	O
(n=1157),	O
500	O
mg	O
of	O
enteric-coated	O
Naproxen	B-D009288

The	O
average	O
number	O
of	O
VIMOVO	O
doses	O
taken	O
over	O
12	O
months	O
was	O
696+44	O

The	O
table	O
below	O
lists	O
all	O
adverse	O
reactions,	O
regardless	O
of	O
Causality	B-D015984

Both	O
of	O
these	O
studies	O
were	O
randomized,	O
multi-center,	O
double-blind,	O
parallel	O
studies	O

The	O
majority	O
of	O
Patients	B-D010361

The	O
majority	O
of	O
Patients	B-D010361

Approximately	O
one	O
quarter	O
were	O
on	O
low-dose	O
Aspirin	B-D001241

Table	O
1:	O
Adverse	O
Reactions	O
occurring	O
in	O
Patients	B-D010361

12.5%	O
Respect	B-D000078682

The	O
most	O
common	O
reasons	O
for	O
discontinuations	O
due	O
to	O
adverse	O
events	O
in	O
the	O
VIMOVO	O
treatment	O
group	O
were	O
upper	O
Abdominal	B-D015746
Pain	I-D015746

Among	O
Patients	B-D010361

The	O
proportion	O
of	O
Patients	B-D010361

The	O
table	O
below	O
lists	O
all	O
adverse	O
reactions,	O
regardless	O
of	O
Causality	B-D015984

Table	O
2:	O
Adverse	O
Reactions	O
occurring	O
in	O
Patients	B-D010361

There	O
were	O
no	O
preferred	O
terms	O
in	O
which	O
more	O
than	O
1%	O
of	O
subjects	O
withdrew	O
from	O
any	O
treatment	O
group	O

The	O
long-term	O
Safety	B-D012449

There	O
were	O
no	O
differences	O
in	O
frequency	O
or	O
types	O
of	O
adverse	O
reactions	O
seen	O
in	O
the	O
long-term	O
Safety	B-D012449

6.2	O
Postmarketing	O
Experience	O
Naproxen	B-D009288
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

These	O
reports	O
are	O
listed	O
below	O
by	O
body	O
system:	O
Body	O
as	O
a	O
Whole:	O
anaphylactoid	O
reactions,	O
angioneurotic	O
Edema	B-D004487

If	O
Skin	B-D012867

Special	O
Senses:	O
Hearing	B-D006309

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

These	O
reports	O
are	O
listed	O
below	O
by	O
body	O
system:	O
Blood	B-D001769
and	O
Lymph	B-D008196
atic:	O
Agranulocytosis	B-D000380

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Celecoxib	B-D000068579
Capsules	B-D002214

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

•	O
Nonsteroidal	O
Anti-Inflammatory	O
Drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
•	O
Celecoxib	B-D000068579
Capsules	B-D002214

(4,	O
5.1)	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O
	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361
•Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

•Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

•Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

•Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

•If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

•In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

The	O
rates	O
of	O
Hypertension	B-D006973

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
]	O
,	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
Capsules	B-D002214

Celecoxib	B-D000068579
Capsules	B-D002214

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
Capsules	B-D002214

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
•Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
•Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
•Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
•Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
•Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Mylan	O
Pharmaceuticals	O
Inc	O

at	O
1-877-446-3679	O
(1-877-4-INFO-RX)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥	O
2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Celecoxib	B-D000068579
Capsules	B-D002214

Celecoxib	B-D000068579
Capsules	B-D002214
(N	O
=	O
4146)	O
Placebo	O
(N	O
=	O
1864)	O
NAP	O
(N	O
=	O
1366)	O
DCF	O
(N	O
=	O
387)	O
IBU	O
(N	O
=	O
345)	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933
Dizziness	B-D004244
2.0%	O
1.7%	O
2.6%	O
1.3%	O
2.3%	O
Headache	B-D006261
15.8%	O
20.2%	O
14.5%	O
15.5%	O
15.4%	O
Psychiatric	O
Insomnia	O
2.3%	O
2.3%	O
2.9%	O
1.3%	O
1.4%	O
Respiratory	O
Pharyngitis	B-D010612
2.3%	O
1.1%	O
1.7%	O
1.6%	O
2.6%	O
Rhinitis	B-D012220
2.0%	O
1.3%	O
2.4%	O
2.3%	O
0.6%	O
Sinusitis	B-D012852
5.0%	O
4.3%	O
4.0%	O
5.4%	O
5.8%	O
Upper	O
Respiratory	O
Infection	O
8.1%	O
6.7%	O
9.9%	O
9.8%	O
9.9%	O
Skin	B-D012867
Rash	O
2.2%	O
2.1%	O
2.1%	O
1.3%	O
1.2%	O
In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
Following	O
Adverse	O
Reactions	O
Occurred	O
in	O
0.1%	O
to	O
1.9%	O
of	O
Patients	B-D010361
Treated	O
with	O
Celecoxib	B-D000068579
Capsules	B-D002214
(100	O
mg	O
to	O
200	O
mg	O
Twice	O
Daily	O
or	O
200	O
mg	O
Once	O
Daily)	O
Gastrointestinal:	O
Constipation	B-D003248
,	O
Diverticulitis	B-D004238

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥	O
5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥	O
5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥	O
5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361
with	O
Events)	O
System	O
Organ	O
Class/	O
Preferred	O
Term	O
All	O
Doses	O
Twice	O
Daily	O
Celecoxib	B-D000068579
3	O
mg/kg	O
N	O
=	O
77	O
Celecoxib	B-D000068579
6	O
mg/kg	O
N	O
=	O
82	O
Naproxen	B-D009288
7.5	O
mg/kg	O
N	O
=	O
83	O
Any	O
Event	O
64	O
70	O
72	O
Eye	B-D005123
Disorders	O
5	O
5	O
5	O
Gastrointestinal	O
26	O
24	O
36	O
Abdominal	B-D015746
Pain	I-D015746

3	O
11	O
7	O
Musculoskeletal	O
8	O
10	O
17	O
Arthralgia	B-D018771
3	O
7	O
4	O
Nervous	B-D009420
System	I-D009420
17	O
11	O
21	O
Headache	B-D006261
NOS	O
13	O
10	O
16	O
Dizziness	B-D004244
(excl	O
Vertigo	B-D014717

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
Reactions	O
from	O
Long-Term,	O
Placebo-Controlled	O
Polyp	O
Prevention	O
Studies	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Cardiovascular:	O
Vasculitis	B-D014657
,	O
deep	O
Venous	B-D020246
Thrombosis	I-D020246

ADMINISTRATION	O
OF	O
Misoprostol	B-D016595

Uterine	B-D014597
Rupture	I-D014597

Diclofenac	B-D004008

Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

In	O
such	O
Patients	B-D010361

●	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

●	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
Misoprostol	B-D016595

●	O
will	O
begin	O
Diclofenac	B-D004008

Cardiovascular	O
Thrombotic	O
Events	O
●	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

●	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
●	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

Diclofenac	B-D004008

ADMINISTRATION	O
OF	O
Misoprostol	B-D016595

Uterine	B-D014597
Rupture	I-D014597

Diclofenac	B-D004008

Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

In	O
such	O
Patients	B-D010361

•	O
is	O
capable	O
of	O
complying	O
with	O
effective	O
contraceptive	O
measures	O

•	O
has	O
received	O
both	O
oral	O
and	O
written	O
warnings	O
of	O
the	O
hazards	O
of	O
Misoprostol	B-D016595

•	O
will	O
begin	O
Diclofenac	B-D004008

Cardiovascular	O
Thrombotic	O
Events	O
Risk	B-D012306
•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Diclofenac	B-D004008
Sodium	B-D012964

Monitor	O
Patients	B-D010361

Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

(5.10,	O
8.1)	O
•	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O
	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

●	O
Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

●	O
Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

●	O
Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

●	O
If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Diclofenac	B-D004008

●	O
In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

These	O
increases	O
were	O
generally	O
transient,	O
and	O
enzyme	O
levels	O
returned	O
to	O
within	O
the	O
normal	O
range	O
upon	O
discontinuation	O
of	O
therapy	O
with	O
Diclofenac	B-D004008

The	O
Misoprostol	B-D016595

In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large,	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
Diclofenac	B-D004008

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Diclofenac	B-D004008

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Diclofenac	B-D004008

The	O
renal	O
effects	O
of	O
Diclofenac	B-D004008

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Diclofenac	B-D004008

If	O
Diclofenac	B-D004008

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
/misoprostol	O
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Diclofenac	B-D004008

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

Diclofenac	B-D004008
Sodium	B-D012964

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Diclofenac	B-D004008
Sodium	B-D012964

Advise	O
Pregnant	B-D037841
Women	I-D037841

Verify	O
the	O
Pregnancy	B-D011247

Advise	O
Female	B-D005260

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Diclofenac	B-D004008

NSAIDs,	O
including	O
Diclofenac	B-D004008

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Diclofenac	B-D004008

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
•Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
•Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
•Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
•Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
•Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
(incidence	O
greater	O
than	O
2%	O
from	O
Clinical	B-D016430
Trial	I-D016430

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Adverse	O
reaction	O
information	O
for	O
Diclofenac	B-D004008

Gastrointestinal	O
GI	O
disorders	O
had	O
the	O
highest	O
reported	O
Incidence	B-D015994

These	O
events	O
were	O
generally	O
minor,	O
but	O
led	O
to	O
discontinuation	O
of	O
therapy	O
in	O
9%	O
of	O
Patients	B-D010361

For	O
GI	O
Ulcer	B-D014456

GI	O
disorder	O
Diclofenac	B-D004008
Sodium	B-D012964
and	O
Misoprostol	B-D016595
Diclofenac	B-D004008
Abdominal	B-D015746
Pain	I-D015746

Diarrhea	B-D003967
and	O
Abdominal	B-D015746
Pain	I-D015746

Rare	O
instances	O
of	O
profound	O
Diarrhea	B-D003967

Patients	B-D010361
with	O
an	O
underlying	O
condition	O
such	O
as	O
inflammatory	O
bowel	O
Disease	B-D004194

The	O
Incidence	B-D015994

Gynecological	O
Gynecological	O
disorders	O
previously	O
reported	O
with	O
Misoprostol	B-D016595

Postmenopausal	O
Vagina	B-D014621

If	O
it	O
occurs,	O
diagnostic	O
Work	B-D014937

Elderly	O
Overall	B-D016424
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
Safety	B-D012449

Other	O
adverse	O
experiences	O
reported	O
occasionally	O
with	O
Diclofenac	B-D004008

Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Digestive:	O
Anorexia	B-D000855

Female	B-D005260
reproductive	O
disorders:	O
Breast	B-D001940

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional:	O
Alanine	B-D000409

Musculoskeletal	B-D009141
System	I-D009141

Psychiatric:	O
Anxiety	B-D001007

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages:	O
Alopecia	B-D000505

Special	O
senses:	O
Taste	B-D013649

Renal	O
and	O
urinary	O
disorders:	O
Dysuria	B-D053159

Vision:	O
Diplopia	B-D004172

6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Body	O
as	O
a	O
whole:	O
Death	B-D003643

Cardiovascular	B-D002319
System	I-D002319

Central	O
and	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Congenital,	O
familial	O
and	O
genetic	O
disorders:	O
birth	O
defects	O

Digestive:	O
Enteritis	B-D004751

Female	B-D005260
reproductive	O
disorders:	O
intermenstrual	O
bleeding,	O
Leukorrhea	B-D007973

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Hypersensitivity	B-D006967
:	O
Angioedema	B-D000799

Liver	B-D008099
and	O
biliary	O
system:	O
abnormal	O
hepatic	O
function,	O
Bilirubin	B-D001663

Male	B-D008297
reproductive	O
disorders:	O
impotence,	O
perineal	O
Pain	B-D010146

Metabolic	O
and	O
nutritional:	O
BUN	O
increased,	O
Glycosuria	B-D006029

Pregnancy	B-D011247
,	O
puerperium	O
and	O
perinatal	O
conditions:	O
abnormal	O
Uterine	B-D014590
Contraction	I-D014590

Psychiatric:	O
Confusion	B-D003221

Reproductive	O
system	O
and	O
Breast	B-D001940

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages:	O
acne,	O
bruising,	O
Erythema	B-D004892
Multiforme	I-D004892

Special	O
senses:	O
Hearing	B-D006309

Renal	O
and	O
urinary	O
disorders:	O
Cystitis	B-D003556

Vision:	O
Amblyopia	B-D000550

ADVERSE	O
REACTIONS	O
If	O
severe	O
reactions	O
occur,	O
discontinue	O
Carisoprodol	B-D002328
and	O
Aspirin	B-D001241
Tablets	B-D013607
and	O
initiate	O
appropriate	O
symptomatic	O
and	O
supportive	O
therapy	O

The	O
following	O
side	O
effects	O
which	O
have	O
occurred	O
with	O
the	O
administration	O
of	O
the	O
individual	O
ingredients	O
alone	O
may	O
also	O
occur	O
with	O
the	O
combination	O

Carisoprodol	B-D002328
:	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Drowsiness	O
is	O
the	O
most	O
frequent	O
complaint	O
and	O
along	O
with	O
other	O
CNS	O
effects	O
may	O
require	O
dosage	O
reduction	O

Observed	O
less	O
frequently	O
are	O
Dizziness	B-D004244

Tremor	B-D014202
,	O
agitation,	O
irritability,	O
Headache	B-D006261

Id	B-D007060
iosyncratic:	O
Id	B-D007060
iosyncratic	O
reactions	O
are	O
very	O
rare	O

They	O
are	O
usually	O
seen	O
within	O
the	O
period	O
of	O
the	O
first	O
to	O
fourth	O
dose	O
in	O
Patients	B-D010361

Allergic:	O
Skin	B-D012867
rash	O
Erythema	B-D004892
Multiforme	I-D004892

If	O
allergic	O
reactions	O
occur,	O
discontinue	O
Carisoprodol	B-D002328
and	O
Aspirin	B-D001241
Tablets	B-D013607
and	O
treat	O
symptomatically	O

In	O
evaluating	O
possible	O
allergic	O
reactions,	O
also	O
consider	O
allergy	O
to	O
Excipients	B-D005079

Cardiovascular:	O
Tachycardia	B-D013610
,	O
postural	O
Hypotension	B-D007022

Gastrointestinal:	O
Nausea	B-D009325
,	O
Vomiting	B-D014839

Hematologic:	O
No	O
serious	O
Blood	B-D001769

Leukopenia	B-D007970
and	O
Pancytopenia	B-D010198

Aspirin	B-D001241
:	O
The	O
most	O
common	O
adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
Aspirin	B-D001241

Gastric	O
erosion,	O
Angioedema	B-D000799

Tinnitus	B-D014012
is	O
a	O
sign	O
of	O
high	O
Serum	B-D044967

Aspirin	B-D001241
Intolerance:	O
Allergic	O
type	O
reactions	O
in	O
Aspirin	B-D001241

Symptoms	O
of	O
the	O
Form	B-D020478

These	O
may	O
occur	O
independently	O
or	O
in	O
combination	O

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
•Hepatotoxicity	O
(see	O
WARNINGS)	O
•Hypertension	O
(see	O
WARNINGS)	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
•Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
•Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
•Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
Fever	B-D005334

This	O
Risk	B-D012306

•Etodolac	O
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse	O
reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
mg/day	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
Whole:	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064
:	O
Dyspepsia	B-D004415
(10%),	O
Abdominal	B-D015746
Pain	I-D015746

Nervous	B-D009420
System	I-D009420
:	O
Asthenia	B-D001247
/malaise5,	O
Dizziness	B-D004244

Skin	B-D012867
and	O
Appendages:	O
Pruritus	B-D011537
,	O
rash	O

Special	O
Senses:	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566
:	O
Dysuria	B-D053159
,	O
urinary	O
frequency	O

Musculoskeletal:	O
Arthralgia	B-D018771
1Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

2Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

3Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

4Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

5Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

6Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
post-marketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319
:	O
Hypertension	B-D006973
,	O
congestive	O
Heart	B-D006333
Failure	I-D006333

Digestive	B-D004064
System	I-D004064
:	O
Thirst	B-D013894
,	O
dry	O
Mouth	B-D009055

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208
:	O
Ecchymosis	B-D004438
,	O
Anemia	B-D000740

Metabolic	O
and	O
Nutritional:	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420
:	O
Insomnia,	O
somnolence	O

Respiratory	B-D012137
System	I-D012137
:	O
Asthma	B-D001249
,	O
pulmonary	O
infiltration	O
with	O
Eosinophilia	B-D004802

Skin	B-D012867
and	O
Appendages:	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
Senses:	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566
:	O
Elevated	O
BUN,	O
renal	O
failure,	O
Renal	B-D051437
Insufficiency	I-D051437

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319
:	O
Arrhythmias,	O
Myocardial	B-D009203
Infarction	I-D009203

Digestive	B-D004064
System	I-D004064
:	O
Esophagitis	B-D004941
with	O
or	O
without	O
stricture	O
or	O
cardiospasm,	O
Colitis	B-D003092

Metabolic	O
and	O
Nutritional:	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420
:	O
Paresthesia	B-D010292
,	O
Confusion	B-D003221

Respiratory	B-D012137
System	I-D012137
:	O
Bronchitis	B-D001991
,	O
bronchospasm,	O
Dyspnea	B-D004417

Skin	B-D012867
and	O
Appendages:	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
Senses:	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566
:	O
Cystitis	B-D003556
,	O
Hematuria	B-D006417

Musculoskeletal:	O
Muscle	O
Pain	B-D010146

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
Whole:	O
Sepsis	B-D018805
,	O
Death	B-D003643

This	O
Risk	B-D012306

•Diclofenac	O
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
•NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS	O
)	O
Hepatotoxicity	O
(see	O
WARNINGS	O
)	O
Hypertension	B-D006973
(see	O
WARNINGS	O
)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS	O
)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS	O
)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS	O
)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS	O
)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS	O
)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

WARNING:	O
Risk	B-D012306

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

This	O
Risk	B-D012306

FLECTOR	O
PATCH	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
Patients	B-D010361

If	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
Patients	B-D010361

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-Treated	O
Patients	B-D010361
:	O
Use	O
the	O
lowest	O
effective	O
dosage	O
for	O
the	O
shortest	O
possible	O
duration	O

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
FLECTOR	O
PATCH	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
In	O
Clinical	B-D016430
Trial	I-D016430

In	O
a	O
large	O
open-label,	O
controlled	O
trial	O
of	O
3,700	O
Patients	B-D010361

Meaningful	O
elevations	O
of	O
ALT	O
and/or	O
AST	O
occurred	O
in	O
about	O
4%	O
of	O
the	O
3,700	O
Patients	B-D010361

In	O
that	O
open-label	O
study,	O
a	O
higher	O
Incidence	B-D015994

Elevations	O
in	O
Transaminases	B-D000637

Almost	O
all	O
meaningful	O
elevations	O
in	O
Transaminases	B-D000637

Abnormal	O
TES	B-C004551

In	O
postmarketing	O
reports,	O
cases	O
of	O
drug-induced	O
hepatotoxicity	O
have	O
been	O
reported	O
in	O
the	O
first	O
month,	O
and	O
in	O
some	O
cases,	O
the	O
first	O
2	O
months	O
of	O
therapy,	O
but	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Postmarketing	O
surveillance	O
has	O
reported	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Liver	B-D008099

Some	O
of	O
these	O
reported	O
cases	O
resulted	O
in	O
fatalities	O
or	O
Liver	B-D016031
Transplantation	I-D016031

In	O
a	O
Europe	B-D005060
an	O
retrospective	O
Population	B-D011153

In	O
this	O
particular	O
study,	O
based	O
on	O
an	O
Overall	B-D016424

Physicians	B-D010820
should	O
measure	O
Transaminases	B-D000637

The	O
optimum	O
Time	B-D013995

Based	O
on	O
Clinical	B-D016430
Trial	I-D016430

However,	O
severe	O
hepatic	O
reactions	O
can	O
occur	O
at	O
any	O
Time	B-D013995

If	O
abnormal	O
Liver	B-D008099

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Exercise	B-D015444
caution	O
when	O
prescribing	O
FLECTOR	O
PATCH	O
with	O
concomitant	O
drugs	O
that	O
are	O
known	O
to	O
be	O
potentially	O
hepatotoxic	O
(e.g.,	O
Acetaminophen	B-D000082

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
FLECTOR	O
PATCH,	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists'	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Diclofenac	B-D004008

Avoid	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
Patients	B-D010361

If	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
Patients	B-D010361

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
Patients	B-D010361

The	O
renal	O
effects	O
of	O
FLECTOR	O
PATCH	O
may	O
hasten	O
the	O
progression	O
of	O
renal	O
dysfunction	O
in	O
Patients	B-D010361

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
FLECTOR	O
PATCH	O
in	O
Patients	B-D010361

If	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
Patients	B-D010361

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Diclofenac	B-D004008
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
FLECTOR	O
PATCH	O
is	O
used	O
in	O
Patients	B-D010361

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
NSAIDs,	O
including	O
Diclofenac	B-D004008

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O

Inform	O
Patients	B-D010361

FLECTOR	O
PATCH	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Diclofenac	B-D004008
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
FLECTOR	O
PATCH,	O
in	O
Pregnant	B-D037841
Women	I-D037841

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
FLECTOR	O
PATCH	O
has	O
any	O
signs	O
or	O
symptoms	O
of	O
Anemia	B-D000740

NSAIDs,	O
including	O
FLECTOR	O
PATCH,	O
may	O
increase	O
the	O
Risk	B-D012306

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders,	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
FLECTOR	O
PATCH	O
in	O
reducing	O
Inflammation	B-D007249

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

5.14	O
Accidental	O
Exposure	O
in	O
Child	B-D002648
ren	O
Even	O
a	O
used	O
FLECTOR	O
PATCH	O
contains	O
a	O
large	O
amount	O
of	O
Diclofenac	B-D004008

The	O
potential	O
therefore	O
exists	O
for	O
a	O
small	O
Child	B-D002648

It	O
is	O
important	O
for	O
Patients	B-D010361

5.15	O
Eye	B-D005123
Exposure	O
Avoid	O
contact	O
of	O
FLECTOR	O
PATCH	O
with	O
Eye	B-D005123

Advise	O
Patients	B-D010361

5.16	O
Oral	O
Nonsteroidal	O
Anti-inflammatory	O
Drugs	O
Concomitant	O
use	O
of	O
oral	O
and	O
topical	O
NSAIDs	O
may	O
result	O
in	O
a	O
higher	O
rate	O
of	O
Hemorrhage	B-D006470

Do	O
not	O
use	O
combination	O
therapy	O
with	O
FLECTOR	O
PATCH	O
and	O
an	O
oral	O
NSAID	O
unless	O
the	O
benefit	O
outweighs	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
are	O
application	O
site	O
conditions,	O
occurring	O
in	O
11%	O
and	O
12%,	O
Respect	B-D000078682

at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
controlled	O
trials	O
during	O
the	O
Prema	B-C070504

Adverse	O
Events	O
Lead	B-D007854
ing	O
to	O
Discontinuation	O
of	O
Treatment	O
In	O
the	O
controlled	O
trials,	O
3%	O
of	O
Patients	B-D010361

The	O
most	O
common	O
adverse	O
events	O
Lead	B-D007854

Application	O
site	O
reactions	O
Lead	B-D007854

Common	O
Adverse	O
Events	O
Localized	O
Reactions	O
Overall	B-D016424
,	O
the	O
most	O
common	O
adverse	O
events	O
associated	O
with	O
FLECTOR	O
PATCH	O
treatment	O
were	O
Skin	B-D012867

Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

A	O
majority	O
of	O
Patients	B-D010361

Common	O
Adverse	O
Events	O
(by	O
body	O
system	O
and	O
preferred	O
term)	O
in	O
≥	O
1%	O
of	O
Patients	B-D010361
treated	O
with	O
FLECTOR	O
PATCH	O
or	O
Placebo	O
Patch	O
The	O
table	O
lists	O
adverse	O
events	O
occurring	O
in	O
placebo-treated	O
Patients	B-D010361

Adverse	O
events	O
in	O
the	O
placebo	O
group	O
may	O
therefore	O
reflect	O
effects	O
of	O
the	O
non-active	O
ingredients	O

Category	O
Diclofenac	B-D004008
N=572	O
Placebo	O
N=564	O
N	O
Percent	O
N	O
Percent	O
Application	O
Site	O
Conditions	O
64	O
11	O
70	O
12	O
Pruritus	B-D011537
31	O
5	O
44	O
8	O
Dermatitis	B-D003872
9	O
2	O
3	O
<1	O
Burning	O
2	O
<1	O
8	O
1	O
OtherIncludes:	O
application	O
site	O
dryness,	O
irritation,	O
Erythema	B-D004890

22	O
4	O
15	O
3	O
Gastrointestinal	O
Disorders	O
49	O
9	O
33	O
6	O
Nausea	B-D009325
17	O
3	O
11	O
2	O
Dysgeusia	B-D004408
10	O
2	O
3	O
<1	O
Dyspepsia	B-D004415
7	O
1	O
8	O
1	O
OtherIncludes:	O
Gastritis	B-D005756

15	O
3	O
11	O
2	O
Nervous	B-D009420
System	I-D009420
Disorders	O
13	O
2	O
18	O
3	O
Headache	B-D006261
7	O
1	O
10	O
2	O
Paresthesia	B-D010292
6	O
1	O
8	O
1	O
Somnolence	O
4	O
1	O
6	O
1	O
Other	O
Includes:	O
hypoesthesia,	O
Dizziness	B-D004244

4	O
1	O
3	O
<1	O
Foreign	O
labeling	O
describes	O
that	O
dermal	O
allergic	O
reactions	O
may	O
occur	O
with	O
FLECTOR	O
PATCH	O
treatment	O

Additionally,	O
the	O
treated	O
area	O
may	O
become	O
irritated	O
or	O
develop	O
itching,	O
Erythema	B-D004890

5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Coagulation	O
Abnormalities:	O
Risk	B-D012306
of	O
increased	O
Bleeding	B-D001760
Time	I-D001760

Monitor	O
Patients	B-D010361

(5.1)	O
GI	O
Adverse	O
Reactions	O
(including	O
Ulcer	B-D014456

(5.2)	O
Bleeding	O
Risk	B-D012306
with	O
Use	O
of	O
Alcohol:	O
Avoid	O
heavy	O
alcohol	O
use	O
(three	O
or	O
more	O
drinks	O
every	O
day)	O

(5.3)	O
Reduction	O
in	O
Antiplatelet	O
Activity	O
with	O
Clopidogrel	B-D000077144
due	O
to	O
Interference	O
with	O
CYP2C19	O
Metabolism	B-D008660
:	O
Consider	O
other	O
antiplatelet	O
therapy	O

(5.4,	O
7)	O
Reduction	O
in	O
Efficacy	O
of	O
Ticagrelor	B-D000077486
:	O
Avoid	O
use	O
with	O
the	O
325/40	O
strength	O
of	O
YOSPRALA	O

(5.5,	O
7)	O
Renal	O
Failure:	O
Avoid	O
YOSPRALA	O
in	O
Patients	B-D010361

(5.6,	O
8.6)	O
Gastric	O
Mali	B-D008302
gnancy:	O
In	O
Adult	B-D000328

(5.7)	O
Acute	O
Interstitial	O
Nephritis	B-D009393
:	O
Observed	O
in	O
Patients	B-D010361

(5.8)	O
Clostridium	B-D016360
difficile	I-D016360
-	O
Associated	O
Diarrhea	B-D003967
:	O
PPI	O
therapy	O
may	O
be	O
associated	O
with	O
increased	O
Risk	B-D012306

(5.9)	O
Bone	O
Fracture:	O
Long-term	O
and	O
multiple	O
daily	O
dose	O
PPI	O
therapy	O
may	O
be	O
associated	O
with	O
an	O
increased	O
Risk	B-D012306

(5.10)	O
Cutaneous	O
and	O
Systemic	O
Lupus	O
Erythema	B-D004890
tosus:	O
Mostly	O
cutaneous;	O
new	O
onset	O
or	O
exacerbation	O
of	O
existing	O
Disease	B-D004194

(5.11)	O
Hepatic	O
Impairment:	O
Avoid	O
YOSPRALA	O
in	O
Patients	B-D010361

(5.12,	O
8.7)	O
Cyanocobalamin	O
(Vitamin	O
B-12)	O
Deficiency:	O
Daily	O
long-term	O
use	O
(e.g.,	O
longer	O
than	O
3	O
years)	O
of	O
PPI	O
may	O
Lead	B-D007854

(5.13)	O
Hypomagnesemia:	O
Reported	O
rarely	O
with	O
prolonged	O
treatment	O
with	O
PPIs;	O
consider	O
monitoring	O
Magnesium	B-D008274

(5.14)	O
Reduced	O
Effect	O
of	O
Omeprazole	B-D009853
with	O
St	O

John’s	O
Wort	O
or	O
Rifampin	B-D012293
:	O
Avoid	O
concomitant	O
use	O

(5.15,	O
7)	O
Interactions	O
with	O
Diagnostic	O
Investigations	O
for	O
Neuroendocrine	B-D018358
Tumors	I-D018358
:	O
Increased	O
Chromogranin	B-D053379
A	I-D053379
(CgA)	O
levels	O
may	O
interfere	O
with	O
diagnostic	O
investigations	O
for	O
Neuroendocrine	B-D018358
Tumors	I-D018358

With	O
high	O
dose	O
Methotrexate	B-D008727

(5.17,	O
7)	O
P	O
remature	O
closure	O
of	O
the	O
Ductus	B-D004373
Arteriosus	I-D004373

(5.18,	O
8.1)	O
Abnormal	O
Laboratory	O
TES	B-C004551

(5.19)	O
Fundic	O
Gland	O
Polyps	B-D011127
:	O
Risk	B-D012306
increases	O
with	O
long-term	O
use,	O
especially	O
beyond	O
one	O
year	O

Use	O
the	O
shortest	O
Duration	B-D000081206
of	I-D000081206
Therapy	I-D000081206

(5.20	O
)	O
5	O

1	O
Coagulation	O
Abnormalities	O
Even	O
low	O
doses	O
of	O
Aspirin	B-D001241

This	O
can	O
adversely	O
Affect	B-D000339

Monitor	O
Patients	B-D010361

5	O

2	O
Gastrointestinal	O
Adverse	O
Reactions	O
Aspirin	B-D001241
is	O
associated	O
with	O
serious	O
gastrointestinal	O
(GI)	O
adverse	O
reactions,	O
including	O
Inflammation	B-D007249

Other	O
adverse	O
reactions	O
with	O
Aspirin	B-D001241

Serious	O
GI	O
adverse	O
reactions	O
reported	O
in	O
the	O
Clinical	B-D016430
Trial	I-D016430

In	O
addition,	O
there	O
were	O
two	O
cases	O
of	O
intestinal	O
Hemorrhage	B-D006470

Although	O
minor	O
upper	O
GI	O
symptoms,	O
such	O
as	O
Dyspepsia	B-D004415

Inform	O
Patients	B-D010361

If	O
active	O
and	O
clinically	O
significant	O
bleeding	O
from	O
any	O
source	O
occurs	O
in	O
Patients	B-D010361

5.3	O
Bleeding	O
Risk	B-D012306
with	O
Use	O
of	O
Alcohol	O
Counsel	O
Patients	B-D010361

5.4	O
Interaction	O
with	O
Clopidogrel	B-D000077144
Avoid	O
concomitant	O
use	O
of	O
YOSPRALA	O
with	O
Clopidogrel	B-D000077144

Clopidogrel	B-D000077144
is	O
a	O
prodrug	O

Inhibition	O
of	O
Platelet	B-D010974
Aggregation	I-D010974

The	O
Metabolism	B-D008660

Co-administration	O
of	O
Clopidogrel	B-D000077144

When	O
using	O
YOSPRALA,	O
consider	O
alternative	O
anti-platelet	O
therapy	O
[see	O
Drug	B-D004347
Interactions	I-D004347
(7)	O
,	O
Clinical	O
Pharmacology	B-D010600
(12.3)	O
]	O

5.5	O
Interaction	O
with	O
Ticagrelor	B-D000077486
Maintenance	B-D008283
doses	O
of	O
Aspirin	B-D001241

Avoid	O
concomitant	O
use	O
of	O
Ticagrelor	B-D000077486

5	O

6	O
Renal	O
Failure	O
Avoid	O
YOSPRALA	O
in	O
Patients	B-D010361

Regular	O
use	O
of	O
Aspirin	B-D001241

Aspirin	B-D001241
use	O
decreases	O
Glomerular	B-D005919
Filtration	I-D005919
Rate	I-D005919

[	O
see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.6)	O
,	O
Clinical	O
Pharmacology	B-D010600
(12.3)	O
]	O

5.7	O
Presence	O
of	O
Gastric	O
Mali	B-D008302
gnancy	O
In	O
Adult	B-D000328

Consider	O
additional	O
gastrointestinal	O
follow-up	O
and	O
diagnostic	O
TES	B-C004551

In	O
older	O
Patients	B-D010361

5	O

8	O
Acute	O
Interstitial	O
Nephritis	B-D009393
Acute	O
interstitial	O
Nephritis	B-D009393

Acute	O
interstitial	O
Nephritis	B-D009393

Discontinue	O
YOSPRALA	O
if	O
acute	O
interstitial	O
Nephritis	B-D009393

5	O

9	O
Clostridium	B-D016360
difficile	I-D016360
-	O
Associated	O
Diarrhea	B-D003967
Published	O
Observation	B-D019370

This	O
Diagnosis	B-D003933

Use	O
the	O
lowest	O
dose	O
and	O
shortest	O
duration	O
of	O
YOSPRALA	O
appropriate	O
to	O
the	O
condition	O
being	O
treated	O

5	O

10	O
Bone	O
Fracture	O
Several	O
published	O
Observation	B-D019370

The	O
Risk	B-D012306

Use	O
the	O
lowest	O
dose	O
and	O
shortest	O
duration	O
of	O
YOSPRALA	O
therapy	O
appropriate	O
to	O
the	O
condition	O
being	O
treated	O

Manage	O
Patients	B-D010361

5	O

11	O
Cutaneous	O
and	O
Systemic	O
Lupus	O
Erythema	B-D004890
tosus	O
Cutaneous	O
lupus	O
Erythema	B-D004890

These	O
events	O
have	O
occurred	O
as	O
both	O
new	O
onset	O
and	O
an	O
exacerbation	O
of	O
existing	O
autoimmune	O
Disease	B-D004194

The	O
majority	O
of	O
PPI-induced	O
lupus	O
Erythema	B-D004890

The	O
most	O
common	O
Form	B-D020478

Generally,	O
histological	O
findings	O
were	O
observed	O
without	O
organ	O
involvement	O

Systemic	O
lupus	O
Erythema	B-D004890

PPI	O
associated	O
SLE	O
is	O
usually	O
milder	O
than	O
non-drug	O
induced	O
SLE	O

Onset	O
of	O
SLE	O
typically	O
occurred	O
within	O
days	O
to	O
years	O
after	O
initiating	O
treatment,	O
but	O
some	O
cases	O
occurred	O
days	O
or	O
years	O
after	O
initiating	O
treatment	O

SLE	O
occurred	O
primarily	O
in	O
Patients	B-D010361

The	O
majority	O
of	O
Patients	B-D010361

Avoid	O
administration	O
of	O
PPIs	O
for	O
longer	O
than	O
medically	O
indicated	O

If	O
signs	O
or	O
symptoms	O
consistent	O
with	O
CLE	O
or	O
SLE	O
are	O
noted	O
in	O
Patients	B-D010361

Most	O
Patients	B-D010361

Serologicial	O
TES	B-C004551

5.12	O
Hepatic	O
Impairment	O
Long-term	O
moderate	O
to	O
high	O
doses	O
of	O
Aspirin	B-D001241

These	O
abnormalities	O
resolve	O
rapidly	O
with	O
discontinuation	O
of	O
Aspirin	B-D001241

The	O
hepatotoxicity	O
of	O
Aspirin	B-D001241

Bilirubin	B-D001663
elevations	O
are	O
usually	O
mild	O
or	O
absent	O

Systemic	O
exposure	O
to	O
Omeprazole	B-D009853

Avoid	O
YOSPRALA	O
in	O
Patients	B-D010361

5.1	O
3	O
Cyanocobalamin	O
(Vitamin	O
B-12)	O
Deficiency	O
Daily	O
treatment	O
with	O
any	O
acid-suppressing	O
medications	O
over	O
a	O
long	O
period	O
of	O
Time	B-D013995

Rare	O
reports	O
of	O
cyanocobalamin	O
deficiency	O
occurring	O
with	O
acid-suppressing	O
therapy	O
have	O
been	O
reported	O
in	O
the	O
Literature	B-D008091

This	O
Diagnosis	B-D003933

5.1	O
4	O
Hypomagnesemia	O
Hypomagnesemia,	O
symptomatic	O
and	O
asymptomatic,	O
has	O
been	O
reported	O
rarely	O
in	O
Patients	B-D010361

Serious	O
adverse	O
events	O
include	O
Tetany	B-D013746

In	O
most	O
Patients	B-D010361

For	O
Patients	B-D010361

5	O

15	O
Reduced	O
Effect	O
of	O
Omeprazole	B-D009853
with	O
St	O

John’s	O
Wort	O
or	O
R	O
ifampin	O
Drugs	O
which	O
induce	O
the	O
CYP2C19	O
or	O
CYP3A4	O
(such	O
as	O
St	O

John’s	O
Wort	O
or	O
Rifampin	B-D012293

Avoid	O
concomitant	O
use	O
of	O
YOSPRALA	O
with	O
St	O

John’s	O
Wort	O
or	O
Rifampin	B-D012293

5	O

16	O
Interactions	O
with	O
Diagnostic	O
Investigations	O
for	O
Neuroendocrine	B-D018358
Tumors	I-D018358
Serum	B-D044967
Chromogranin	B-D053379
A	I-D053379

The	O
increased	O
CgA	O
level	O
may	O
cause	O
false	O
positive	O
results	O
in	O
diagnostic	O
interventions	O
for	O
Neuroendocrine	B-D018358
Tumors	I-D018358

TEMPO	B-C003959

If	O
serial	O
TES	B-C004551

5	O

17	O
Interaction	O
with	O
Methotrexate	B-D008727
Literature	B-D008091
suggests	O
that	O
concomitant	O
use	O
of	O
PPIs	O
with	O
Methotrexate	B-D008727

In	O
high-dose	O
Methotrexate	B-D008727

5	O

18	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
NSAIDs	O
including	O
Aspirin	B-D001241

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
YOSPRALA,	O
in	O
Pregnant	B-D037841
Women	I-D037841

[see	O
Use	O
in	O
Specific	O
Population	B-D011153
s	O
(8.1)	O
]	O

5	O

19	O
Abnormal	O
Laboratory	O
TES	B-C004551

5	O

20	O
Fundic	O
Gland	O
Polyps	B-D011127
PPI	O
use	O
is	O
associated	O
with	O
an	O
increased	O
Risk	B-D012306

Most	O
PPI	O
users	O
who	O
developed	O
fundic	O
gland	O
Polyps	B-D011127

Use	O
the	O
shortest	O
duration	O
of	O
PPI	O
therapy	O
appropriate	O
to	O
the	O
condition	O
being	O
treated	O

6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
in	O
Adult	B-D000328

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Aralez	O
Pharmaceuticals	O
at	O
1-866-207-6592	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

YOSPRALA	O
325	O
mg/40	O
mg	O
was	O
studied	O
primarily	O
in	O
two	O
randomized,	O
double-blind	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Table	O
1	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>2%	O
of	O
Patients	B-D010361

Table	O
1:	O
Most	O
Common	O
Adverse	O
Reactions	O
in	O
Study	O
1	O
and	O
Study	O
2*	O
Preferred	O
Term	O
YOSPRALA	O
325	O
mg/40	O
mg	O
once	O
daily	O
(n=521)	O
%	O
EC-Aspirin	O
325	O
mg	O
once	O
daily	O
(n=524)	O
%	O
Gastritis	B-D005756
18	O
16	O
Nausea	B-D009325
3	O
2	O
Diarrhea	B-D003967
3	O
2	O
Gastric	O
Polyps	B-D011127

The	O
most	O
common	O
reasons	O
for	O
discontinuations	O
due	O
to	O
adverse	O
reactions	O
in	O
the	O
YOSPRALA	O
treatment	O
group	O
were	O
upper	O
Abdominal	B-D015746
Pain	I-D015746

Less	O
Common	O
Adverse	O
Reactions	O
In	O
YOSPRALA-treated	O
Patients	B-D010361

See	O
also	O
the	O
full	O
prescribing	O
information	O
of	O
Aspirin	B-D001241

6.2	O
Post-	O
M	O
arketing	O
E	O
xperience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Aspirin	B-D001241
Body	O
as	O
a	O
Whole	O
:	O
Fever	B-D005334
,	O
Hypothermia	B-D007035

Patients	B-D010361
with	O
high	O
frequency	O
Hearing	B-D034381
Loss	I-D034381

In	O
these	O
Patients	B-D010361

Urogenital:	O
Interstitial	O
Nephritis	B-D009393

Gastroduodenal	O
carcinoids	O
have	O
been	O
reported	O
in	O
Patients	B-D010361

This	O
finding	O
is	O
believed	O
to	O
be	O
a	O
manifestation	O
of	O
the	O
underlying	O
condition,	O
which	O
is	O
known	O
to	O
be	O
associated	O
with	O
such	O
tumors	O

Hematologic:	O
Agranulocytosis	B-D000380
(some	O
fatal),	O
hemolytic	O
Anemia	B-D000740

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS	O
)	O

Etodolac	B-D017308
Capsules	B-D002214

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

Musculoskeletal—Arthralgia	O

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Musculoskeletal—Muscle	O
Pain	B-D010146

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

4	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
5	O

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4	O
,	O
5.1)	O
6	O

NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
1	O

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

2	O

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
1	O

NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
10	O

Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Hypertension	B-D006973
:	O
Patients	B-D010361
taking	O
some	O
antihypertensive	O
medications	O
may	O
have	O
impaired	O
response	O
to	O
these	O
therapies	O
when	O
taking	O
NSAIDs	O

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
:	O
Avoid	O
use	O
of	O
Celecoxib	B-D000068579

Renal	O
Toxicity:	O
Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
use	O
of	O
Celecoxib	B-D000068579

Anaphylactic	O
Reactions:	O
Seek	O
emergency	O
help	O
if	O
an	O
anaphylactic	O
reaction	O
occurs	O
(5.7)	O
15	O

Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity:	O
Celecoxib	B-D000068579
Capsules	B-D002214

Monitor	O
Patients	B-D010361

Serious	O
Skin	B-D012867
Reactions:	O
Discontinue	O
Celecoxib	B-D000068579

Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
:	O
Avoid	O
use	O
in	O
Pregnant	B-D037841
Women	I-D037841

Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
Risk	B-D012306

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

A	O
Randomized	B-D016449
Controlled	I-D016449
Trial	I-D016449

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
Risk	B-D012306

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
Naproxen	B-D009288

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

2.Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

3.Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

4.Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

6.In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
Blood	B-D001794
Pressure	I-D001794

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
1.Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
2.GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
3.Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
4.Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
5.Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
6.Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
7.Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
8.Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
9.Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
%	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-	O
controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

This	O
Risk	B-D012306

·	O
Ibuprofen	B-D007052
Tablets	B-D013607
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
most	O
frequent	O
type	O
of	O
adverse	O
reaction	O
occurring	O
with	O
Ibuprofen	B-D007052

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

In	O
controlled	O
studies	O
when	O
Ibuprofen	B-D007052

Adverse	O
reactions	O
observed	O
during	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Those	O
reactions	O
listed	O
in	O
Column	O
one	O
encompass	O
Observation	B-D019370

More	O
than	O
500	O
of	O
these	O
Patients	B-D010361

Still	O
other	O
reactions	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100	O
were	O
reported	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

These	O
reactions	O
have	O
been	O
divided	O
into	O
two	O
categories:	O
Column	O
two	O
of	O
the	O
table	O
lists	O
reactions	O
with	O
therapy	O
with	O
Ibuprofen	B-D007052

Reported	O
side	O
effects	O
were	O
higher	O
at	O
doses	O
of	O
3200	O
mg/day	O
than	O
at	O
doses	O
of	O
2400	O
mg	O
or	O
less	O
per	O
day	O
in	O
Clinical	B-D016430
Trial	I-D016430

The	O
increases	O
in	O
Incidence	B-D015994

Incidence	B-D015994
Greater	O
than	O
1%	O
(but	O
less	O
than	O
3%)	O
Probable	O
Causal	O
Relationship	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Probable	O
Causal	O
Relationship**	O
Precise	O
Incidence	B-D015994
Unknown	O
(but	O
less	O
than	O
1%)	O
Causal	O
Relationship	O
Unknown**	O
GASTROINTESTINAL	O
Nausea	B-D009325
*,	O
epigastric	O
Pain	B-D010146

Henoch-Schonlein	O
Vasculitis	B-D014657

(Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
Patients	B-D010361

**Reactions	O
are	O
classified	O
under	O
“Probable	O
Causal	O
Relationship	O
(PCR)”	O
if	O
there	O
has	O
been	O
one	O
positive	O
rechallenge	O
or	O
if	O
three	O
or	O
more	O
cases	O
occur	O
which	O
might	O
be	O
causally	O
related	O

Reactions	O
are	O
classified	O
under	O
“Causal	O
Relationship	O
Unknown”	O
if	O
seven	O
or	O
more	O
events	O
have	O
been	O
reported	O
but	O
the	O
criteria	O
for	O
PCR	O
have	O
not	O
been	O
met	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Enter	O
section	O
text	O
here	O
Increased	O
Bleeding	B-D001760
Time	I-D001760
With	O
some	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
including	O
NEVANAC	O
®	O
,	O
there	O
exists	O
the	O
potential	O
for	O
increased	O
Bleeding	B-D001760
Time	I-D001760

There	O
have	O
been	O
reports	O
that	O
ocularly	O
applied	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
may	O
cause	O
increased	O
bleeding	O
of	O
ocular	O
Tissues	B-D014024

It	O
is	O
recommended	O
that	O
NEVANAC	O
®	O
ophthalmic	O
suspension	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.2	O
Delayed	O
Healing	O
Topical	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
including	O
NEVANAC	O
®	O
,	O
may	O
slow	O
or	O
delay	O
healing	O

Topical	O
corticosteroids	O
are	O
also	O
known	O
to	O
slow	O
or	O
delay	O
healing	O

Concomitant	O
use	O
of	O
topical	O
NSAIDs	O
and	O
topical	O
Steroids	B-D013256

5.3	O
Cornea	B-D003315
l	O
Effects	O
Use	O
of	O
topical	O
NSAIDs	O
may	O
result	O
in	O
Keratitis	B-D007634

In	O
some	O
susceptible	O
Patients	B-D010361

These	O
events	O
may	O
be	O
sight	O
threatening	O

Patients	B-D010361
with	O
evidence	O
of	O
Cornea	B-D003315

Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
suggests	O
that	O
Patients	B-D010361

Topical	O
NSAIDs	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Postmarketing	O
experience	O
with	O
topical	O
NSAIDs	O
also	O
suggests	O
that	O
use	O
more	O
than	O
1	O
day	O
prior	O
to	O
surgery	O
or	O
use	O
beyond	O
14	O
days	O
post	O
surgery	O
may	O
increase	O
patient	O
Risk	B-D012306

5.4	O
Contact	O
Lens	O
Wear	O
NEVANAC	O
®	O
should	O
not	O
be	O
administered	O
while	O
using	O
Contact	B-D003261
Lenses	I-D003261

6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
cannot	O
be	O
directly	O
compared	O
to	O
the	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O

Most	O
common	O
adverse	O
reactions	O
(5	O
to	O
10%)	O
are	O
capsular	O
opacity,	O
decreased	O
Visual	B-D014792
Acuity	I-D014792

(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Alcon	O
Laboratories	B-D007753
,	O
Inc	O

at	O
1-800-757-9195	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Ocular	O
Adverse	O
Reactions	O
The	O
most	O
frequently	O
reported	O
ocular	O
adverse	O
events	O
following	O
Cataract	B-D002386

These	O
events	O
occurred	O
in	O
approximately	O
5	O
to	O
10%	O
of	O
Patients	B-D010361

Other	O
ocular	O
adverse	O
events	O
occurring	O
at	O
an	O
Incidence	B-D015994

Some	O
of	O
these	O
events	O
may	O
be	O
the	O
consequence	O
of	O
the	O
Cataract	B-D002386

6.2	O
Non-Ocular	O
Adverse	O
Reactions	O
Non-ocular	O
adverse	O
events	O
reported	O
at	O
an	O
Incidence	B-D015994

WARNING:	O
ADDICTION,	O
ABUSE,	O
AND	O
MISUSE;	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938

Assess	O
each	O
patient’s	O
Risk	B-D012306

Opioid	O
Analgesic	O
Risk	B-D000073938
Evaluation	I-D000073938
and	I-D000073938
Mitigation	I-D000073938
Strategy	O
(REMS)	O
To	O
ensure	O
that	O
the	O
benefits	O
of	O
opioid	O
Analgesics	B-D000700

Under	O
the	O
requirements	O
of	O
the	O
REMS,	O
drug	O
companies	O
with	O
approved	O
opioid	O
analgesic	O
products	O
must	O
make	O
REMS-compliant	O
Education	B-D004493

Health	B-D006262
care	O
providers	O
are	O
strongly	O
encouraged	O
to	O
complete	O
a	O
REMS-compliant	O
Education	B-D004493

counsel	O
Patients	B-D010361

emphasize	O
to	O
Patients	B-D010361

consider	O
other	O
tools	O
to	O
ImProv	B-C413303

Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Serious,	O
Life	B-D019369

Monitor	O
for	O
respiratory	O
Depression	B-D003863
)	O

Accidental	O
Ingestion	O
Accidental	O
ingestion	O
of	O
even	O
one	O
dose	O
of	O
Hydrocodone	B-D006853

Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Prolonged	O
use	O
of	O
Hydrocodone	B-D006853

If	O
opioid	O
use	O
is	O
required	O
for	O
a	O
prolonged	O
period	O
in	O
a	O
pregnant	O
woman,	O
advise	O
the	O
patient	O
of	O
the	O
Risk	B-D012306

Cytochrome	O
P450	O
3A4	O
Interaction	O
The	O
concomitant	O
use	O
of	O
Hydrocodone	B-D006853

In	O
addition,	O
discontinuation	O
of	O
a	O
concomitantly	O
used	O
cytochrome	O
P450	O
3A4	O
inducer	O
may	O
result	O
in	O
an	O
increase	O
in	O
Hydrocodone	B-D006853

Monitor	O
Patients	B-D010361

Risk	B-D012306
s	O
From	O
Concomitant	O
Use	O
With	O
Benzodiazepines	B-D001569
Or	O
Other	O
CNS	O
Depressants	O
Concomitant	O
use	O
of	O
opioids	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants,	O
PRECAUTIONS:	O
Drug	B-D004347
Interactions	I-D004347
)	O

Reserve	O
concomitant	O
prescribing	O
of	O
Hydrocodone	B-D006853

Limit	O
dosages	O
and	O
durations	O
to	O
the	O
minimum	O
required	O

Follow	O
Patients	B-D010361

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Hydrocodone	B-D006853
bitartrate	O
and	O
Ibuprofen	B-D007052

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
described	O
below	O
and	O
elsewhere	O
in	O
the	O
labeling	O
including	O
the	O
WARNINGS	O
section	O

Addiction,	O
Abuse,	O
and	O
Misuse	O
Life	B-D019369
-Threatening	O
Respiratory	O
Depression	B-D003863
Neon	B-D009356
atal	O
Opioid	O
Withdrawal	O
Syndrome	B-D013577
Interactions	O
with	O
Cytochrome	O
P450	O
3A4	O
Inhibitors	O
and	O
Inducers	O
Interactions	O
with	O
Benzodiazepines	B-D001569
or	O
Other	O
CNS	O
Depressants	O
Adrenal	B-D000309
Insufficiency	I-D000309
Severe	O
Hypotension	B-D007022
Seizures	B-D012640
Withdrawal	O
Cardiovascular	O
Thrombotic	O
Events	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Hepatotoxicity	O
Hypertension	B-D006973
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Anaphylactic	O
Reactions	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
Serious	O
Skin	B-D012867
Reactions	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Hematologic	O
Toxicity	O
Aseptic	O
Meningitis	B-D008581
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

Hydrocodone	B-D006853
bitartrate	O
and	O
Ibuprofen	B-D007052

Adverse	O
event	O
rates	O
generally	O
increased	O
with	O
increasing	O
daily	O
dose	O

The	O
event	O
rates	O
reported	O
below	O
are	O
from	O
approximately	O
150	O
Patients	B-D010361

The	O
Overall	B-D016424

The	O
following	O
lists	O
adverse	O
events	O
that	O
occurred	O
with	O
an	O
Incidence	B-D015994

To	O
distinguish	O
different	O
rates	O
of	O
occurrence	O
in	O
clinical	O
studies,	O
the	O
adverse	O
events	O
are	O
listed	O
as	O
follows:	O
name	O
of	O
adverse	O
event	O
=	O
less	O
than	O
3%	O
adverse	O
events	O
marked	O
with	O
an	O
asterisk	O
*	O
=	O
3%	O
to	O
9%	O
adverse	O
event	O
rates	O
over	O
9%	O
are	O
in	O
parentheses	O

Body	O
as	O
a	O
Whole	O
Abdominal	B-D015746
Pain	I-D015746

Cardiovascular	O
Palpitations;	O
Vasodilation	B-D014664
	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Anxiety	B-D001007
*;	O
Confusion	B-D003221
;	O
Dizziness	B-D004244
(14%);	O
Hypertonia;	O
Insomnia*;	O
Nervousness*;	O
Paresthesia	B-D010292
;	O
Somnolence	O
(22%);	O
Thinking	B-D013850
abnormalities	O

Digestive	O
Anorexia	B-D000855
;	O
Constipation	B-D003248
(22%);	O
Diarrhea	B-D003967
*;	O
Dry	O
Mouth	B-D009055
Ulcer	B-D014456

Metabolic	O
and	O
Nutritional	O
Disorders	O
Edema	B-D004487
*	O

Respiratory	O
Dyspnea	B-D004417
;	O
Hiccup	B-D006606
s;	O
Pharyngitis	B-D010612
;	O
Rhinitis	B-D012220
	O

Skin	B-D012867
and	O
Appendages	O
Pruritus	B-D011537
*;	O
Sweating	B-D013546
*	O

Special	O
Senses	O
Tinnitus	B-D014012
	O

Urogenital	O
Urinary	O
frequency	O

Incidence	B-D015994
less	O
than	O
1%	O
Body	O
as	O
a	O
Whole	O
Allergic	O
reaction	O

Cardiovascular	O
Arrhythmia;	O
Hypotension	B-D007022
;	O
Tachycardia	B-D013610
	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Agitation;	O
Abnormal	O
Dreams	B-D004325

Digestive	O
Chalky	O
stool;	O
"Clenching	O
teeth";	O
Dysphagia;	O
Esophageal	O
Spasm	B-D013035

Metabolic	O
and	O
Nutritional	O
Weight	O
decrease	O

Musculoskeletal	O
Arthralgia	B-D018771
;	O
Myalgia	B-D063806
	O

Respiratory	O
Asthma	B-D001249
;	O
Bronchitis	B-D001991
;	O
Hoarseness	B-D006685
;	O
Increased	O
Cough	B-D003371

Skin	B-D012867
and	O
Appendages	O
Rash;	O
Urticaria	B-D014581
	O

Special	O
Senses	O
Altered	O
vision;	O
Bad	O
Taste	B-D013649

Urogenital	O
Cystitis	B-D003556
;	O
Glycosuria	B-D006029
;	O
Impotence;	O
Urinary	B-D014549
Incontinence	I-D014549

Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
Id	B-D007060

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Serotonin	B-D020230
Syndrome	I-D020230

Adrenal	B-D000309
Insufficiency	I-D000309

Anaphylaxis	B-D000707
:	O
Anaphylaxis	B-D000707
has	O
been	O
reported	O
with	O
ingredients	O
contained	O
in	O
Hydrocodone	B-D006853

Androgen	O
deficiency:	O
Cases	O
of	O
androgen	O
deficiency	O
have	O
occurred	O
with	O
chronic	O
use	O
of	O
opioids	O
(see	O
CLINICAL	O
Pharmacology	B-D010600

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Amneal	O
Pharmaceuticals	O
at	O
1-877-835-5472	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
	O

PrevidolRx	O
Analgesic	O
PakGenPak	O
Solutions	B-D012996
LLCPrevidolRx	O
Analgesic	O
Pak	O
(Part	O
1	O
of	O
3)	O
DESCRIPTION:	O
Diclofenac	B-D004008

Rx	O
onlyPrevidolRx	O
Analgesic	O
Pak	O
Cardiovascular	O
Risk	B-D012306
ASAIDs	O
may	O
cause	O
an	O
increase	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(see	O
WARNINGS)	O
Diclofenac	B-D004008
Sodium	B-D012964

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(see	O
WARNINGS.)	O
WARNINGS	O
AND	O
PRECAUTIONS	O
•	O
Symptomatic	O
response	O
does	O
not	O
preclude	O
the	O
presence	O
of	O
gastric	O
Mali	B-D008302

(5.3)•	O
Cyanocobalamin	O
(vitamin	O
B-12)	O
Deficiency:	O
Daily	O
long-term	O
use	O
(e.g.,	O
longer	O
than	O
3	O
years)	O
may	O
Lead	B-D007854

(5.4)•	O
PPI	O
therapy	O
may	O
be	O
associated	O
with	O
increased	O
Risk	B-D012306

(5.5)•	O
Avoid	O
concomitant	O
use	O
of	O
Omeprazole	B-D009853

(5.6)•Bone	O
Fracture:	O
Long-term	O
and	O
multiple	O
daily	O
dose	O
PPI	O
therapy	O
may	O
be	O
associated	O
with	O
an	O
increased	O
Risk	B-D012306

(5.7)•	O
Hypomagnesemia	O
has	O
been	O
reported	O
rarely	O
with	O
prolonged	O
treatment	O
with	O
PPIs	O

(5.8)•	O
Avoid	O
concomitant	O
use	O
of	O
Omeprazole	B-D009853

(5.10,	O
12.2)	O
ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
And	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
(see	O
WARNINGS)	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
(see	O
WARNINGS)	O
Hepatotoxicity	O
(see	O
WARNINGS)	O
Hypertension	B-D006973
(see	O
WARNINGS)	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
(see	O
WARNINGS)	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
(see	O
WARNINGS)	O
Anaphylactic	O
Reactions	O
(see	O
WARNINGS)	O
Serious	O
Skin	B-D012867
Reactions	O
(see	O
WARNINGS)	O
Hematologic	O
Toxicity	O
(see	O
WARNINGS)	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole	O
:	O
Fever	B-D005334

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS)	O

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
Cardiovascular	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
CELEBREX	O
immediately	O
if	O
abnormal	O
Liver	B-D008099

New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

Fluid	O
retention	O
and	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Renal	O
papillary	O
Necrosis	B-D009336

Use	O
CELEBREX	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
Heart	B-D006333
Failure	I-D006333

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
CELEBREX	O
in	O
Patients	B-D010361

Serious	O
Skin	B-D012867

Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
Skin	B-D012867

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
CELEBREX	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
CELEBREX,	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
CELEBREX,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
Ulcer	B-D014456

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
CELEBREX	O
is	O
not	O
recommended	O
in	O
these	O
Patients	B-D010361

If	O
CELEBREX	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

CELEBREX	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
CELEBREX	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

CELEBREX	O
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
CELEBREX	O
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
Inflammation	B-D007249

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
CELEBREX	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
Risk	B-D012306

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
CELEBREX-treated	O
Patients	B-D010361

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
CELEBREX	O
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
Dyspepsia	B-D004415

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
Diclofenac	B-D004008

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
Dysmenorrhea	B-D004412

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
nonselective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

Hypertension	B-D006973
NSAIDs,	O
including	O
Flurbiprofen	B-D005480

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
Flurbiprofen	B-D005480

Blood	B-D001794
Pressure	I-D001794

Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

Flurbiprofen	B-D005480
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Gastrointestinal	O
Effects	O
Risk	B-D012306
of	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
PerforationNSAIDs,	O
including	O
Flurbiprofen	B-D005480

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

These	O
trends	O
continue	O
with	O
longer	O
duration	O
of	O
use,	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
those	O
with	O
a	O
prior	O
History	B-D006664

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Patients	B-D010361
and	O
Physicians	B-D010820

This	O
should	O
include	O
discontinuation	O
of	O
the	O
NSAID	O
until	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
ruled	O
out	O

For	O
high	O
Risk	B-D012306

Renal	O
EffectsLong-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Advanced	O
Renal	O
Disease	B-D004194
In	O
clinical	O
studies,	O
the	O
elimination	O
Half-Life	B-D006207

Flurbiprofen	B-D005480
metabolites	O
are	O
eliminated	O
primarily	O
by	O
the	O
Kidney	B-D007668

Elimination	O
of	O
4'-hydroxy-flurbiprofen	O
was	O
reduced	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
Flurbiprofen	B-D005480

If	O
Flurbiprofen	B-D005480

Anaphylactoid	O
ReactionsAs	O
with	O
other	O
NSAIDs,	O
anaphylactoid	O
reactions	O
may	O
occur	O
in	O
Patients	B-D010361

Flurbiprofen	B-D005480
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249
)	O

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

PRECAUTIONS	O
GeneralFlurbiprofen	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

The	O
pharmacological	O
activity	O
of	O
Flurbiprofen	B-D005480

Hepatic	O
EffectsBorderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Notable	O
elevations	O
of	O
ALT	O
or	O
AST	O
(approximately	O
three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

Hematological	O
EffectsAnemia	O
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
fluid	O
retention,	O
GI	O
Blood	B-D001769

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
non-steroidal	O
anti-inflammatory	O
drugs,	O
including	O
Flurbiprofen	B-D005480

Non-steroidal	O
anti-inflammatory	O
drugs	O
inhibit	O
Platelet	B-D010974
Aggregation	I-D010974

Unlike	O
Aspirin	B-D001241

Flurbiprofen	B-D005480
does	O
not	O
generally	O
Affect	B-D000339

Patients	B-D010361
receiving	O
Flurbiprofen	B-D005480

Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross-reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

Vision	O
ChangesBlurred	O
and/or	O
diminished	O
vision	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
Flurbiprofen	B-D005480

Patients	B-D010361
experiencing	O
Eye	B-D005123

Adverse	O
event	O
rates	O
generally	O
increased	O
with	O
increasing	O
daily	O
dose	O

The	O
event	O
rates	O
reported	O
below	O
are	O
from	O
approximately	O
150	O
Patients	B-D010361

The	O
Overall	B-D016424

The	O
following	O
lists	O
adverse	O
events	O
that	O
occurred	O
with	O
an	O
Incidence	B-D015994

To	O
distinguish	O
different	O
rates	O
of	O
occurrence	O
in	O
clinical	O
studies,	O
the	O
adverse	O
events	O
are	O
listed	O
as	O
follows:	O
name	O
of	O
adverse	O
event	O
=	O
less	O
than	O
3%	O
adverse	O
events	O
marked	O
with	O
an	O
asterisk	O
*	O
=	O
3%	O
to	O
9%	O
adverse	O
event	O
rates	O
over	O
9%	O
are	O
in	O
parentheses	O

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

Cardiovascular:	O
Palpitations;	O
Vasodilation	B-D014664
	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Anxiety	B-D001007
*;	O
Confusion	B-D003221
;	O
Dizziness	B-D004244
(14%);	O
Hypertonia;	O
Insomnia*;	O
Nervousness*;	O
Paresthesia	B-D010292
;	O
Somnolence	O
(22%);	O
Thinking	B-D013850
abnormalities	O

Digestive:	O
Anorexia	B-D000855
;	O
Constipation	B-D003248
(22%);	O
Diarrhea	B-D003967
*;	O
Dry	O
Mouth	B-D009055
Ulcer	B-D014456

Metabolic	O
and	O
Nutritional	O
Disorders:	O
Edema	B-D004487
*	O

Respiratory:	O
Dyspnea	B-D004417
;	O
Hiccup	B-D006606
s;	O
Pharyngitis	B-D010612
;	O
Rhinitis	B-D012220
	O

Skin	B-D012867
and	O
Appendages:	O
Pruritus	B-D011537
*;	O
Sweating	B-D013546
*	O

Special	O
Senses:	O
Tinnitus	B-D014012
	O

Urogenital:	O
Urinary	O
frequency	O

Incidence	B-D015994
less	O
than	O
1%	O
Body	O
as	O
a	O
Whole:	O
Allergic	O
reaction	O

Cardiovascular:	O
Arrhythmia;	O
Hypotension	B-D007022
;	O
Tachycardia	B-D013610
	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
:	O
Agitation;	O
Abnormal	O
Dreams	B-D004325

Digestive:	O
Chalky	O
stool;	O
"Clenching	O
teeth";	O
Dysphagia;	O
Esophageal	O
Spasm	B-D013035

Metabolic	O
and	O
Nutritional:	O
Weight	O
decrease	O

Musculoskeletal:	O
Arthralgia	B-D018771
;	O
Myalgia	B-D063806
	O

Respiratory:	O
Asthma	B-D001249
;	O
Bronchitis	B-D001991
;	O
Hoarseness	B-D006685
;	O
Increased	O
Cough	B-D003371

Skin	B-D012867
and	O
Appendages:	O
Rash;	O
Urticaria	B-D014581
	O

Special	O
Senses:	O
Altered	O
vision;	O
Bad	O
Taste	B-D013649

Urogenital:	O
Cystitis	B-D003556
;	O
Glycosuria	B-D006029
;	O
Impotence;	O
Urinary	B-D014549
Incontinence	I-D014549

Cardiovascular	O
Risk	B-D012306
Non-Steroidal	O
Anti-Inflammatory	O
Drugs	O
(NSAIDs)	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Fenoprofen	B-D005279
Calcium	B-D002118
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
During	O
clinical	O
studies	O
for	O
Rheum	B-D012250

These	O
encompass	O
Observation	B-D019370

For	O
comparison,	O
data	O
are	O
also	O
presented	O
from	O
complaints	O
received	O
from	O
the	O
266	O
Patients	B-D010361

During	O
short-term	O
studies	O
for	O
Analgesia	B-D000698

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
>	O
1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—During	O
Clinical	B-D016430
Trial	I-D016430

In	O
descending	O
order	O
of	O
frequency,	O
these	O
reactions	O
included	O
Dyspepsia	B-D004415

2.3%	O
placebo),	O
Nausea	B-D009325

7.1%),	O
Constipation	B-D003248

1.5%),	O
Vomiting	B-D014839

1.9%),	O
Abdominal	B-D015746
Pain	I-D015746

1.1%),	O
and	O
Diarrhea	B-D003967

4.1%)	O

The	O
drug	O
was	O
discontinued	O
because	O
of	O
adverse	O
gastrointestinal	O
reactions	O
in	O
less	O
than	O
2%	O
of	O
Patients	B-D010361

Nervous	B-D009420
System	I-D009420
—The	O
most	O
frequent	O
adverse	O
neurologic	O
reactions	O
were	O
Headache	B-D006261

7.5%)	O
and	O
somnolence	O
(8.5%	O
vs	O

6.4%)	O

Dizziness	B-D004244
(6.5%	O
vs	O

5.6%),	O
Tremor	B-D014202

0.4%),	O
and	O
Confusion	B-D003221

none)	O
were	O
noted	O
less	O
frequently	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Skin	B-D012867
and	O
Appendages—	O
Increased	O
Sweating	B-D013546

0.4%),	O
Pruritus	B-D011537

0.8%),	O
and	O
rash	O
(3.7%	O
vs	O

0.4%)	O
were	O
reported	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
about	O
1%	O
of	O
Patients	B-D010361

Special	O
Senses—Tinnitus	O
(4.5%	O
vs	O

0.4%),	O
blurred	O
vision	O
(2.2%	O
vs	O

none),	O
and	O
decreased	O
Hearing	B-D006309

none)	O
were	O
reported	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
less	O
than	O
0.5%	O
of	O
Patients	B-D010361

Cardiovascular—Palpitations	O
(2.5%	O
vs	O

0.4%)	O

Fenoprofen	B-D005279
Calcium	B-D002118
was	O
discontinued	O
in	O
about	O
0.5%	O
of	O
Patients	B-D010361

Miscellaneous—Nervousness	O
(5.7%	O
vs	O

1.5%),	O
Asthenia	B-D001247

0.4%),	O
peripheral	O
Edema	B-D004487

0.4%),	O
Dyspnea	B-D004417

none),	O
Fatigue	B-D005221

1.5%),	O
upper	O
respiratory	O
infection	O
(1.5%	O
vs	O

5.6%),	O
and	O
nas	B-C015378
opharyngitis	O
(1.2%	O
vs	O

none)	O

Adverse	O
Drug	O
Reactions	O
Reported	O
in	O
<1%	O
of	O
Patients	B-D010361
During	O
Clinical	B-D016430
Trial	I-D016430
s	O
Digestive	B-D004064
System	I-D004064
—Gastritis,	O
Peptic	B-D010437
Ulcer	I-D010437

Increases	O
in	O
Alkaline	B-D000469
Phosphatase	I-D000469

Cardiovascular—Atrial	O
fibrillation,	O
Pulmonary	B-D011654
Edema	I-D011654

Genitourinary	O
Tract—Renal	O
failure,	O
Dysuria	B-D053159

Hypersensitivity	B-D006967
—Angioedema	O
(angioneurotic	O
Edema	B-D004487

Hematologic—Purpura,	O
bruising,	O
Hemorrhage	B-D006470

Nervous	B-D009420
System	I-D009420
—Depression,	O
disorientation,	O
Seizures	B-D012640

Special	O
Senses—Burning	O
Tongue	B-D014059

Skin	B-D012867
and	O
Appendages—Exfoliative	O
Dermatitis	B-D003872

Miscellaneous—Anaphylaxis,	O
Urticaria	B-D014581

WARNING:	O
Risk	B-D012306

This	O
Risk	B-D012306

•	O
Celecoxib	B-D000068579
Capsules	B-D002214

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

WARNING:	O
Risk	B-D012306

•	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

Monitor	O
Patients	B-D010361

(5.10,	O
8.1)	O
•	O
Hematologic	O
Toxicity:	O
Monitor	O
hemoglobin	O
or	O
Hematocrit	B-D006400

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(	O
4	O
)]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

•Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

•Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

•Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

•If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

•In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

The	O
rates	O
of	O
Hypertension	B-D006973

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(	O
14.6	O
)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
a	O
sulfonamide	O
and	O
both	O
NSAIDs	O
and	O
Sulfonamides	B-D013449

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
Patients	B-D010361

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematological	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
•Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)]	O
•GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
•Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)]	O
•Hypertension	O
[see	O
Warnings	O
and	O
Precautions	O
(5.4)]	O
•Heart	O
Failure	O
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)]	O
•Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)]	O
•Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)]	O
•Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)]	O
•Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
TEVA	O
USA,	O
Pharmacovigilance	B-D060735

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥	O
2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Celecoxib	B-D000068579
N	O
=	O
4146	O
Placebo	O
N	O
=	O
1864	O
NAP	O
N	O
=	O
1366	O
DCF	O
N	O
=	O
387	O
IBU	O
N	O
=	O
345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥	O
5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥	O
5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥	O
5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

(5.1)	O
Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

(4	O
,	O
5.1)	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.2)	O
Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Celecoxib	B-D000068579
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

[see	O
Warnings	O
and	O
Precautions	O
(5.2)]	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Hepatotoxicity:	O
Inform	O
Patients	B-D010361

Discontinue	O
if	O
abnormal	O
Liver	B-D008099

Monitor	O
Blood	B-D001794
Pressure	I-D001794

Avoid	O
use	O
of	O
Celecoxib	B-D000068579
Capsules	B-D002214

Monitor	O
Patients	B-D010361

Based	O
on	O
available	O
data,	O
it	O
is	O
unclear	O
that	O
the	O
Risk	B-D012306

The	O
relative	O
increase	O
in	O
serious	O
CV	O
thrombotic	O
events	O
over	O
baseline	O
conferred	O
by	O
NSAID	O
use	O
appears	O
to	O
be	O
similar	O
in	O
those	O
with	O
and	O
without	O
known	O
CV	O
Disease	B-D004194

However,	O
Patients	B-D010361

Some	O
Observation	B-D019370

The	O
increase	O
in	O
CV	O
thrombotic	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
there	O
was	O
about	O
a	O
threefold	O
increased	O
Risk	B-D012306

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

A	O
Randomized	B-D016449
Controlled	I-D016449
Trial	I-D016449

Ibuprofen	B-D007052
Or	O
Naproxen	B-D009288
(PRECISION)	O
was	O
conducted	O
to	O
assess	O
the	O
relative	O
cardiovascular	O
thrombotic	O
Risk	B-D012306

Celecoxib	B-D000068579
100	O
mg	O
twice	O
daily	O
was	O
non-inferior	O
to	O
Naproxen	B-D009288

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
symptoms	O
of	O
serious	O
CV	O
events	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Status	O
Post	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026
Graft	O
(CABG)	O
Surgery	O
Two	O
large,	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

NSAIDs	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
CABG	O
[see	O
Contraindications	B-D000075202
(4)	O
]	O

Post-MI	O
Patients	B-D010361
Observation	B-D019370
al	O
studies	O
conducted	O
in	O
the	O
Danish	O
National	O
Registry	O
have	O
demonstrated	O
that	O
Patients	B-D010361

In	O
this	O
same	O
cohort,	O
the	O
Incidence	B-D015994

Although	O
the	O
absolute	O
rate	O
of	O
Death	B-D003643

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.2	O
Gastrointestinal	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Upper	O
GI	O
Ulcer	B-D014456

However,	O
even	O
short-term	O
NSAID	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

Risk	B-D012307
Factors	I-D012307
for	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation,	O
and	O
Perforation	O
Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
postmarketing	O
reports	O
of	O
fatal	O
GI	O
events	O
occurred	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

Additionally,	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

Strategies	O
to	O
Minimize	O
the	O
GI	O
Risk	B-D012306
s	O
in	O
NSAID-treated	O
Patients	B-D010361

Avoid	O
administration	O
of	O
more	O
than	O
one	O
NSAID	O
at	O
a	O
Time	B-D013995

Avoid	O
use	O
in	O
Patients	B-D010361

For	O
such	O
Patients	B-D010361

Remain	O
alert	O
for	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

If	O
a	O
serious	O
GI	O
adverse	O
event	O
is	O
suspected,	O
promptly	O
initiate	O
evaluation	O
and	O
treatment,	O
and	O
discontinue	O
Celecoxib	B-D000068579

In	O
the	O
setting	O
of	O
concomitant	O
use	O
of	O
low-dose	O
Aspirin	B-D001241

5.3	O
Hepatotoxicity	O
Elevations	O
of	O
ALT	O
or	O
AST	O
(three	O
or	O
more	O
Time	B-D013995

In	O
addition,	O
rare,	O
sometimes	O
fatal,	O
cases	O
of	O
severe	O
hepatic	O
injury,	O
including	O
fulminant	O
Hepatitis	B-D006505

Elevations	O
of	O
ALT	O
or	O
AST	O
(less	O
than	O
three	O
Time	B-D013995

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Inform	O
Patients	B-D010361

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.4	O
Hypertension	B-D006973
NSAIDs,	O
including	O
Celecoxib	B-D000068579

Patients	B-D010361
taking	O
angiotensin	O
converting	O
enzyme	O
(ACE)	O
inhibitors,	O
thiazide	O
Diuretics	B-D004232

See	O
Clinical	O
Studies	O
(14.6,	O
14.7)	O
for	O
additional	O
Blood	B-D001794
Pressure	I-D001794

Monitor	O
Blood	B-D001794
Pressure	I-D001794

5.5	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
The	O
Coxib	O
and	O
traditional	O
NSAID	O
Trialists’	O
Collaboration	O
Meta-Analysis	B-D017418

In	O
a	O
Danish	O
National	O
Registry	O
study	O
of	O
Patients	B-D010361

Additionally,	O
fluid	O
retention	O
and	O
Edema	B-D004487

Use	O
of	O
Celecoxib	B-D000068579

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.7)],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

5.6	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
Renal	O
Toxicity	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
Celecoxib	B-D000068579

The	O
renal	O
effects	O
of	O
Celecoxib	B-D000068579

Correct	O
volume	O
status	O
in	O
dehydrated	O
or	O
hypovolemic	O
Patients	B-D010361

Monitor	O
renal	O
function	O
in	O
Patients	B-D010361

Avoid	O
the	O
use	O
of	O
Celecoxib	B-D000068579

If	O
Celecoxib	B-D000068579

Hyperkalemia	B-D006947
Increases	O
in	O
Serum	B-D044967

In	O
Patients	B-D010361

5.7	O
Anaphylactic	O
Reactions	O
Celecoxib	B-D000068579
has	O
been	O
associated	O
with	O
anaphylactic	O
reactions	O
in	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

Seek	O
emergency	O
help	O
if	O
any	O
anaphylactic	O
reaction	O
occurs	O

5.8	O
Exacerbation	O
of	O
Asthma	B-D001249
Related	O
to	O
Aspirin	B-D001241
Sensitivity	O
A	O
subpopulation	O
of	O
Patients	B-D010361

Because	O
cross-reactivity	O
between	O
Aspirin	B-D001241

When	O
Celecoxib	B-D000068579

5.9	O
Serious	O
Skin	B-D012867
Reactions	O
Serious	O
Skin	B-D012867

These	O
serious	O
events	O
may	O
occur	O
without	O
warning	O
and	O
can	O
be	O
fatal	O

Inform	O
Patients	B-D010361

Celecoxib	B-D000068579
Capsules	B-D002214

5.10	O
Prema	B-C070504
ture	O
Closure	O
of	O
Fetal	O
Ductus	B-D004373
Arteriosus	I-D004373
Celecoxib	B-D000068579
may	O
cause	O
Prema	B-C070504

Avoid	O
use	O
of	O
NSAIDs,	O
including	O
Celecoxib	B-D000068579

5.11	O
Hematologic	O
Toxicity	O
Anemia	B-D000740
has	O
occurred	O
in	O
NSAID-treated	O
Patients	B-D010361

This	O
may	O
be	O
due	O
to	O
occult	O
or	O
gross	O
Blood	B-D001769

If	O
a	O
patient	O
treated	O
with	O
Celecoxib	B-D000068579

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
Celecoxib	B-D000068579

NSAIDs,	O
including	O
Celecoxib	B-D000068579

Co-morbid	O
conditions	O
such	O
as	O
coagulation	O
disorders	O
or	O
concomitant	O
use	O
of	O
Warfarin	B-D014859

Monitor	O
these	O
Patients	B-D010361

5.12	O
Masking	O
of	O
Inflammation	B-D007249
and	O
Fever	B-D005334
The	O
pharmacological	O
activity	O
of	O
Celecoxib	B-D000068579

5.13	O
Laboratory	O
Monitoring	O
Because	O
serious	O
GI	O
bleeding,	O
hepatotoxicity,	O
and	O
renal	O
injury	O
can	O
occur	O
without	O
warning	O
symptoms	O
or	O
signs,	O
consider	O
monitoring	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.14	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
Because	O
of	O
the	O
Risk	B-D012306

6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling:	O
Cardiovascular	O
Thrombotic	O
Events	O
[see	O
Warnings	O
and	O
Precautions	O
(5.1)	O
]	O
GI	O
Bleeding,	O
Ulcer	B-D014456
ation	O
and	O
Perforation	O
[see	O
Warnings	O
and	O
Precautions	O
(5.2)	O
]	O
Hepatotoxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.3)	O
]	O
Hypertension	B-D006973
[see	O
Warnings	O
and	O
Precautions	O
(5.4)	O
]	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
[see	O
Warnings	O
and	O
Precautions	O
(5.5)	O
]	O
Renal	O
Toxicity	O
and	O
Hyperkalemia	B-D006947
[see	O
Warnings	O
and	O
Precautions	O
(5.6)	O
]	O
Anaphylactic	O
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.7)	O
]	O
Serious	O
Skin	B-D012867
Reactions	O
[see	O
Warnings	O
and	O
Precautions	O
(5.9)	O
]	O
Hematologic	O
Toxicity	O
[see	O
Warnings	O
and	O
Precautions	O
(5.11)	O
]	O
Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Apotex	O
Corp	O

at	O
1-800-706-5575	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Of	O
the	O
Celecoxib	B-D000068579

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
Celecoxib	B-D000068579
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBX	O
N=4146	O
Placebo	O
N=1864	O
NAP	O
N=1366	O
DCF	O
N=387	O
IBU	O
N=345	O
Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

In	O
placebo-	O
or	O
active-controlled	O
Clinical	B-D016430
Trial	I-D016430

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
Celecoxib	B-D000068579

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
%	O
to	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
Celecoxib	B-D000068579

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RA	O
studies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
Celecoxib	B-D000068579

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-	O
controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
Celecoxib	B-D000068579

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
Population	B-D011153

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS)	O

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
As	O
A	O
Whole:fever,	O
infection,	O
Sepsis	B-D018805

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS)	O

Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
Cardiovascular	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
CELEBREX	O
immediately	O
if	O
abnormal	O
Liver	B-D008099

New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

Fluid	O
retention	O
and	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Renal	O
papillary	O
Necrosis	B-D009336

Use	O
CELEBREX	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
Heart	B-D006333
Failure	I-D006333

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
CELEBREX	O
in	O
Patients	B-D010361

Serious	O
Skin	B-D012867

Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
Skin	B-D012867

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
CELEBREX	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
CELEBREX,	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
CELEBREX,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
Ulcer	B-D014456

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

Celebrex	O
is	O
contraindicated	O
in	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
CELEBREX	O
is	O
not	O
recommended	O
in	O
these	O
Patients	B-D010361

If	O
CELEBREX	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

CELEBREX	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
CELEBREX	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

CELEBREX	O
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
CELEBREX	O
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
Inflammation	B-D007249

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
CELEBREX	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
Risk	B-D012306

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
CELEBREX-treated	O
Patients	B-D010361

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
CELEBREX	O
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
Dyspepsia	B-D004415

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
Diclofenac	B-D004008

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
Dysmenorrhea	B-D004412

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

-	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

ADVERSE	O
REACTIONS	O
Of	O
the	O
423	O
Patients	B-D010361

Eighty-seven	O
percent	O
(87%)	O
of	O
the	O
Diclofenac	B-D004008

The	O
majority	O
of	O
these	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
upon	O
discontinuation	O
of	O
therapy	O

Of	O
the	O
211	O
Patients	B-D010361

Application	O
site	O
reactions	O
(ASRs)	O
were	O
the	O
most	O
frequent	O
AEs	O
in	O
both	O
Diclofenac	B-D004008

Of	O
note,	O
four	O
reactions,	O
contact	O
Dermatitis	B-D003872

Eighteen	O
percent	O
of	O
Diclofenac	B-D004008

These	O
discontinuations	O
were	O
mainly	O
due	O
to	O
Skin	B-D012867

Table	O
1	O
below	O
presents	O
the	O
AEs	O
reported	O
at	O
an	O
Incidence	B-D015994

Table	O
1	O

Adverse	O
Events	O
Reported	O
(>1%	O
in	O
Any	O
Treatment	O
Group)	O
During	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
Phase	O
3	O
Clinical	B-D016430
Trial	I-D016430
s	O
Incidence	B-D015994
s	O
for	O
60-Day	O
and	O
90-Day	O
Treatments	O
60-day	O
Treatment	O
90-day	O
Treatment	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
(%)	O
N=48	O
Gel	O
Vehicle	O
(%)	O
N=49	O
Diclofenac	B-D004008
Sodium	B-D012964
Gel,	O
3%	O
(%)	O
N=114	O
Gel	O
Vehicle	O
(%)	O
N=114	O
BODY	O
AS	O
A	O
WHOLE	O
21	O
20	O
20	O
18	O
Abdominal	B-D015746
Pain	I-D015746
2	O
0	O
1	O
0	O
Accidental	O
Injury	O
0	O
0	O
4	O
2	O
Allergic	O
Reaction	O
0	O
0	O
1	O
3	O
Asthenia	B-D001247
0	O
0	O
2	O
0	O
Back	B-D001416
Pain	I-D001416
4	O
0	O
2	O
2	O
Chest	B-D002637
Pain	I-D002637
2	O
0	O
1	O
0	O
Chills	B-D023341
0	O
2	O
0	O
0	O
Flu	O
Syndrome	B-D013577
10	O
6	O
1	O
4	O
Headache	B-D006261
0	O
6	O
7	O
6	O
Infection	O
4	O
6	O
4	O
5	O
Neck	B-D019547
Pain	I-D019547
0	O
0	O
2	O
0	O
Pain	B-D010146
2	O
0	O
2	O
2	O
Cardiovascular	B-D002319
System	I-D002319

Adverse	O
Reactions	O
Reported	O
for	O
Oral	O
Diclofenac	B-D004008
Dosage	O
Form	B-D020478
(not	O
topical	O
Diclofenac	B-D004008

Body	O
as	O
a	O
Whole:	O
Abdominal	B-D015746
Pain	I-D015746

Cardiovascular:	O
Hypertension	B-D006973

Digestive:	O
Diarrhea	B-D003967

Hemic	O
and	O
Lymph	B-D008196
atic:	O
hemoglobin	B-C032001
D	I-C032001

Metabolic	O
and	O
Nutritional	O
Disorders:	O
Azotemia	B-D053099

Nervous	B-D009420
System	I-D009420
:	O
Dizziness	B-D004244

Respiratory:	O
Epistaxis	B-D004844

Skin	B-D012867
and	O
Appendages:	O
rash*,	O
Pruritus	B-D011537

Special	O
Senses:	O
Tinnitus	B-D014012

Urogenital:	O
Nephrotic	B-D009404
Syndrome	I-D009404

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Etodolac	B-D017308
Extended-Release	O
Tablets	B-D013607
,	O
400	O
mg,	O
500	O
mg	O
and	O
600	O
mg	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
A	O
total	O
of	O
1552	O
Patients	B-D010361

In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
Incidence	B-D015994

As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
Time	B-D013995

In	O
Patients	B-D010361

gross	O
bleeding/perforation	O
Nausea	B-D009325

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Etodolac	B-D017308
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1,000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
or	O
Equal	O
to	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

Musculoskeletal	O
-	O
Arthralgia	B-D018771
	O

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Musculoskeletal	O
-	O
Muscle	O
Pain	B-D010146

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
–	O
Sepsis	B-D018805
,	O
Death	B-D003643

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Urogenital	B-D014566
System	I-D014566

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS)	O

Naproxen	B-D009288
as	O
NAPRELAN	O
®	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
people	O
are	O
at	O
greater	O
Risk	B-D012306

(SeeWARNINGS)	O

ADVERSE	O
REACTIONS	O
As	O
with	O
all	O
drugs	O
in	O
this	O
class,	O
the	O
frequency	O
and	O
severity	O
of	O
adverse	O
events	O
depends	O
on	O
several	O
factors:	O
the	O
dose	O
of	O
the	O
drug	O
and	O
duration	O
of	O
treatment;	O
the	O
age,	O
the	O
Sex	B-D012723

The	O
following	O
adverse	O
reactions	O
are	O
divided	O
into	O
three	O
parts	O
based	O
on	O
frequency	O
and	O
whether	O
or	O
not	O
the	O
possibility	O
exists	O
of	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
these	O
adverse	O
events	O

In	O
those	O
reactions	O
listed	O
as	O
“Probable	O
Causal	O
Relationship”	O
there	O
is	O
at	O
least	O
one	O
case	O
for	O
each	O
adverse	O
reaction	O
where	O
there	O
is	O
evidence	O
to	O
suggest	O
that	O
there	O
is	O
a	O
causal	O
relationship	O
between	O
drug	O
usage	O
and	O
the	O
reported	O
event	O

The	O
adverse	O
reactions	O
reported	O
were	O
based	O
on	O
the	O
results	O
from	O
two	O
double-blind	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
total	O
of	O
542	O
Patients	B-D010361

Of	O
these	O
542	O
Patients	B-D010361

Adverse	O
reactions	O
reported	O
by	O
Patients	B-D010361

Those	O
adverse	O
reactions	O
observed	O
with	O
Naproxen	B-D009288

The	O
most	O
frequent	O
adverse	O
events	O
from	O
the	O
double-blind	O
and	O
open-label	O
Clinical	B-D016430
Trial	I-D016430

The	O
Incidence	B-D015994

Those	O
reactions	O
occurring	O
in	O
less	O
than	O
3%	O
of	O
the	O
Patients	B-D010361

Incidence	B-D015994

Gastrointestinal—Nausea*,	O
Diarrhea	B-D003967

Hematologic—Anemia,	O
Ecchymosis	B-D004438

Respiratory—Pharyngitis*,	O
Rhinitis	B-D012220

Renal—Urinary	O
tract	O
infection*,	O
Cystitis	B-D003556

Dermatologic—Skin	O
rash*,	O
Skin	B-D012867

Metabolic	O
and	O
Nutrition—Peripheral	O
Edema	B-D004487

Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Dizziness,	O
Paresthesia	B-D010292

Cardiovascular—Hypertension,	O
Edema	B-D004487

Musculoskeletal—Cramps	O
(leg),	O
Myalgia	B-D063806

Special	O
Senses—Tinnitus*,	O
Hearing	B-D006309

General—Thirst	O

Incidence	B-D015994

Gastrointestinal—Anorexia,	O
Cholecystitis	B-D002764

Renal—Dysmenorrhea,	O
Dysuria	B-D053159

Hematologic—Leukopenia,	O
Bleeding	B-D001760
Time	I-D001760

Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Depression,	O
Anxiety	B-D001007

Dermatologic:	O
Angiodermatitis,	O
Herpes	B-D006561
Simplex	I-D006561

Special	O
Senses—Amblyopia,	O
Scleritis	B-D015423

Cardiovascular—Angina	O
pectoris,	O
Coronary	B-D003324
Artery	I-D003324
Disease	I-D003324

Respiratory—Asthma,	O
Dyspnea	B-D004417

Musculoskeletal—Myasthenia,	O
bone	O
disorder,	O
spontaneous	O
bone	O
fracture,	O
fibrotendinitis,	O
bone	O
Pain	B-D010146

Metabolic	O
and	O
Nutrition—Creatinine	O
increase,	O
glucosuria,	O
hypercholesteremia,	O
Albuminuria	B-D000419

General—Anaphylactoid	O
reactions,	O
angioneurotic	O
Edema	B-D004487

Incidence	B-D015994

These	O
Observation	B-D019370

Hematologic—Aplastic	O
Anemia,	B-D000743
Hemolytic	I-D000743

Central	B-D002490
Nervous	I-D002490
System	I-D002490
—Aseptic	O
Meningitis	B-D008581

Dermatologic—Epidermal	O
necrolysis,	O
Erythema	B-D004892
Multiforme	I-D004892

Gastrointestinal—Non-peptic	O
GI	O
Ulcer	B-D014456

Cardiovascular—Vasculitis	O

Cardiovascular	O
Thrombotic	O
Events	O
Nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Etodolac	B-D017308
is	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1,000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

Musculoskeletal	O
-	O
Arthralgia	B-D018771
*Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient-complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Musculoskeletal	O
-	O
Muscle	O
Pain	B-D010146

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDS	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

at	O
1-855-361-3993;	O
email	O
drugsafety@avkare.com	O
;	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
	O

Cardiovascular	O
Risk	B-D012306
NSAIDs1	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

Etodolac	B-D017308
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

1	O
Throughout	O
this	O
package	O
insert,	O
the	O
term	O
NSAID	O
refers	O
to	O
a	O
non-aspirin	O
non-steroidal	O
anti-inflammatory	O
drug	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1,000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
or	O
Equal	O
to	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

Digestive	B-D004064
System	I-D004064

Nervous	B-D009420
System	I-D009420

Skin	B-D012867
and	O
appendages	O
-	O
Pruritus	B-D011537
,	O
rash	O

Special	O
senses	O
-	O
Blurred	O
vision,	O
Tinnitus	B-D014012

Urogenital	B-D014566
System	I-D014566

Musculoskeletal	O
-	O
Arthralgia	B-D018771
	O

*	O
Drug-related	O
patient	O
complaints	O
occurring	O
in	O
3	O
to	O
9%	O
of	O
Patients	B-D010361

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Angioedema	B-D000799
,	O
Sweating	B-D013546

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances	O

Urogenital	B-D014566
System	I-D014566

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Metabolic	O
and	O
nutritional	O
-	O
Change	O
in	O
weight	O

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Skin	B-D012867
and	O
appendages	O
-	O
Alopecia	B-D000505
,	O
maculopapular	O
rash,	O
photosensitivity,	O
Skin	B-D012867

Special	O
senses	O
-	O
Conjunctivitis	B-D003231
,	O
Deafness	B-D003638

Urogenital	B-D014566
System	I-D014566

Musculoskeletal	O
-	O
Muscle	O
Pain	B-D010146

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
–	O
Sepsis	B-D018805
,	O
Death	B-D003643

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Nervous	B-D009420
System	I-D009420

Respiratory	B-D012137
System	I-D012137

Urogenital	B-D014566
System	I-D014566

WARNING:	O
CARDIOVASCULAR	O
AND	O
GASTROINTESTINAL	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
NSAIDs	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
Cardiovascular	O
Risk	B-D012306
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

All	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(NSAIDs)	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(5.1,14.6)	O
CELEBREX	O
is	O
contraindicated	O
for	O
the	O
treatment	O
of	O
peri-operative	O
Pain	B-D010146

(4,	O
5.1)	O
Gastrointestinal	O
Risk	B-D012306
NSAIDs,	O
including	O
CELEBREX,	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(5.4)	O
5	O

WARNINGS	O
AND	O
PRECAUTIONS	O
Serious	O
and	O
potentially	O
fatal	O
cardiovascular	O
(CV)	O
thrombotic	O
events,	O
Myocardial	B-D009203
Infarction	I-D009203

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

Serious	O
gastrointestinal	O
(GI)	O
adverse	O
events,	O
which	O
can	O
be	O
fatal	O

The	O
Risk	B-D012306

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
Patients	B-D010361

Elevated	O
Liver	B-D008099

Discontinue	O
use	O
of	O
CELEBREX	O
immediately	O
if	O
abnormal	O
Liver	B-D008099

New	O
onset	O
or	O
worsening	O
of	O
Hypertension	B-D006973

Blood	B-D001794
Pressure	I-D001794

Fluid	O
retention	O
and	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Renal	O
papillary	O
Necrosis	B-D009336

Use	O
CELEBREX	O
with	O
caution	O
in	O
the	O
elderly,	O
those	O
with	O
impaired	O
renal	O
function,	O
Heart	B-D006333
Failure	I-D006333

Anaphylactoid	O
reactions	O

Do	O
not	O
use	O
CELEBREX	O
in	O
Patients	B-D010361

Serious	O
Skin	B-D012867

Discontinue	O
CELEBREX	O
at	O
first	O
appearance	O
of	O
rash	O
or	O
Skin	B-D012867

5.1	O
Cardiovascular	O
Thrombotic	O
Events	O
Chronic	O
use	O
of	O
CELEBREX	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

In	O
the	O
APC	O
(Adenoma	O
Prevention	O
with	O
Celecoxib	B-D000068579
)	O
trial,	O
the	O
hazard	O
ratio	O
for	O
the	O
composite	O
endpoint	O
of	O
cardiovascular	O
Death	B-D003643

Cumulative	O
rates	O
for	O
this	O
composite	O
endpoint	O
over	O
3	O
years	O
were	O
3.0%	O
(20/671	O
subjects)	O
and	O
2.5%	O
(17/685	O
subjects),	O
Respect	B-D000078682

The	O
increases	O
in	O
both	O
Celecoxib	B-D000068579

All	O
NSAIDs,	O
both	O
COX-2	O
selective	O
and	O
non-selective,	O
may	O
have	O
a	O
similar	O
Risk	B-D012306

Patients	B-D010361
with	O
known	O
CV	O
Disease	B-D004194

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
signs	O
and/or	O
symptoms	O
of	O
serious	O
CV	O
toxicity	O
and	O
the	O
steps	O
to	O
take	O
if	O
they	O
occur	O

There	O
is	O
no	O
consistent	O
evidence	O
that	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

The	O
concurrent	O
use	O
of	O
Aspirin	B-D001241

Two	O
large,	O
controlled,	O
Clinical	B-D016430
Trial	I-D016430

5.2	O
Hypertension	B-D006973
As	O
with	O
all	O
NSAIDs,	O
CELEBREX	O
can	O
Lead	B-D007854

Patients	B-D010361
taking	O
Thiazides	B-D049971

NSAIDs,	O
including	O
CELEBREX,	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

Blood	B-D001794
Pressure	I-D001794

The	O
rates	O
of	O
Hypertension	B-D006973

5.3	O
Congestive	O
Heart	B-D006333
Failure	I-D006333
and	O
Edema	B-D004487
Fluid	O
retention	O
and	O
Edema	B-D004487

In	O
the	O
CLASS	O
study	O
[see	O
Clinical	O
Studies	O
(14.6)	O
],	O
the	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
of	O
peripheral	O
Edema	B-D004487

CELEBREX	O
should	O
be	O
used	O
with	O
caution	O
in	O
Patients	B-D010361

5.4	O
Gastrointestinal	O
(GI)	O
Effects	O
Risk	B-D012306
of	O
GI	O
Ulcer	B-D014456
ation,	O
Bleeding,	O
and	O
Perforation	O
NSAIDs,	O
including	O
CELEBREX,	O
can	O
cause	O
serious	O
gastrointestinal	O
events	O
including	O
bleeding,	O
Ulcer	B-D014456

These	O
serious	O
adverse	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Only	O
one	O
in	O
five	O
Patients	B-D010361

Complicated	O
and	O
symptomatic	O
Ulcer	B-D014456

Patients	B-D010361
65	O
years	O
of	O
age	O
and	O
older	O
had	O
an	O
Incidence	B-D015994

With	O
longer	O
duration	O
of	O
use	O
of	O
NSAIDs,	O
there	O
is	O
a	O
trend	O
for	O
increasing	O
the	O
likelihood	O
of	O
developing	O
a	O
serious	O
GI	O
event	O
at	O
some	O
Time	B-D013995

However,	O
even	O
short-term	O
therapy	O
is	O
not	O
without	O
Risk	B-D012306

NSAIDs	O
should	O
be	O
prescribed	O
with	O
extreme	O
caution	O
in	O
Patients	B-D010361

Patients	B-D010361
with	O
a	O
prior	O
History	B-D006664

Other	O
factors	O
that	O
increase	O
the	O
Risk	B-D012306

Most	O
spontaneous	O
reports	O
of	O
fatal	O
GI	O
events	O
are	O
in	O
elderly	O
or	O
debilitated	O
Patients	B-D010361

To	O
minimize	O
the	O
potential	O
Risk	B-D012306

Physicians	B-D010820
and	O
Patients	B-D010361

For	O
high-risk	O
Patients	B-D010361

5.5	O
Hepatic	O
Effects	O
Borderline	O
elevations	O
of	O
one	O
or	O
more	O
Liver	B-D008099

These	O
laboratory	O
abnormalities	O
may	O
progress,	O
may	O
remain	O
unchanged,	O
or	O
may	O
be	O
transient	O
with	O
continuing	O
therapy	O

Rare	O
cases	O
of	O
severe	O
hepatic	O
reactions,	O
including	O
Jaundice	B-D007565

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

A	O
patient	O
with	O
symptoms	O
and/or	O
signs	O
suggesting	O
Liver	B-D008099

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.6	O
Renal	O
Effects	O
Long-term	O
administration	O
of	O
NSAIDs	O
has	O
resulted	O
in	O
renal	O
papillary	O
Necrosis	B-D009336

Renal	O
toxicity	O
has	O
also	O
been	O
seen	O
in	O
Patients	B-D010361

In	O
these	O
Patients	B-D010361

Patients	B-D010361
at	O
greatest	O
Risk	B-D012306

Discontinuation	O
of	O
NSAID	O
therapy	O
is	O
usually	O
followed	O
by	O
recovery	O
to	O
the	O
pretreatment	O
state	O

Clinical	B-D016430
Trial	I-D016430

No	O
information	O
is	O
available	O
from	O
controlled	O
clinical	O
studies	O
regarding	O
the	O
use	O
of	O
CELEBREX	O
in	O
Patients	B-D010361

Therefore,	O
treatment	O
with	O
CELEBREX	O
is	O
not	O
recommended	O
in	O
these	O
Patients	B-D010361

If	O
CELEBREX	O
therapy	O
must	O
be	O
initiated,	O
close	O
monitoring	O
of	O
the	O
patient's	O
renal	O
function	O
is	O
advisable	O

5.7	O
Anaphylactoid	O
Reactions	O
As	O
with	O
NSAIDs	O
in	O
general,	O
anaphylactoid	O
reactions	O
have	O
occurred	O
in	O
Patients	B-D010361

In	O
post-marketing	O
experience,	O
rare	O
cases	O
of	O
anaphylactic	O
reactions	O
and	O
Angioedema	B-D000799

CELEBREX	O
should	O
not	O
be	O
given	O
to	O
Patients	B-D010361

This	O
symptom	O
complex	O
typically	O
occurs	O
in	O
Asthma	B-D001249

Emergency	O
help	O
should	O
be	O
sought	O
in	O
cases	O
where	O
an	O
anaphylactoid	O
reaction	O
occurs	O

5.8	O
Skin	B-D012867
Reactions	O
CELEBREX	O
is	O
a	O
sulfonamide	O
and	O
can	O
cause	O
serious	O
Skin	B-D012867

These	O
serious	O
events	O
can	O
occur	O
without	O
warning	O
and	O
in	O
Patients	B-D010361

Patients	B-D010361
should	O
be	O
informed	O
about	O
the	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.9	O
Pregnancy	B-D011247
In	O
late	O
Pregnancy	B-D011247

5.10	O
Corticosteroid	O
Treatment	O
CELEBREX	O
cannot	O
be	O
expected	O
to	O
substitute	O
for	O
corticosteroids	O
or	O
to	O
treat	O
corticosteroid	O
insufficiency	O

Abrupt	O
discontinuation	O
of	O
corticosteroids	O
may	O
Lead	B-D007854

Patients	B-D010361
on	O
prolonged	O
corticosteroid	O
therapy	O
should	O
have	O
their	O
therapy	O
tapered	O
slowly	O
if	O
a	O
decision	O
is	O
made	O
to	O
discontinue	O
corticosteroids	O

5.11	O
Hematological	O
Effects	O
Anemia	B-D000740
is	O
sometimes	O
seen	O
in	O
Patients	B-D010361

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
CELEBREX	O
should	O
have	O
their	O
hemoglobin	O
or	O
Hematocrit	B-D006400

CELEBREX	O
does	O
not	O
generally	O
Affect	B-D000339

5.12	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211
(DIC)	O
CELEBREX	O
should	O
be	O
used	O
only	O
with	O
caution	O
in	O
pediatric	O
Patients	B-D010361

5.13	O
Preexisting	O
Asthma	B-D001249
Patients	B-D010361
with	O
Asthma	B-D001249

The	O
use	O
of	O
Aspirin	B-D001241

Since	O
cross	O
reactivity,	O
including	O
bronchospasm,	O
between	O
Aspirin	B-D001241

5.14	O
Laboratory	O
TES	B-C004551

Patients	B-D010361
on	O
long-term	O
treatment	O
with	O
NSAIDs	O
should	O
have	O
a	O
CBC	O
and	O
a	O
Chemistry	B-D002621

If	O
abnormal	O
Liver	B-D008099

In	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

This	O
laboratory	O
abnormality	O
was	O
also	O
seen	O
in	O
Patients	B-D010361

The	O
clinical	O
significance	O
of	O
this	O
abnormality	O
has	O
not	O
been	O
established	O

5.15	O
Inflammation	B-D007249
The	O
pharmacological	O
activity	O
of	O
CELEBREX	O
in	O
reducing	O
Inflammation	B-D007249

5.16	O
Concomitant	O
NSAID	O
Use	O
The	O
concomitant	O
use	O
of	O
CELEBREX	O
with	O
any	O
dose	O
of	O
a	O
non-aspirin	O
NSAID	O
should	O
be	O
avoided	O
due	O
to	O
the	O
potential	O
for	O
increased	O
Risk	B-D012306

6	O

ADVERSE	O
REACTIONS	O
Of	O
the	O
CELEBREX-treated	O
Patients	B-D010361

More	O
than	O
8,500	O
Patients	B-D010361

Approximately	O
3,900	O
Patients	B-D010361

Because	O
Clinical	B-D016430
Trial	I-D016430

The	O
adverse	O
reaction	O
information	O
from	O
Clinical	B-D016430
Trial	I-D016430

Most	O
common	O
adverse	O
reactions	O
in	O
Arthritis	B-D001168

To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Pfizer	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
Table	O
1	O
lists	O
all	O
adverse	O
events,	O
regardless	O
of	O
Causality	B-D015984

Since	O
these	O
12	O
trials	O
were	O
of	O
different	O
durations,	O
and	O
Patients	B-D010361

Table	O
1:	O
Adverse	O
Events	O
Occurring	O
in	O
≥2%	O
of	O
CELEBREX	O
Patients	B-D010361
from	O
Pre-marketing	O
Controlled	O
Arthritis	B-D001168
Trials	O
CBXN=4146	O
PlaceboN=1864	O
NAPN=1366	O
DCFN=387	O
IBUN=345	O
CBX	O
=	O
CELEBREX	O
100	O
–	O
200	O
mg	O
twice	O
daily	O
or	O
200	O
mg	O
once	O
daily;NAP	O
=	O
Naproxen	B-D009288
500	O
mg	O
twice	O
daily;DCF	O
=	O
Diclofenac	B-D004008
75	O
mg	O
twice	O
daily;IBU	O
=	O
Ibuprofen	B-D007052
800	O
mg	O
three	O
Time	B-D013995

Gastrointestinal	O
Abdominal	B-D015746
Pain	I-D015746
4.1%	O
2.8%	O
7.7%	O
9.0%	O
9.0%	O
Diarrhea	B-D003967
5.6%	O
3.8%	O
5.3%	O
9.3%	O
5.8%	O
Dyspepsia	B-D004415
8.8%	O
6.2%	O
12.2%	O
10.9%	O
12.8%	O
Flatulence	B-D005414
2.2%	O
1.0%	O
3.6%	O
4.1%	O
3.5%	O
Nausea	B-D009325
3.5%	O
4.2%	O
6.0%	O
3.4%	O
6.7%	O
Body	O
as	O
a	O
whole	O
Back	B-D001416
Pain	I-D001416
2.8%	O
3.6%	O
2.2%	O
2.6%	O
0.9%	O
Peripheral	O
Edema	B-D004487
2.1%	O
1.1%	O
2.1%	O
1.0%	O
3.5%	O
Injury-Accidental	O
2.9%	O
2.3%	O
3.0%	O
2.6%	O
3.2%	O
Central,	O
Peripheral	B-D017933
Nervous	I-D017933
System	I-D017933

Among	O
the	O
most	O
common	O
reasons	O
for	O
discontinuation	O
due	O
to	O
adverse	O
events	O
in	O
the	O
CELEBREX	O
treatment	O
groups	O
were	O
Dyspepsia	B-D004415

Among	O
Patients	B-D010361

The	O
following	O
adverse	O
reactions	O
occurred	O
in	O
0.1	O
–	O
1.9%	O
of	O
Patients	B-D010361

The	O
lower	O
Incidence	B-D015994

Withdrawals/Serious	O
Adverse	O
Events	O
:	O
Kaplan-Meier	O
cumulative	O
rates	O
at	O
9	O
months	O
for	O
withdrawals	O
due	O
to	O
adverse	O
events	O
for	O
CELEBREX,	O
Diclofenac	B-D004008

Rates	O
for	O
serious	O
adverse	O
events	O
(i.e.,	O
causing	O
Hospitalization	B-D006760

6.3	O
Juvenile	O
Rheum	B-D012250
atoid	O
Arthritis	B-D001168
Study	O
In	O
a	O
12-week,	O
double-blind,	O
active-controlled	O
study,	O
242	O
JRA	O
Patients	B-D010361

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
events	O
in	O
Celecoxib	B-D000068579

The	O
most	O
commonly	O
occurring	O
(≥5%)	O
adverse	O
experiences	O
for	O
Naproxen	B-D009288

Compared	O
with	O
Naproxen	B-D009288

There	O
was	O
no	O
substantial	O
difference	O
in	O
the	O
number	O
of	O
clinical	O
exacerbations	O
of	O
Uveitis	B-D014605

In	O
a	O
12-week,	O
open-label	O
extension	O
of	O
the	O
double-blind	O
study	O
described	O
above,	O
202	O
JRA	O
Patients	B-D010361

The	O
Incidence	B-D015994

Table	O
2:	O
Adverse	O
Events	O
Occurring	O
in	O
≥5%	O
of	O
JRA	O
Patients	B-D010361
in	O
Any	O
Treatment	O
Group,	O
by	O
System	O
Organ	O
Class	O
(%	O
of	O
Patients	B-D010361

Doses	O
up	O
to	O
400	O
mg	O
once	O
daily	O
were	O
studied	O

The	O
types	O
of	O
adverse	O
events	O
reported	O
in	O
the	O
AS	O
studies	O
were	O
similar	O
to	O
those	O
reported	O
in	O
the	O
OA/RAstudies	O

Adverse	O
Events	O
from	O
Analgesia	B-D000698
and	O
Dysmenorrhea	B-D004412
Studies:	O
Approximately	O
1,700	O
Patients	B-D010361

All	O
Patients	B-D010361

Doses	O
up	O
to	O
600	O
mg/day	O
of	O
CELEBREX	O
were	O
studied	O
in	O
primary	O
Dysmenorrhea	B-D004412

The	O
types	O
of	O
adverse	O
events	O
in	O
the	O
Analgesia	B-D000698

The	O
only	O
additional	O
adverse	O
event	O
reported	O
was	O
post-dental	O
extraction	O
alveolar	O
Osteitis	B-D010000

6.5	O
The	O
APC	O
and	O
PreSAP	O
Trials	O
Adverse	O
reactions	O
from	O
long-term,	O
placebo-controlled	O
polyp	O
prevention	O
studies:	O
Exposure	O
to	O
CELEBREX	O
in	O
the	O
APC	O
and	O
PreSAP	O
trials	O
was	O
400	O
to	O
800	O
mg	O
daily	O
for	O
up	O
to	O
3	O
years	O
[see	O
Special	O
Studies	O
Adenoma	B-D000236
tous	O
Polyp	O
Prevention	O
Studies	O
(14.6)	O
]	O

Some	O
adverse	O
reactions	O
occurred	O
in	O
higher	O
percentages	O
of	O
Patients	B-D010361

The	O
adverse	O
reactions	O
for	O
which	O
these	O
differences	O
in	O
Patients	B-D010361

This	O
Risk	B-D012306

•	O
Diflunisal	B-D004061
Tablets	B-D013607

Gastrointestinal	O
Risk	B-D012306
•	O
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

ADVERSE	O
REACTIONS	O
The	O
adverse	O
reactions	O
observed	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

Listed	O
below	O
are	O
the	O
adverse	O
reactions	O
reported	O
in	O
the	O
1,314	O
of	O
these	O
Patients	B-D010361

Five	O
hundred	O
thirteen	O
Patients	B-D010361

In	O
general,	O
the	O
adverse	O
reactions	O
listed	O
below	O
were	O
2	O
to	O
14	O
Time	B-D013995

Incidence	B-D015994
Greater	O
Than	O
1%	O
Gastrointestinal	O
The	O
most	O
frequent	O
types	O
of	O
adverse	O
reactions	O
occurring	O
with	O
Diflunisal	B-D004061

Psychiatric	O
Somnolence,	O
insomnia	O

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Dizziness	B-D004244
	O

Special	O
Senses	O
Tinnitus	B-D014012
	O

Dermatologic	O
Rash*	O

Miscellaneous	O
Headache	B-D006261
*,	O
Fatigue	B-D005221

*	O
Incidence	B-D015994
between	O
3%	O
and	O
9%	O

Those	O
reactions	O
occurring	O
in	O
1%	O
to	O
3%	O
are	O
not	O
marked	O
with	O
an	O
asterisk	O

Incidence	B-D015994
Less	O
Than	O
1	O
in	O
100	O
The	O
following	O
adverse	O
reactions,	O
occurring	O
less	O
frequently	O
than	O
1	O
in	O
100,	O
were	O
reported	O
in	O
Clinical	B-D016430
Trial	I-D016430

The	O
Probability	B-D011336

Dermatologic	O
Erythema	B-D004892
Multiforme	I-D004892

Gastrointestinal	O
Peptic	B-D010437
Ulcer	I-D010437

Liver	B-D008099
function	O
abnormalities;	O
Jaundice	B-D007565

Hematologic	O
Thrombocytopenia	B-D013921
;	O
Agranulocytosis	B-D000380

Genitourinary	O
Dysuria	B-D053159
;	O
renal	O
impairment,	O
including	O
renal	O
failure;	O
interstitial	O
Nephritis	B-D009393

Psychiatric	O
Nervousness,	O
Depression	B-D003863

Central	B-D002490
Nervous	I-D002490
System	I-D002490
Vertigo	B-D014717
;	O
Light	B-D008027

Special	O
Senses	O
Transient	O
visual	O
disturbances	O
including	O
blurred	O
vision	O

Hypersensitivity	B-D006967
Reactions	O
Acute	O
anaphylactic	O
reaction	O
with	O
bronchospasm;	O
Angioedema	B-D000799

Hypersensitivity	B-D006967
Vasculitis	B-D014657

Hypersensitivity	B-D006967
Syndrome	B-D013577

Miscellaneous	O
Asthenia	B-D001247
,	O
Edema	B-D004487

Causal	O
Relationship	O
Unknown	O
Other	O
reactions	O
have	O
been	O
reported	O
in	O
Clinical	B-D016430
Trial	I-D016430

However,	O
in	O
these	O
rarely	O
reported	O
events,	O
that	O
possibility	O
cannot	O
be	O
excluded	O

Therefore,	O
these	O
Observation	B-D019370

Respiratory	O
Dyspnea	B-D004417
	O

Cardiovascular	O
Palpitation,	O
Syncope	B-D013575

Musculoskeletal	O
Muscle	B-D009120
Cramp	I-D009120

Genitourinary	O
Nephrotic	B-D009404
Syndrome	I-D009404

Special	O
Senses	O
Hearing	B-D034381
Loss	I-D034381

Miscellaneous	O
Chest	B-D002637
Pain	I-D002637

A	O
rare	O
occurrence	O
of	O
fulminant	O
necrotizing	O
Fasciitis	B-D005208

Potential	O
Adverse	O
Effects	O
In	O
addition,	O
a	O
variety	O
of	O
adverse	O
effects	O
not	O
observed	O
with	O
Diflunisal	B-D004061

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS.)	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS.)	O
ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

Other	O
adverse	O
reactions,	O
which	O
occur	O
rarely	O
are:	O
Body	O
as	O
a	O
Whole:	O
anaphylactic	O
reactions,	O
Appetite	B-D001066

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS	O
)	O

Etodolac	B-D017308
Capsules	B-D002214

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Other	O
events	O
including:	O
abnormal	O
renal	O
function,	O
Anemia	B-D000740

Adverse-reaction	O
information	O
for	O
Etodolac	B-D017308

In	O
Clinical	B-D016430
Trial	I-D016430

The	O
discontinuation	O
rate	O
in	O
Controlled	B-D018848
Clinical	I-D018848
Trial	I-D018848

New	O
patient	O
complaints	O
(with	O
an	O
Incidence	B-D015994

The	O
Incidence	B-D015994

(i.e.,	O
600	O
to	O
1000	O
mg/day)	O

Incidence	B-D015994
Greater	O
Than	O
Or	O
Equal	O
To	O
1%	O
-	O
Probably	O
Causally	O
Related	O
Body	O
as	O
a	O
whole	O
-	O
Chills	B-D023341
and	O
Fever	B-D005334

,	O
Diarrhea	B-D003967

,	O
Flatulence	B-D005414

,	O
Nausea	B-D009325

,	O
abdominal	O
distension,	O
epigastric	O
Pain	B-D010146

,	O
Dizziness	B-D004244

,	O
Depression	B-D003863

Drug-related	O
patient	O
complaints	O
occurring	O
in	O
fewer	O
than	O
3%,	O
but	O
more	O
than	O
1%,	O
are	O
unmarked	O

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Probably	O
Causally	O
Related	O
(Adverse	O
reactions	O
reported	O
only	O
in	O
worldwide	O
postmarketing	O
experience,	O
not	O
seen	O
in	O
Clinical	B-D016430
Trial	I-D016430

Cardiovascular	B-D002319
System	I-D002319

Digestive	B-D004064
System	I-D004064

Hemic	O
and	O
Lymphatic	B-D008208
System	I-D008208

Metabolic	O
and	O
nutritional	O
-	O
Edema	B-D004487
,	O
Serum	B-D044967

Nervous	B-D009420
System	I-D009420

Special	O
senses	O
-	O
Photophobia	B-D020795
,	O
transient	O
visual	O
disturbances.Urogenital	O
system	O
-	O
Elevated	O
BUN,	O
renal	O
failure,	O
Renal	B-D051437
Insufficiency	I-D051437

Incidence	B-D015994
Less	O
Than	O
1%	O
-	O
Causal	O
Relationship	O
Unknown	O
(Medical	O
events	O
occurring	O
under	O
circumstances	O
where	O
causal	O
relationship	O
to	O
Etodolac	B-D017308

These	O
reactions	O
are	O
listed	O
as	O
alerting	O
information	O
for	O
Physicians	B-D010820

Additional	O
Adverse	O
Reactions	O
Reported	O
with	O
NSAIDs	O
Body	O
as	O
a	O
whole	O
-	O
Sepsis	B-D018805
,	O
Death	B-D003643

(5.1)	O
Monitor	O
for	O
signs	O
of	O
hepatic	O
reactions	O

Indomethacin	B-D007213
for	O
Injection	O
may	O
need	O
to	O
be	O
discontinued	O

(5.2)	O
Indomethacin	B-D007213
for	O
Injection	O
may	O
inhibit	O
Platelet	B-D010974
Aggregation	I-D010974

(5.3)	O
Gastrointestinal	O
Effects:	O
Monitor	O
Neon	B-D009356

(5.4)	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects:	O
Monitor	O
Neon	B-D009356

(5.5)	O
Renal	O
Effects:	O
Monitor	O
renal	O
function	O
and	O
Serum	B-D044967

(5.6)	O
5.1	O
Infection	O
Indomethacin	B-D007213
may	O
mask	O
the	O
usual	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

Therefore,	O
the	O
physician	O
must	O
be	O
continually	O
on	O
the	O
alert	O
for	O
this	O
and	O
should	O
use	O
the	O
drug	O
with	O
extra	O
care	O
in	O
the	O
presence	O
of	O
existing	O
controlled	O
infection	O

5.2	O
Hepatic	O
Reactions	O
Severe	O
hepatic	O
reactions	O
have	O
been	O
reported	O
in	O
Adult	B-D000328

[For	O
further	O
information,	O
see	O
package	O
insert	O
for	O
oral	O
Indomethacin	B-D007213

If	O
clinical	O
Signs	B-D012816
and	I-D012816
Symptoms	I-D012816

5.3	O
Platelet	B-D010974
Aggregation	I-D010974
Indomethacin	B-D007213
for	O
Injection	O
may	O
inhibit	O
Platelet	B-D010974
Aggregation	I-D010974

In	O
one	O
small	O
study,	O
Platelet	B-D010974
Aggregation	I-D010974

Platelet	B-D010974
Aggregation	I-D010974

Observe	O
Prema	B-C070504

5.4	O
Gastrointestinal	O
Effects	O
In	O
the	O
collaborative	O
study,	O
major	O
gastrointestinal	O
bleeding	O
was	O
no	O
more	O
common	O
in	O
Neon	B-D009356

However,	O
minor	O
gastrointestinal	O
bleeding	O
(i.e.,	O
chemical	O
detection	O
of	O
Blood	B-D001769

Severe	O
gastrointestinal	O
effects	O
have	O
been	O
reported	O
in	O
Adult	B-D000328

[For	O
further	O
information,	O
see	O
package	O
insert	O
for	O
oral	O
Indomethacin	B-D007213

5.5	O
Central	B-D002490
Nervous	I-D002490
System	I-D002490
Effects	O
Prema	B-C070504
turity	O
per	O
se	O
is	O
associated	O
with	O
an	O
increased	O
Incidence	B-D015994

Because	O
Indomethacin	B-D007213

However,	O
in	O
the	O
large	O
Multicenter	B-D016448
Study	I-D016448

5.6	O
Renal	O
Effects	O
Indomethacin	B-D007213
for	O
Injection	O
may	O
cause	O
significant	O
reduction	O
in	O
Urine	B-D014556

These	O
effects	O
in	O
most	O
Neon	B-D009356

However,	O
because	O
adequate	O
renal	O
function	O
can	O
depend	O
upon	O
renal	O
prostaglandin	O
synthesis,	O
Indomethacin	B-D007213
for	O
Injection	O
may	O
precipitate	O
Renal	B-D051437
Insufficiency	I-D051437

When	O
significant	O
suppression	O
of	O
Urine	B-D014556

Indomethacin	B-D007213
for	O
Injection	O
in	O
pre-term	O
Infant	B-D007223

When	O
this	O
occurs,	O
a	O
significant	O
reduction	O
in	O
Serum	B-D044967

Monitor	O
renal	O
function	O
and	O
Serum	B-D044967

5.7	O
Administration	O
Administer	O
Indomethacin	B-D007213
for	O
Injection	O
carefully	O
to	O
avoid	O
extravascular	O
injection	O
or	O
leakage	O
as	O
the	O
solution	O
may	O
be	O
irritating	O
to	O
tissue	O

6	O
ADVERSE	O
REACTIONS	O
Most	O
common	O
adverse	O
reactions	O
are	O
bleeding	O
problems,	O
higher	O
Incidence	B-D015994

(6.1)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS,	O
contact	O
Fresenius	O
Kabi	O
USA,	O
LLC	O
at	O
1-800-551-7176	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O

6.1	O
Clinical	B-D016430
Trial	I-D016430
s	O
Experience	O
In	O
a	O
double-blind,	O
placebo-controlled	O
trial	O
of	O
405	O
Prema	B-C070504

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
treatment	O
groups	O
in	O
intracranial	O
Hemorrhage	B-D006470

The	O
Neon	B-D009356

The	O
Incidence	B-D015994

The	O
following	O
additional	O
adverse	O
reactions	O
in	O
Neon	B-D009356

The	O
rates	O
are	O
calculated	O
from	O
a	O
Database	B-D019991

One	O
year	O
follow-up	O
is	O
available	O
on	O
175	O
Neon	B-D009356

In	O
controlled	O
clinical	O
studies,	O
only	O
electrolyte	O
imbalance	O
and	O
renal	O
dysfunction	O
(of	O
the	O
reactions	O
listed	O
below)	O
occurred	O
statistically	O
significantly	O
more	O
frequently	O
after	O
Indomethacin	B-D007213
for	O
Injection	O
than	O
after	O
placebo	O

Reactions	O
marked	O
with	O
a	O
single	O
asterisk	O
(*)	O
occurred	O
in	O
3	O
to	O
9	O
percent	O
of	O
Indomethacin	B-D007213

Unmarked	O
reactions	O
occurred	O
in	O
less	O
than	O
3	O
percent	O
of	O
Neon	B-D009356

Renal:	O
renal	O
failure,	O
renal	O
dysfunction	O
in	O
41	O
percent	O
of	O
Neon	B-D009356

Cardiovascular:	O
intracranial	O
bleeding**,	O
pulmonary	O
Hypertension	B-D006973

Gastrointestinal:	O
gastrointestinal	O
bleeding*,	O
Vomiting	B-D014839

Metabolic:	O
Hyponatremia	B-D007010

Coagulation:	O
decreased	O
Platelet	B-D010974
Aggregation	I-D010974

The	O
following	O
adverse	O
reactions	O
have	O
also	O
been	O
reported	O
in	O
Neon	B-D009356

Respiratory:	O
Apnea	B-D001049

Metabolic:	O
Acidosis	B-D000138

Hematologic:	O
Disseminated	B-D004211
Intravascular	I-D004211
Coagulation	I-D004211

Ophthalmic:	O
retrolental	O
fibroplasia.**	O
A	O
variety	O
of	O
additional	O
adverse	O
experiences	O
have	O
been	O
reported	O
in	O
Adult	B-D000328

Their	O
relevance	O
to	O
the	O
pre-term	O
Infant	B-D007223

Cardiovascular	O
Risk	B-D012306
NSAIDs	O
may	O
cause	O
an	O
increased	O
Risk	B-D012306

This	O
Risk	B-D012306

Patients	B-D010361
with	O
cardiovascular	O
Disease	B-D004194

(See	O
WARNINGS	O
.)	O
Diclofenac	B-D004008
Sodium	B-D012964

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
In	O
Patients	B-D010361

Abnormal	O
renal	O
function,	O
Anemia	B-D000740

Additional	O
adverse	O
experiences	O
reported	O
occasionally	O
include:	O
Body	O
as	O
a	O
Whole:	O
Fever	B-D005334

This	O
Risk	B-D012306

Etodolac	B-D017308
Extended-Release	O
Tablets	B-D013607
,	O
400	O
mg,	O
500	O
mg	O
and	O
600	O
mg	O
are	O
contraindicated	O
in	O
the	O
setting	O
of	O
Coronary	B-D001026
Artery	I-D001026
Bypass	I-D001026

Gastrointestinal	O
Risk	B-D012306
NSAIDs	O
cause	O
an	O
increased	O
Risk	B-D012306

These	O
events	O
can	O
occur	O
at	O
any	O
Time	B-D013995

Elderly	O
Patients	B-D010361

(See	O
WARNINGS	O
)	O

ADVERSE	O
REACTIONS	O
A	O
total	O
of	O
1552	O
Patients	B-D010361

In	O
the	O
tabulations	O
below,	O
adverse	O
event	O
rates	O
are	O
generally	O
categorized	O
based	O
on	O
the	O
Incidence	B-D015994

As	O
with	O
other	O
NSAIDs,	O
the	O
cumulative	O
adverse	O
event	O
rates	O
may	O
increase	O
significantly	O
over	O
Time	B-D013995

In	O
Patients	B-D010361

gross	O
bleeding/perforation	O
Nausea	B-D009325

